

## *Curriculum vitae*

**JAVIER MARTINEZ-PICADO, M.Sc., Ph.D.**

ICREA Research Professor  
@ IrsiCaixa Immunopathology Research Institute

Associate Professor  
@ UVic-UCC

# INDEX

<b>EDUCATION</b> .....	<b>3</b>
<b>CURRENT POSITION</b> .....	<b>3</b>
<b>PROFESSIONAL EXPERIENCE</b> .....	<b>3</b>
<b>PARTICIPATION IN COMPETITIVE RESEARCH PROJECTS</b> .....	<b>4</b>
<b>PARTICIPATION IN RESEARCH PROJECTS FOUNDED BY PRIVATE COMPANIES</b> .....	<b>8</b>
<b>PUBLICATIONS</b> .....	<b>10</b>
<b>BOOKS AND MONOGRAPHS</b> .....	<b>27</b>
<b>PATENTS AND UTILITY MODELS</b> .....	<b>29</b>
<b>INVITED TALKS</b> .....	<b>31</b>
<b>RESEARCH ACTIVITIES IN INTERNATIONAL CENTERS</b> .....	<b>39</b>
<b>CONFERENCE CONTRIBUTIONS</b> .....	<b>40</b>
<b>RESEARCHERS IN THE GROUP</b> .....	<b>59</b>
<b>DOCTORAL THESES</b> .....	<b>60</b>
<b>MASTER THESES (FROM 2009)</b> .....	<b>63</b>
<b>EXPERIENCE ORGANIZING R+D ACTIVITIES</b> .....	<b>65</b>
<b>AWARDS</b> .....	<b>69</b>
<b>OTHER SCIENTIFIC, TECHNICAL OR EDUCATIONAL QUALIFICATIONS</b> .....	<b>70</b>

---

## EDUCATION

1989	Master in Science, University of Barcelona
1994	PhD in Microbiology, University of Barcelona
2002	Postgraduate course, <i>Leadership of personal development: professional applications</i> , Universitat Oberta de Catalunya.
2005	Accreditation in Research for the category of Assistant Professor by the AQU
2014	Accreditation in Advanced Research for the category of Full Professor by the AQU (Quality Assurance Agency for the University System in Catalonia; <a href="http://www.aqu.cat">www.aqu.cat</a> )

---

## CURRENT POSITION

- ICREA\* Research Professor at the AIDS Research Institute IrsiCaixa  
*\*ICREA: Catalan Institution for Research and Advanced Studies*
- Associate Professor of Medicine at the Universitat of Vic (UVic-UCC)

Working Address: AIDS Research Institute IrsiCaixa  
University Hospital “Germans Trias i Pujol”  
Ctra. de canyet s/n, 08916 Badalona, Barcelona  
Tel. +34 – 934 656 374 ext. 150  
E-mail: [jmpicado@irsicaixa.es](mailto:jmpicado@irsicaixa.es)

---

## PROFESSIONAL EXPERIENCE

<u>PERIOD</u>	<u>POSITION</u>	<u>CENTER</u>
2006–now	Full Research Professor	Catalan Institution for Research and Advanced Studies (ICREA)
2014–now	Associate Prof. of Medicine	University of Vic (UVic-UCC)
2011-2016	Associate Prof. of Medicine	Autonomous University of Barcelona (UAB)
2004	Visiting scientist	University of Montreal
2002	Visiting scientist	University of California San Diego
2000-2006	Associated researcher	Retrovirology Lab., Univ. Hosp. “Germans Trias i Pujol”
1996-1999	Postdoctoral researcher	Harvard University & Massachusetts General Hospital
1995-1996	Postdoctoral researcher	Retrovirology Lab., Univ. Hosp. “Germans Trias i Pujol”
1994-1996	Lecturer	Microbiology Department, Univ. of Barcelona
1994-1994	Postdoctoral researcher	“Bosch i Gimpera” Foundation
1992	Visiting scientist	University of Umeå
1991-1993	Technical Director of the 1 <sup>st</sup> Master in Biotechnology	UAB, UPC and UB
1990-1993	Lecturer	Univ. Polytechnic of Catalonia (UPC)
1990-1994	PhD student (FPI)	Microbiology Department, Univ. of Barcelona
1990	PhD student "Grants for Research Projects	Interdepartmental Science and Technology Commission (CIRIT), Generalitat de Catalunya

---

## PARTICIPATION IN COMPETITIVE RESEARCH PROJECTS

**PROJECT TITLE: Multi-OMICS identification and validation of mechanisms triggered by Immune interventions aimed at reducing the size of the replication competent Reservoir**

AGENCY: National Institute of Health (NIH), ref. 1P01AI178376-01

CENTER: IrsiCaixa Immunopathology Research Institute

FUNDING: 6,108,119€ project budget; 500,00€ center budget.

PERIOD: **03/07/2023 – 30/04/2028**

ROLE: Dr. J Martinez-Picado is Principal Investigator at IrsiCaixa

**PROJECT TITLE: Dissecting CD169-mediated endocytic mechanisms in myeloid cells and their contribution to virus dissemination (VIRCOM)**

AGENCY: Spanish Ministry of Science and Innovation, ref. PID2022-139271OB-I00

CENTER: IrsiCaixa Immunopathology Research Institute

FUNDING: 318,750€ project budget (+1 fellowship)

PERIOD: **01/09/2023 – 31/08/2026**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Characterization and rehabilitation of post-COVID-19 condition in pediatric population**

AGENCY: Barcelona City Hall

CENTER: IrsiCaixa Immunopathology Research Institute

FUNDING: 51,590€ project budget.

PERIOD: **22/12/2022 – 24/06/2024**

ROLE: Dr. Sara Morón-López is Principal Investigator; Dr. J Martinez-Picado is Associated Investigator

**PROJECT TITLE: Impact and viability of a novel mass PCR testing method as a pandemic-fighting strategy (PCR4ALL)**

AGENCY: European Commission; Horizon Europe, ref. 101095606

CENTER: IrsiCaixa Immunopathology Research Institute

FUNDING: 3,397,612€ project budget; 467,438€ center budget.

PERIOD: **01/12/2022 – 30/11/2026**

ROLE: Dr. J Martinez-Picado is IrsiCaixa Principal Investigator

**PROJECT TITLE: The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: towards personalised medicine (UNDINE)**

AGENCY: European Commission; Horizon Europe, ref. 101057100

CENTER: Germans Trias i Pujol Research Institute (IGTP)

FUNDING: 6,718,138€ project budget; 71,503€ center budget.

PERIOD: **01/06/2022 – 31/05/2026**

ROLE: Dr. J Martinez-Picado is Principal Investigator at IGTP

**PROJECT TITLE: Network of Centers for Biomedical Research (CIBER) in Infectious Diseases**

AGENCY: Spanish Health Department (ISCIII)

CENTER: Germans Trias i Pujol Research Institute (IGTP); CB21/13/00063.

FUNDING: 210,000€ (70,000€ per year)

PERIOD: **01/01/2022 – 31/12/2024**

ROLE: Dr. J Martinez-Picado is IGTP Principal Investigator

**PROJECT TITLE: Neurodegeneration triggered by SARS-CoV-2: brain organoids as an analytical and predictive model (NeuroCOVID)**

AGENCY: Fundació La Marató de TV3, ref. 202130-30-31-32

CENTER: IrsiCaixa, UB, BBRC

FUNDING: 399,750€ project budget; 182,750€ center budget.

PERIOD: **01/09/2021 – 31/08/2024**

ROLE: Dr. J Martinez-Picado is Project Coordinator and IrsiCaixa Principal Investigator

**PROJECT TITLE: High-Throughput Synthetic Biology**

**Platform for Surveillance and Therapeutics Development Against Current and Future SARS-Coronaviruses**

AGENCY: Fundació La Marató de TV3

CENTER: UPF, Univ Valencia, IrsiCaixa

FUNDING: 395,500€ project budget

PERIOD: **30/07/2021 – 29/07/2024**

ROLE: Dr. A. Rahmeh is Project Coordinator, Dr. J. Martinez-Picado is Associated Investigator at IrsiCaixa

**PROJECT TITLE: Reversing Immune Dysfunction for HIV Eradication (RIDHIV)**

AGENCY: National Institute of Health (NIH), ref. 1UM1A|164561-01

CENTER: IrsiCaixa Immunopathology Research Institute and other 10 research groups

FUNDING: \$25,009,035 project budget; \$1,294,400 center budget.

PERIOD: **01/05/2021 – 30/04/2026**

ROLE: Dr. J Martinez-Picado is IrsiCaixa co-Principal Investigator; Dr. S Chanda is Project Coordinator.

**PROJECT TITLE: EU Research Scholars Program in HIV to Sara Morón-López**

AGENCY: Gilead Sciences

CENTER: IrsiCaixa Immunopathology Research Institute

FUNDING: \$130,000

PERIOD: **01/07/2021 – 30/06/2023**

ROLE: Dr. J Martinez-Picado is Awardee's Mentor.

**PROJECT TITLE: Elimination of the HIV-1 latent reservoir by using novel anti-CD4 chimeric antigen receptor T cells (αCD4-CAR)**

AGENCY: Spanish Ministry of Science and Innovation

CENTER: IrsiCaixa AIDS Research Institute

FUNDING: 169400€

PERIOD: **01/09/2021 – 31/08/2024**

ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. M Salgado is Principal Investigator.

**PROJECT TITLE: Discovery of novel HIV-1 RNA biogenesis inhibitors based on disrupting the RRE-Rev ribonucleoprotein**

AGENCY: Generalitat Valenciana, PROMETEO/2021/036

CENTER: IrsiCaixa Immunopathology Research Institute and other 3 research groups

FUNDING: 543,684€ project budget; 95,000€ center budget.

PERIOD: **01/01/2021 – 31/12/2024**

ROLE: Dr. J Martinez-Picado is IrsiCaixa Principal Investigator; Dr. J Gallego is Project Coordinator.

**PROJECT TITLE: Halt the entry of enveloped viruses into immune cells: novel monoclonal antibodies and blockage of intracellular cascade (HALTVIR)**

AGENCY: Spanish Ministry of Science and Innovation, ref. PID2019-109870RB-I00

CENTER: IrsiCaixa AIDS Research Institute

FUNDING: 363,000€ project budget (+1 fellowship)

PERIOD: **01/06/2020 – 31/05/2023**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: 3D human organoids for biomarker identification and treatment assessment in COVID-19 (3D4COVID)**

AGENCY: Merck SARS-CoV-2 competitive international call, ref. IISP # 60258

CENTER: IrsiCaixa AIDS Research Institute, UPF, EMBL

FUNDING: 488,986€ project budget

PERIOD: **01/10/2020 – 30/09/2022**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: CRISPR Screen to Identify Drug-**

**Repurposing Host Targets for SARS-CoV-2 Infection (CRISPR-CoV2)**

AGENCY: CRUE Spanish Universities  
CENTER: UPF and IrsiCaixa AIDS Research Institute  
FUNDING: 100,000€ project budget; 50,000€ center budget.  
PERIOD: **01/10/2020 – 30/09/2021**  
ROLE: Dr. J Martinez-Picado is IrsiCaixa Principal Investigator; Dr. M Güell is UPF Principal Investigator.

**PROJECT TITLE: New therapeutic strategies based on tyrosine kinase inhibitors for the elimination of the latent reservoir of HIV-1 (TKICure)**

AGENCY: Spanish Ministry of Science and Innovation; ref. PID2019-110275RB-I00  
CENTER: Instituto de Salud Carlos III and IrsiCaixa  
FUNDING: 157,300€ project budget; 48,713€ center budget.  
PERIOD: **01/06/2020 – 31/05/2023**  
ROLE: Dr. M Coiras is Principal Investigator at the ISCIII, Dr. J Martinez-Picado is Associated Investigator at IrsiCaixa (subcontract)

**PROJECT TITLE: Novel detection strategy in the characterization of persistent HIV-1 antigen production in ART-suppressed individuals and its central role in inflammation and chronic immune activation (GLD17/00267).**

COMPANY: 5<sup>th</sup> Fellowship Program in HIV, hepatitis and hemato-oncology (competitive call by Gilead Sciences)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 49,973 €  
PERIOD: **01/01/2018 – 31/12/2019**  
ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. MC Puertas is Principal Investigator.

**PROJECT TITLE: Spanish Network for AIDS Research**

AGENCY: Spanish Ministry of Science and Innovation, Carlos III Health Institute; ref. RETIC RD16/0025/0041  
CENTER: IrsiCaixa AIDS Research Institute and other 36 national research groups  
FUNDING: 300.000€ to the center  
PERIOD: **01/01/2017 – 31/12/2021**  
ROLE: Dr. J Martinez-Picado is Associated Investigator, member of the Steering Committee, and co-chair of the Vaccines Program.

**PROJECT TITLE: AIDS Clinical and Basic Research Group**

AGENCY: Research Centers of Catalonia (CERCA); ref. 2017 SGR 252  
CENTER: IrsiCaixa AIDS Research Institute  
FUNDING: 62.150€  
PERIOD: **01/01/2017 – 30/11/2021**  
ROLE: Dr. J Martinez-Picado is Associated Investigator

**PROJECT TITLE: Non-invasive viral reservoir characterization in Lymph Nodes through Fine Needle Biopsies in patients with distinct HIV progression profiles (GLD16/00163).**

COMPANY: 4<sup>th</sup> Fellowship Program in HIV, hepatitis and hemato-oncology (competitive call by Gilead Sciences)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: **49.738 €**  
PERIOD: **01/01/2017 – 31/12/2019**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Novel therapeutic agents to block interactions between enveloped viruses and myeloid cells: combating the settlement of infections (BLOCKER-PRO)**

AGENCY: Spanish Ministry of Economy and Competitiveness, Secretariat of state for research, development and innovation; ref. SAF2016-80033-R  
CENTER: AIDS Research Institute –IrsiCaixa–  
FUNDING: 423,500€ project budget.  
PERIOD: **01/01/2017 – 31/12/2019**  
ROLE: Dr. J Martinez-Picado is co-Principal Investigator

**PROJECT TITLE: New genetic engineering tools for the treatment of AIDS "STOP-AIDS"**

AGENCY: Spanish Ministry of Economy and Competitiveness, Secretariat of state for research, development and innovation; Retos-Colaboración RTC-2016-5324-1  
CENTER: AIDS Research Institute –IrsiCaixa– and 3 other Spanish centers  
FUNDING: 942.137€ project budget; 170.769€ center budget.  
PERIOD: **01/10/2016 – 31/07/2020**  
ROLE: Dr. J Martinez-Picado is PI at IrsiCaixa

**PROJECT TITLE: Allogeneic Stem Cell Transplantation in HIV-1 Infected Individuals**

AGENCY: Foundation for AIDS research **amfAR**; (ARCHE program: 108930-56-RGRL, 109293-59-RGRL, 109552-61-RGRL, 109858-64-RSRL)  
CENTER: AIDS Research Institute –IrsiCaixa– and 6 other European centers  
FUNDING: \$3,998,637 project budget; \$1,158,081 center budget.  
PERIOD: **01/07/2014 – 30/06/2020**  
ROLE: Dr. J Martinez-Picado is Project Chair

**PROJECT TITLE: Generation of Novel Therapeutic Agents to Block HIV-1 Cell-to-Cell Transmission Mediated by Dendritic Cells (Blocker)**

AGENCY: Spanish Ministry of Economy and Competitiveness, Secretariat of state for research, development and innovation; ref. SAF2013-49042-R  
CENTER: AIDS Research Institute –IrsiCaixa–  
FUNDING: 435,600€ project budget.  
PERIOD: **01/01/2014 – 31/12/2016**  
ROLE: Dr. J Martinez-Picado is co-Principal Investigator

**PROJECT TITLE: Hematopoietic CCR5Δ32 stem cell transplantation of an HIV-1-infected person (ref. 14\_0086)**

COMPANY: 3<sup>rd</sup> Fellowship Program in HIV, hepatitis and hemato-oncology (Gilead Sciences)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: **30.000 €**  
PERIOD: **01/09/2014 – 31/08/2015**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Therapeutic TriMix / mRNA-based vaccine in chronic HIV-1 infected patients on antiretroviral therapy (iHIVARNA)**

AGENCY: European Union, Safety and efficacy of therapeutic vaccines **FP7-HEALTH-2013**  
CENTER: AIDS Research Institute –IrsiCaixa– and 7 other European centers  
FUNDING: 5.996.880€ project budget; 669.300€ center budget.  
PERIOD: **01/12/2013 – 30/11/2017**  
ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. F García is Principal Investigator.

**PROJECT TITLE: Targeting engineered nanoliposomes for therapeutic purge of HIV-1 reservoirs**

AGENCY: Foundation for AIDS research **amfAR**, M Krim fellowship in basic biomedical research (ref. 08676-55-RKRL)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: \$150.000  
PERIOD: **30/10/2013-30/10/2015**  
ROLE: Dr. N izquierdo-Useros is Principal Investigator; Dr. J Martinez-Picado is mentor's project

**PROJECT TITLE: Viral Reservoirs in MVA-based immunotherapies**

AGENCY: Oxford University  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 12,620€ project budget  
PERIOD: **01/04/2014 – 31/12/2014**  
ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. L Dorrell is Principal Investigator.

**PROJECT TITLE: Immune correlates of viral rebound after therapeutic HIV vaccination**

AGENCY: **Foundation for AIDS research amfAR** (ref.

108532-53-RGRL)  
CENTER: AIDS Research Institute –IrsiCaixa–  
FUNDING: 180,000€ project budget; 16,000€ group budget.  
PERIOD: **01/02/2013 – 21/01/2014**  
ROLE: Dr. J Martínez-Picado is Associated Investigator; Dr. C Brander is Principal Investigator.

PROJECT TITLE: **HIV-1 reverse transcriptase “connection” subdomain mutations and their role in resistance to non-nucleoside reverse transcriptase inhibitors.**  
AGENCY: Spanish Ministry of Health, Social Services and Equality, ref. EC11-025  
CENTER: Centro de Biología Molecular “Severo Ochoa” and IrsiCaixa Foundation  
FUNDING: 78.552 € project budget; 35,868€ group budget.  
PERIOD: **01/01/2012 – 30/10/2013**  
ROLE: Dr. J Martínez-Picado is Associated Investigator; Dr. L Menéndez is Principal Investigator.

PROJECT TITLE: **Study of immunological, virological and cellular mechanisms contributing to control of infection in HIV controllers with weak or strong T-CD8 antiviral capacities**  
AGENCY: ANRS (Agence Nationale de recherches sur la SIDA et les hépatites virales)  
CENTER: IrsiCaixa Foundation in collaboration with three other centers in France  
FUNDING: **160.296€** project budget; 50.380€ center budget  
PERIOD: **01/01/2011 – 31/12/2014**  
ROLE: Dr. A Venet (Project coordinator) & Dr. J Martínez-Picado is Center Coordinator

PROJECT TITLE: **Molecular mechanisms of HIV uptake and antigen presentation by Dendritic cells: Rationale to enhance HIV mediated immune triggering**  
AGENCY: Spanish Ministry of Science and Innovation, ref. SAF2010-21224  
CENTER: IrsiCaixa Foundation  
FUNDING: 302.500 € (+ 1 FPI fellowship)  
PERIOD: **01/01/2011 – 31/12/2013**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Pilot study for the identification of markers for the replication of XMRV (xenotropic murine leukemia virus-related virus) in waxed tissue of patients with prostatic adenocarcinoma undergoing radical prostatectomy**  
AGENCY: Foundation for the Research in Urology (FIU), “Rafael Mollá y Rodrigo 2010”.  
CENTER: Hospital Germans Trias i Pujol & Fundació IrsiCaixa  
FUNDING: 13.200 € project budget.  
PERIOD: **01/07/2010 – 31/06/2011**  
ROLE: Dr. J Martínez-Picado is Associated Investigator; Dr. J Arial is Principal Investigator.

PROJECT TITLE: **Analysis of differential resistance emergence risk for differential treatment application schedules**  
AGENCY: University of Delaware  
CENTER: IrsiCaixa Foundation  
FUNDING: 23.600 € center budget  
PERIOD: **01/01/2010 – 31/12/2012**  
ROLE: Dr. J Martínez-Picado is researcher and advisor

PROJECT TITLE: **Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)**  
AGENCY: European Commission, **FP7-HEALTH-2007-B, ref. 223131**  
CENTER: Fundació IrsiCaixa and 21 other European centers  
FUNDING: 9.998.096 € project budget; 947.980 € center budget.  
PERIOD: **01/04/2009 – 31/03/2014**  
ROLE: Dr. J Martínez-Picado is Associated Investigator; Dr. B Clotet is Principal Investigator.

PROJECT TITLE: **Investigation of gene variants associated with resistance and susceptibility to HIV-1 infection in HIV-1 exposed but uninfected individuals with haemophilia A**  
AGENCY: National Institutes of Health through The Center for HIV/AIDS Vaccine Immunology (CHAVI)  
CENTER: IrsiCaixa Foundation  
FUNDING: 11.200 €  
PERIOD: **30/04/2008 – 31/12/2010**  
ROLE: Dr. J Martínez-Picado is Spanish coordinator

PROJECT TITLE: **Spanish HIV-infection Network**  
AGENCY: Spanish Health Ministry, ref. **RD06/0006/0020**  
CENTER: “Germans Trias i Pujol” Hospital  
FUNDING: 115.000 € center budget/year  
PERIOD: **01/2007 - 12/2012**  
ROLE: Dr. J Martínez-Picado serves as senior researcher in the antiretroviral resistance and the pathogenesis groups.

PROJECT TITLE: **Mature dendritic cells enhance HIV-1 transmission to CD4+ T-cells: molecular mechanisms and implications for viral pathogenesis**  
AGENCY: Spanish Ministry of Science and Innovation, ref. **SAF2007-64696**  
CENTER: IrsiCaixa Foundation  
FUNDING: 235.950 € (+ 1 FPI fellowship)  
PERIOD: **01/10/2007 – 24/10/2010**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Secondary mutations and polymorphisms in the VIH-1 reverse transcriptase: modulation of resistance to nucleoside analogues and associated molecular mechanisms.**  
AGENCY: Spanish Foundation for AIDS Research and Prevention, ref. **FIPSE 36771/08**  
CENTER: IrsiCaixa Foundation in collaboration with Severo Ochoa Foundation  
FUNDING: 164.739 € project budget; 42.178 € center budget  
PERIOD: **12/2008 - 12/2010**  
ROLE: Dr. L Menéndez Arias is Project coordinator; Dr. J Martínez-Picado is Principal Investigator.

PROJECT TITLE: **New methodology to test the phenotypic susceptibility of HIV-1 clinical isolates to protease inhibitors**  
AGENCY: Spanish Foundation for AIDS Research and Prevention, ref. **FIPSE 36668/07**  
CENTER: IrsiCaixa Foundation  
FUNDING: 94.901 €  
PERIOD: **10/10/2007 – 09/10/2010**  
ROLE: Dr. J Martínez-Picado is Associated Investigator; Dr. L Ruiz is Principal Investigator.

PROJECT TITLE: **SLC22 and SLC221: new genes involved in the cell transport of antiretroviral drugs in lymphocytes**  
AGENCY: Spanish Foundation for AIDS Research and Prevention, ref. **FIPSE 36621/06**  
CENTER: IrsiCaixa Foundation in collaboration with University of Barcelona  
FUNDING: 175.548€ project budget; 87.287 € center budget  
PERIOD: 1/2007 - 12/2009  
ROLE: Dr. M Pastor-Anglada is Project coordinator; Dr. J Martínez-Picado is Principal Investigator.

PROJECT TITLE: **Host genetic factors affecting HIV disease progression**  
AGENCY: EuroCHAVI - National Institute of Health, ref. **EuroCHAVI**.  
CENTER: 9 centers from five European countries (including IrsiCaixa Foundation) and Australia  
FUNDING: 106.980 € project budget; 6927 center budget.  
PERIOD: **1/2006 - 12/2007**  
ROLE: Dr. A Telenti is Project Coordinator; Dr. J Martínez-Picado is National Coordinator.

PROJECT TITLE: **New profiles of multi-drug resistance in**

**the HIV-1 reverse transcriptase**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 36523/05**

CENTER: "Germans Trias i Pujol" Hospital in collaboration with Severo Ochoa Foundation

FUNDING: 148.828 € project budget; 42.968 € center budget

PERIOD: **12/2005 - 12/2008**

ROLE: Dr. L Menéndez Arias is Project Coordinator; Dr. J Martinez-Picado is Principal Investigator.

**PROJECT TITLE: Phase II study on autologous myeloid dendritic cells as cellular adjuvant in an HIV-1 vaccine during early HIV-1 infection**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 36356/05**

CENTER: "Germans Trias i Pujol" Hospital in collaboration with five other hospitals in Spain

FUNDING: 354.065 € project budget; 45.166 € center budget

PERIOD: **12/2005 - 12/2008**

ROLE: Dr. T Gallart is Project Coordinator; Dr. J Martinez-Picado is Principal Investigator.

**PROJECT TITLE: Influence of genetic polymorphisms in DC-SIGN in the ability of dendritic cells to facilitate the infection in trans of T4 lymphocytes by HIV-1.**

AGENCY: Spanish Ministry of Education and Science. ref. **SAF2004-06991**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 136.850 €

PERIOD: **12/2004 - 12/2007**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Pharmacogenomics of antiviral nucleoside analogue transporters in human T lymphocytes: effect of the HIV-1 infection and therapeutical implications.**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 36372/03**

CENTER: "Germans Trias i Pujol" Hospital in collaboration with University of Barcelona

FUNDING: 187.199 € project budget; 90.652 € center budget.

PERIOD: **01/2004 - 12/2006**

ROLE: Dr. M Pastor-Anglada is Project coordinator; Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Molecular and cellular immunity in identical twins infected by the same Human Immunodeficiency Virus (HIV-1) strain**

AGENCY: Marató de TV3 Foundation. ref. **021110**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 147.124 €

PERIOD: **01/2003 - 12/2005**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Spanish HIV-infection Network**

AGENCY: Spanish Health Ministry. ref. **G03/173**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 1.450.530 € network budget; 185.038 center budget/year.

PERIOD: **01/2003 - 12/2006**

ROLE: Dr. J Martinez-Picado serves as senior researcher in the antiretroviral resistance working and the pathogenesis groups.

**PROJECT TITLE: Insertions in the reverse transcriptase of HIV-1: influence of the nucleotide sequence context in the resistance to nucleoside analogues.**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 36207/01**

CENTER: "Germans Trias i Pujol" Hospital in collaboration with Severo Ochoa Foundation

FUNDING: 139.268 € project budget; 61.221 € center budget.

PERIOD: **10/2001 - 09/2004**

ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. L Menéndez-Arias is Principal Investigator.

**PROJECT TITLE: In vitro hypersusceptibility to protease inhibitors and loss of replicative capacity in HIV infected patients.**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 36177/01**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 102.440 €

PERIOD: **07/2001 - 06/2004**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Drug susceptibility, replicative capacity and viral evolution of HIV-1 with pol gen mutations conferring antiretroviral drug resistance.**

AGENCY: Spanish Health Ministry. ref. **FIS 01/1122**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 99.167 €

PERIOD: **01/2001 - 12/2003**

ROLE: Dr. J Martinez-Picado is Principal Investigator

**PROJECT TITLE: Immune reconstitution driven by sequential structured treatment interruptions in patients with chronic HIV-1 infection.**

AGENCY: Spanish Foundation for AIDS Research and Prevention. ref. **FIPSE 3025/99**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 104.877 €

PERIOD: **2000-2002**

ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. B Clotet is Principal Investigator.

**PROJECT TITLE: Role of the CD4+ T cells and the cytokines receptors during apoptosis induced by HIV-1. Implications in the pathogenesis of AIDS.**

AGENCY: Spanish Health Ministry. ref. **FIS 00/0893**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 74.525 €

PERIOD: **2000-2002**

ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. J Blanco is Principal Investigator.

**PROJECT TITLE: Virological and immunological efficacy of proactive antiretroviral swithing during HIV-1 treatment.**

AGENCY: Spanish Science & Technology Ministry. ref. **I+D PM98-0064**

CENTER: "Germans Trias i Pujol" Hospital

FUNDING: 102.172 €

PERIOD: **1999-2001**

ROLE: Dr. J Martinez-Picado is Associated Investigator; Dr. B Clotet is Principal Investigator.

# PARTICIPATION IN RESEARCH PROJECTS FUNDED BY PRIVATE COMPANIES or PHILANTHROPY

## (Pharma and biotechs)

PROJECT TITLE: Characterization and rehabilitation of post-COVID-19 condition in pediatric population  
COMPANY: Private Legacy at the IGTP  
CENTRE: AIDS Immunopathology Institute IrsiCaixa  
BUDGET: 93,000€ project budget  
PERIOD: **03/07/2023 - 30/04/2028**  
ROLE: Dr. Maria Méndez is Project Coordinator; Dr. J Martínez-Picado is Associated Investigator

PROJECT TITLE: **Determination of auto-antibodies against IFN $\alpha$  and IFN $\omega$  in plasma of COVID-19 cases**  
COMPANY: Grifols  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: 26,550€ project budget  
PERIOD: **01/07/2021 - 30/06/2022**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy in HIV-1 reservoir and in peripheral compartments in HIV-infected patients (DUALITY)**  
COMPANY: ViiV Healthcare  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: 587,674€ project budget; 218,238€ group budget  
PERIOD: **01/11/2019 - 31/10/2023**  
ROLE: Dr. J Martínez-Picado and Dr. J Moltó are Principal Investigators

PROJECT TITLE: **Vaccine against Covid-19: pilot project of plasma-derived exosomes from patients (ExoCoVac)**  
AGENCY: ISGlobal and YoMeCorono (crowdfunding)  
CENTER: ISGlobal and IrsiCaixa AIDS Research Institute  
FUNDING: 40,000€ project budget; 20,000€ center budget.  
PERIOD: **01/06/2020 - 31/06/2022**  
ROLE: Dr. Hernando del Portillo is Principal Investigator at ISGlobal, Dr. J Martínez-Picado is Associated Investigator at IrsiCaixa

PROJECT TITLE: **COVID Human Genetic Effort**  
AGENCY: YoMeCorono (crowdfunding)  
CENTER: IrsiCaixa AIDS Research Institute  
FUNDING: 60,000€ project budget  
PERIOD: **01/06/2020 - 31/12/2021**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Intrauterine HIV-1 infection in South Africa**  
COMPANY: Oxford University  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: 73,020€  
PERIOD: **01/01/2019 - 31/12/2020**  
ROLE: Dr. P Goulder is Principal Investigator; Dr. J Martínez-Picado is Scientific Collaborator

PROJECT TITLE: **Cutting Edge Strategies on HIV Cure (ViroCure)**  
COMPANY: Grifols  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: 450,000 €  
PERIOD: **01/07/2018 - 30/06/2023**  
ROLE: Dr. J Martínez-Picado is Scientific Director; Dr. MC Puertas & M Salgado are Principal Investigators

PROJECT TITLE: **New Technologies Mimicking Virus-Cell Interaction to Fight Infectious Diseases (Sigtech)**  
COMPANY: Grifols

CENTRE: IrsiCaixa Immunopathology Research Institute  
BUDGET: 1,322,732€  
PERIOD: **01/07/2018 - 31/12/2024**  
ROLE: Dr. J Martínez-Picado is Scientific Director; Dr. P Resa-Infante is Principal Investigator

PROJECT TITLE: **Treatment with immunological checkpoint inhibitors of HIV-infected subjects with cancer**  
COMPANY: MSD  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: \$107,806  
PERIOD: **01/03/2018 - 31/12/2019**  
ROLE: Dr. Javier Martínez-Picado is Principal Investigator

PROJECT TITLE: **Evaluation of mechanisms mediating anti-viral activity of PT compounds Treatment with immunological checkpoint inhibitors of HIV-infected subjects with cancer**  
COMPANY: POP TEST Oncology LLC  
CENTRE: AIDS Research Institute IrsiCaixa  
BUDGET: 58,819 €  
PERIOD: **01/03/2017 - 30/09/2017**  
ROLE: Dr. MC Puertas and Dr. Javier Martínez-Picado are Principal Investigators

PROJECT TITLE: **An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive adult subjects**  
COMPANY: ABIVAX  
CENTRE: AIDS Research Institute IrsiCaixa & Fundació Lluita Contra la Sida  
BUDGET: 839,864€ project budget; 406,758€ center budget  
PERIOD: **Q4 2016 - Q1 2018**  
ROLE: Dr. R Crason and Dr. J Martínez-Picado are Principal Investigators

PROJECT TITLE: **DURVAST: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors (ESR-15-10869).**  
COMPANY: AstraZeneca  
CENTER: Spanish Lung Cancer Cooperative Group & AIDS Research Institute IrsiCaixa  
FUNDING: 343,861 €  
PERIOD: **01/01/2017 - 31/12/2019**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Low Viral Reservoir in treated Subjects (LoViReT). Predictors of Extremely Low HIV-1 DNA Reservoir in Subjects Initiating cART during Chronic Infection (IISP 54925).**  
COMPANY: MSD  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 165,024 €  
PERIOD: **01/09/2016 - 30/08/2017**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen. A phase IV open randomized trial.**  
COMPANY: ViiV HealthCare.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 395,683 €  
PERIOD: **01/01/2015 - 31/12/2017**  
ROLE: Dr. J Martínez-Picado is Principal Investigator

PROJECT TITLE: **Cross-roads program in applied clinical research in AIDS**  
COMPANY: Gilead Sciences



CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 20.000 €  
PERIOD: **22/02/2016 – 31/12/2016**  
ROLE: Dr. J Martinez-Picado is Coordinator

PROJECT TITLE: **Impact of interferon alfa-2a treatment on the HIV reservoir in peripheral CD4+ T cells, in HCV-coinfected patients** (ref. 13\_00045)  
COMPANY: 2<sup>nd</sup> Fellowship Program in HIV, hepatitis and hemato-oncology (Gilead Sciences)  
CENTER: AIDS Research Institute IrsiCaixa & Hospital “Vall d’Hebron”  
FUNDING: 44.275€ (36.675€ center budget)  
PERIOD: **01/09/2013 – 30/08/2014**  
ROLE: Dr. J Martinez-Picado is Associate Researcher; Dr. M Crespo is Principal Investigator.

PROJECT TITLE: **Very small size proteoliposomes derived from *Neisseria meningitidis*.**  
COMPANY: CHEMO  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 37.280€  
PERIOD: **01/04/2014 – 31/12/2014**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Impact of raltegravir intensification on HIV-1-infected subjects with complete viral suppression under monotherapy with protease inhibitors: a 24-week open-label, proof-of-concept pilot clinical trial.**  
COMPANY: Merck Sharp & Dohme.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 199.961 €  
PERIOD: **01/04/2012 – 30/03/2014**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Testing for the presence of HIV-1 integrase mutations in plasma samples using the prototype Siemens Diagnostics assay for DNA sequencing of HIV-1 integrase.**  
COMPANY: Siemens Healthcare Diagnostics Inc.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 22.000 €  
PERIOD: **01/10/2010 – 30/09/2011**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Study of the mechanisms of Raltegravir cellular entry and efflux: Implications in Raltegravir resistance, drug-interactions and pharmacokinetics.**  
COMPANY: Merck Sharp & Dohme  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 99.550 €  
PERIOD: **01/05/2010 – 30/04/2011**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Short-time dynamics of episomal HIV-1 2-LTR forms detection during raltegravir intensification in patients with complete viral suppression.**  
COMPANY: Merck & Co.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 39.900 €  
PERIOD: **01/04/2010 – 31/03/2011**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Pilot study to assess the role of immune activation and apoptosis as a marker for treatment intensification with raltegravir (DiscoRAL).**

COMPANY: Merck & Co.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 55.000 €  
PERIOD: **01/01/2009 – 31/12/2010**  
ROLE: Dr. J Martinez-Picado is Associate Researcher; Dr. J Blanco is Principal Investigator;

PROJECT TITLE: **Integrase Resistance Analysis in Treated Experienced HIV patients who Interrupted Raltegravir due to Incomplete Viral Suppression: RAL-Dyn Study.**

COMPANY: Merck & Co.  
CENTER: Hospital Clínic de Barcelona & AIDS Research Institute IrsiCaixa  
FUNDING: 127.300 € project budget, 40.000 € center budget  
PERIOD: **01/09/2009 – 30/04/2011**  
ROLE: Dr. J Martinez-Picado is Associate Researcher; Dr. JL Blanco is Principal Investigator

PROJECT TITLE: **Efficacy of treatment intensification with maraviroc on HIV-1 viral latency in recently infected HIV-1 naïve patients starting raltegravir plus tenofovir/emtricitabine (MaraviBoost).**

COMPANY: Pfizer  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 71.500 €  
PERIOD: **01/01/2009 – 31/12/2010**  
ROLE: Dr. J Martinez-Picado is Associate Researcher; Dr. J Blanco is Principal Investigator

PROJECT TITLE: **Genetic and phenotypic evolution of the HIV-1 integrase coding region in long-term antiretroviral-experienced patients.**

COMPANY: Merck & Co. (August 2007)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 76.550 €  
PERIOD: **08/2007 – 12/2008**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Impact of Raltegravir Intensification on HIV-1 viral latency in Patients with Previous Complete Viral Suppression: a 48 week randomized, controlled, open-label, proof-of-concept pilot clinical trial (Integral).**

COMPANY: Merck & Co. (August 2007)  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 155.000 € project budget, 90.000 € center budget  
PERIOD: **08/2007 – 12/2008**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

PROJECT TITLE: **Study of cell transport systems involved in the uptake of nucleoside analogs which inhibit the HIV-1 reverse transcriptase.**

COMPANY: Gilead Sciences S.L.  
CENTER: AIDS Research Institute IrsiCaixa  
FUNDING: 24.000 €  
PERIOD: **01/2003 – 12/2003**  
ROLE: Dr. J Martinez-Picado is Principal Investigator

## PUBLICATIONS

### Scholar Google Metrics:

- ❑ 269 original articles
- ❑ 27,172 citations
- ❑ 101 citations per article (average)
- ❑ 75 h-index

1. Bayón-Gil A, Martínez-Picado J\*, Puertas MC\*. **2025**. *Viremic non-progression in HIV/SIV infection: a tied game between virus and host*. **Cell Reports Medicine**, accepted.
2. Gunst J, Gohil J, Li J, Bosch R, White A, Seamon C, Chun T-W, Mothe B, Gittens K, Praiss L, De Scheerder M-A, Vandekerckhove L, Escandón K, Thorkelson A, Schacker T, SenGupta D, Brander C, Papisavvas E, Montaner L, Martínez-Picado J, Calin R, Castagna A, Muccini C, Jong W, Leal L, Garcia F, Gruters R, Tipoe T, Frater J, Søgaard O, Fidler S. **2025**. *Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: An individual data-based meta-analysis of 24 prospective studies*. **Nature Communications**, accepted.
3. Laguía F, Chojnacki J, Erkizia I, Geli MI, Enrich C, Martínez-Picado J\*, Resa-Infante P\*. **2025**. *Massive endocytosis mechanisms are involved in uptake of HIV-1 viral particles by monocyte-derived dendritic cells*. **Frontiers in Immunology** 15:1505840. doi: 10.3389/fimmu.2024.1505840.
4. González-Navarro I, Urrea V, Gálvez C, García-Guerrero MDC, Morón-López S, Puertas MC, Grau E, Mothe B, Bailón L, Miranda C, García F, Leal L, Vandekerckhove L, Marconi VC, Sekaly RP, Clotet B, Martínez-Picado J\*, Salgado M\*. **2025**. *Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir*. **Journal of Clinical Investigation** 135(2):e183952. doi: 10.1172/JCI183952.
5. Bailón L, Puertas MC, García-Guerrero MC, Moraes-Cardoso I, Aparicio E, Alarcón-Soto Y, Rivero A, Rosen EP, Estes JD, Blanco J, Olvera A, Mothe B, Martínez-Picado J\*, Moltó J\*. **2024**. *Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood*. **Journal of Infectious Diseases** jiae530. doi: 10.1093/infdis/jiae530.
6. Gualdrón-López M, Ayllon-Hermida A, Cortes-Serra N, Resa-Infante P, Bech-Serra JJ, Aparici-Herraiz I, Nicolau-Fernandez M, Erkizia I, Gutierrez-Chamorro L, Marfil S, Pradenas E, Ávila Nieto C, Cucurull B, Montaner-Tarbés S, Muelas M, Sotil R, Ballana E, Urrea V, Fraile L, Montoya M, Vergara J, Segales J, Carrillo J, Izquierdo-Useros N, Blanco J, Fernandez-Becerra C, de La Torre C, Pinazo MJ, Martínez-Picado J,\* Del Portillo HA\*. **2024**. *Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides*. **Frontiers in Cellular and Infection Microbiology** 14:1442743. doi: 10.3389/fcimb.2024.1442743.
7. Bayón-Gil Á, Hernández I, Dalmau J, Nieto JC, Urrea V, Garrido-Sanz L, Caratú G, García-Guerrero MC, Gálvez C, Salgado M, Erkizia I, Laguía F, Resa-Infante P, Massanella M, Tonda R, Morata J, Hong KY, Koshy J, Goldman AR, Giron L, Abdel-Mohsen M, Heyn H, Martínez-Picado J\*, Puertas MC\*. **2024**. *Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors*. **Med** 6, 100518. doi: 10.1016/j.medj.2024.09.007.
8. Fornt-Suñé M, Puertas MC, Martínez-Picado J, García-Pardo J, Ventura S. **2024**. *Protein nanoparticles for targeted SARS-CoV-2 trapping and neutralization*. **Advanced Healthcare Materials** 14:e2402744. doi: 10.1002/adhm.202402744.
9. Salgado M, Migueles SA, Yu XG, Martínez-Picado J. **2024**. *Exceptional, naturally occurring HIV-1 control: Insight into a functional cure*. **Med** 5(9):1071-1082. doi:10.1016/j.medj.2024.06.008.
10. Sáez-Cirió A, Mamez AC, Avettand-Fenoel V, Nabergoj M, Passaes C, Thoueille P, Decosterd L, Hentzien M, Perdomo-Celis F, Salgado M, Nijhuis M, Melard A, Gardiennet E, Lorin V, Monceaux V, Chapel A, Gourves M, Lechartier M, Mouquet H, Wensing A, Martínez-Picado J, Yerly S, Rougemont M, Calmy A. **2024**. *Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells*. **Nature Medicine** 30(12):3544-3554 doi: 10.1038/s41591-024-03277-z.
11. Gálvez C, Salgado M, Martínez-Picado J\*. **2024**. *40 years fighting the human immunodeficiency virus (HIV), but still no definitive cure*. *Treballs de la Societat Catalana de Biologia*, 74: 11-24. doi: 10.2436/20.1501.02.228
12. Bengu N, Cromhout G, Adland E, Govender K, Herbert N, Lim N, Fillis R, Sprenger K, Vieira V, Kannie S, van Lobenstein J, Chinniah K, Kapongo C, Bhoola R, Krishna M, Mchunu N, Pascucci GR, Cotugno N, Palma P, Tagarro A, Rojo P, Roider J, Garcia-Guerrero MC, Ochsenbauer C, Groll A, Reddy K, Giaquinto C, Rossi P, Hong S, Dong K, Ansari MA, Puertas MC, Ndung'u T, Capparelli E, Lichterfeld M, Martínez-Picado J, Kappes JC, Archary M, Goulder P. **2024**. *Sustained aviraemia despite anti-retroviral therapy non-adherence in male children following in utero HIV transmission*. **Nature Medicine** 30(10):2796-2804. https://doi.org/10.1038/s41591-024-03105-4.
13. Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, Jensen BO, Vandekerckhove L, Jurado M, Raj K, Schulze Zur Wiesch J, Bailén R, Eberhard JM, Nabergoj M, Hütter G, Saldaña-Moreno R, Oldford S, Barrett L, Ramirez MLM, Garba S, Gupta RK, Revollo B, Ferra-Coll C, Kuball J, Alter G, Sáez-Cirió A, Diez-Martin JL, Duke ER, Schiffer JT, Wensing A, Martínez-Picado J; IciStem Consortium. **2024**. *Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort*

- study. **Lancet HIV** 11(6):e389-e405. doi: 10.1016/S2352-3018(24)00090-0.
14. Resa-Infante P, Erkizia I, Muñoz-Trabudua X, Linty F, Bentlage AEH, Perez-Zsolt D, Muñoz-Basagoiti J, Raich-Regué D, Izquierdo-Useros N, Rispens T, Vidarsson G, [Martinez-Picado J](#). 2024 *Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy*. **Biomed Pharmacother** 175: 116726. doi: 10.1016/j.biopha.2024.116726.
  15. Izquierdo-Pujol J, Puertas MC, [Martinez-Picado J](#), Morón-López S. 2024 *Targeting Viral Transcription for HIV Cure Strategies*. **Microorganisms** 12(4), 752. doi.org/10.3390/microorganisms12040752
  16. O'Doherty U, [Martinez-Picado J](#), Sáez-Cirión A. 2023. *Highlights from the Inaugural HIV Reservoirs and Immune Control Conference, October 1st-4th 2023, Malahide Ireland*. **Pathogens and Immunity** 8(1):161-169. doi: 10.20411/pai.v8i1.653.
  17. Chumillas S, Loharch S, Beltrán M, Szewczyk MP, Bernal S, Puertas MC, [Martinez-Picado J](#), Alcami J, Bedoya LM, Marchán V, Gallego J. 2023. *Exploring the HIV-1 Rev Recognition Element (RRE)-Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs*. **Molecules** 28(20):7031. doi: 10.3390/molecules28207031.
  18. McLaren PJ, Porreca I, Iaconis G, Mok HP, Mukhopadhyay S, Karakoc E, Cristinelli S, Pomilla C, Bartha I, Thorball CW, Tough RH, Angelino P, Kiar CS, Carstensen T, Fatumo S, Porter T, Jarvis I, Skarnes WC, Bassett A, DeGorter MK, Sathya Moorthy MP, Tuff JF, Kim EY, Walter M, Simons LM, Bashirova A, Buchbinder S, Carrington M, Cossarizza A, De Luca A, Goedert JJ, Goldstein DB, Haas DW, Herbeck JT, Johnson EO, Kaleebu P, Kilembe W, Kirk GD, Kootstra NA, Kral AH, Lambotte O, Luo M, Mallal S, [Martinez-Picado J](#), Meyer L, Miro JM, Moodley P, Motala AA, Mullins JI, Nam K, Obel N, Pirie F, Plummer FA, Poli G, Price MA, Rauch A, Theodorou I, Trkola A, Walker BD, Winkler CA, Zagury JF, Montgomery SB, Ciuffi A, Hultquist JF, Wolinsky SM, Dougan G, Lever AML, Gurdasani D, Groom H, Sandhu MS, Fellay J. 2023. *Africa-specific human genetic variation near CHD1L associates with HIV-1 load*. **Nature** 620(7976):1025-1030. doi: 10.1038/s41586-023-06370-4.
  19. Rosado-Sánchez I, Herrero-Fernández I, Sobrino S, Carvajal AE, Genebat M, Tarancón-Díez L, García-Guerrero MC, Puertas MC, de Pablos RM, Ruiz R, [Martinez-Picado J](#), Leal M, Pacheco YM. 2023. *Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection*. **Journal of Microbiology, Immunology and Infection** 56(6):1129-1138. doi: 10.1016/j.jmii.2023.08.011. Online ahead
  20. Bernal S, Puertas MC, Morón-López S, Cranston RD, Urrea V, Dalmau J, Salgado M, Gálvez C, Erkizia I, McGowan I, Scherrer D, Revollo B, Sirera G, Santos JR, Clotet B, Paredes R, [Martinez-Picado J](#). 2023. *Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy*. **Journal of Infectious Diseases** 228(9):1280-1291. doi: 10.1093/infdis/jiad251.
  21. García-González L, Martí-Sarrias A, Puertas MC, Bayón-Gil Á, Resa-Infante P, [Martinez-Picado J](#), Navarro A, Acosta S. 2023. *Understanding the neurological implications of acute and long COVID using brain organoids*. **Disease Models & Mechanisms**, 16(7):dmm050049. doi: 10.1242/dmm.050049. Epub 2023 Jul 17.
  22. Duran-Castells C, Prats A, Oriol-Tordera B, Llano A, Galvez C, [Martinez-Picado J](#), Ballana E, Garcia-Vidal E, Clotet B, Muñoz-Moreno JA, Hanke T, Moltó J, Mothe B, Brander C, Ruiz-Riol M. 2023. *Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination*. **EbioMedicine** 95:104732. doi: 10.1016/j.ebiom.2023.104732.
  23. Paton B, Herrero P, Peraire J, Del Pino A, Chafino S, [Martinez-Picado J](#), Gómez-Bertomeu F, Rull A, Canela N, Suárez M. 2023. *Fucosylated N-glycans as early biomarkers of COVID-19 severity*. **Frontiers in Immunology** 14:1204661. doi: 10.3389/fimmu.2023.1204661.
  24. Campos-Gonzalez G, [Martinez-Picado J](#), Velasco-Hernandez T, Salgado M. 2023. *Opportunities for CAR-T Cell Immunotherapy in HIV Cure*. **Viruses** 15(3):789. doi: 10.3390/v15030789.
  25. Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, Zhang Y, Bolze A, Chaldebass M, Milisavljevic B, Gervais A, Bastard P, Asano T, Bizien L, Barzaghi F, Abolhassani H, Abou Tayoun A, Aiuti A, Alavi Darazam I, Allende LM, Alonso-Arias R, Arias AA, Aytakin G, Bergman P, Bondesan S, Bryceson YT, Bustos IG, Cabrera-Marante O, Carcel S, Carrera P, Casari G, Chaïbi K, Colobran R, Condino-Neto A, Covill LE, Delmonte OM, El Zein L, Flores C, Gregersen PK, Gut M, Haerynck F, Halwani R, Hancerli S, Hammarström L, Hatipoğlu N, Karbuz A, Keles S, Kyheng C, Leon-Lopez R, Franco JL, Mansouri D, [Martinez-Picado J](#), Metin Akcan O, Migeotte I, Morange PE, Morelle G, Martin-Nalda A, Novelli G, Novelli A, Ozelik T, Palabiyik F, Pan-Hammarström Q, de Diego RP, Planas-Serra L, Pleguezuelo DE, Prando C, Pujol A, Reyes LF, Rivière JG, Rodriguez-Gallego C, Rojas J, Rovere-Querini P, Schlüter A, Shahrooei M, Sobh A, Soler-Palacin P, Tandjaoui-Lambiotte Y, Tipu I, Tresoldi C, Troya J, van de Beek D, Zatz M, Zawadzki P, Al-Muhsen SZ, Alosaimi MF, Alshohime FM, Baris-Feldman H, Butte MJ, Constantinescu SN, Cooper MA, Dalgard CL, Fellay J, Heath JR, Lau YL, Lifton RP, Maniatis T, Mogensen TH, von Bernuth H, Lermine A, Vidaud M, Boland A, Deleuze JF, Nussbaum R, Kahn-Kirby A, Mentre F, Tubiana S, Gorochov G, Tubach F, Hausfater P; COVID Human Genetic Effort; COVIDeF Study Group; French COVID Cohort Study Group; CoV-Contact Cohort; COVID-STORM Clinicians; COVID Clinicians; Orchestra Working Group; Amsterdam UMC Covid-19 Biobank; NIAID-USUHS COVID Study Group; Meyts I, Zhang SY, Puel A, Notarangelo LD, Boisson-Dupuis S, Su HC, Boisson B, Jouanguy E, Casanova JL, Zhang Q, Abel L, Cobat A. 2023. *Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19*. **Genome Medicine** 15(1):22. doi: 10.1186/s13073-023-01173-8.
  26. Morón-López S, Riveira-Muñoz E, Urrea V, Gutiérrez-Chamorro L, Ávila-Nieto C, Noguera-Julian M, Carrillo J, Mitjà O, Mateu L, Massanella M, Ballana E, [Martinez-Picado J](#). 2023. *Comparison of reverse-transcription qPCR and droplet digital PCR detecting genomic and subgenomic SARS-CoV-2 RNA*. **Microbiology Spectrum** 11(2):e0415922. doi: 10.1128/spectrum.04159-22.
  27. Gutiérrez-Martínez E, Benet Garrabé S, Mateos N, Erkizia I, Nieto-Garai JA, Lorizate M, Borgman KJE, Manzo C, Campelo F, Izquierdo-Useros N, [Martinez-Picado J](#).

- Picado J\*, Garcia-Parajo MF\*. **2023**. *Actin-regulated Siglec-1 nanoclustering influences HIV-1 capture and virus-containing compartment formation in dendritic cells*. **eLife** 12:e78836. doi: 10.7554/eLife.78836.
28. Archin N, Bar KJ, Burdo T, Caskey M, Chahroudi A, Farzan M, Ho Y-C, Jones RB, Kearney M, Kuritzkes D, Margolis D, Martinez-Picado D, Okoye A, Salgado M, Stevenson M. **2023**. *Highlights from the 10th International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA*. **Journal of Virus Eradication** 9:100315.
  29. Raïch-Regué D, Resa-Infante P, Gallemí M, Laguia F, Muñiz-Trabudua X, Muñoz-Basagoiti J, Perez-Zsolt D, Chojnaki J, Benet S, Clotet B, Martinez-Picado J, Izquierdo-Useros M. **2023**. *Role of Siglecs in viral infections: a double-edged sword interaction*. **Molecular Aspects of Medicine** 90:101113. doi.org/10.1016/j.mam.2022.101113
  30. Jensen BO, Knops E, Cords L, Lübke N, Salgado M, Busman-Sahay K, Estes JD, Huyveneers LEP, Perdomo-Celis F, Wittner M, Gálvez C, Mummert C, Passaes C, Eberhard JM, Münk C, Hauber I, Hauber J, Heger E, De Clercq J, Vandekerckhove L, Bergmann S, Dunay GA, Klein F, Häussinger D, Fischer JC, Nachtkamp K, Timm J, Kaiser R, Harrer T, Luedde T, Nijhuis M, Sáez-Cirión A\*, Schulze zur Wiesch J\*, Wensing AMJ\*, Martinez-Picado J\*, Kobbe G\*. **2023**. *In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation*. **Nature Medicine** 29(3):583-587. doi: 10.1038/s41591-023-02213-x.
  31. Duran-Castells C, Llano A, Kawana-Tachikawa A, Prats A, Martinez-Zalacain I, Kobayashi-Ishihara M, Oriol-Tordera B, Peña R, Gálvez C, Silva-Arrieta S, Clotet B, Riveira-Muñoz E, Ballana E, Prado JG, Martinez-Picado J, Sanchez J, Mothe B, Hartigan-O'Connor D, Wyss-Coray T, Meyerhans A, Gisslén M, Price RW, Soriano-Mas C, Muñoz-Moreno JA, Brander C, Ruiz-Riol M. **2023**. *Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction*. **Journal of Virology** 97(2):e0165522. doi: 10.1128/jvi.01655-22
  32. Gunst JD, Pahus MH, Rosás-Umbert M, Lu IN, Benfield T, Nielsen H, Johansen IS, Mohey R, Østergaard L, Klastrup V, Khan M, Schleimann MH, Olesen R, Støvring H, Denton PW, Kinloch NN, Copertino DC, Ward AR, Alberto WDC, Nielsen SD, Puertas MC, Ramos V, Reeves JD, Petropoulos CJ, Martinez-Picado J, Brumme ZL, Jones RB, Fox J, Tolstrup M, Nussenzweig MC, Caskey M, Fidler S, Søgaard OS. **2022**. *Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial*. **Nature Medicine** 28: 2424–2435. doi: 10.1038/s41591-022-02023-7
  33. Gonzalez-Aumatell A, Bovo MV, Carreras-Abad C, Cuso-Perez S, Domènech Marsal E, Coll Fernández R, Goicoechea Calvo A, Giral López M, Ensenyat Cantallops A, Moron-Lopez S, Martinez-Picado J, Sol Ventura P, Rodrigo C, Méndez Hernández M. **2022**. *Social, academic, and health status impact of long COVID on children and young people: an observational, descriptive and longitudinal cohort study*. **Children** 9(11):1677. doi: 10.3390/children9111677
  34. Huyveneers LEP, Bruns A, Stam A, Ellerbroek P, de Jong D, Nagy NA, Gumbs SBH, Tesselaar K, Bosman K, Salgado M, Hütter G, Brosens LAA, Kwon M, Diez Martin J, van der Meer JTM, de Kort TM, Sáez-Cirión A, Schulze Zur Wiesch J, Boelens JJ, Martinez-Picado J, Kuball JHE, Wensing AMJ, Nijhuis M; IciStem Consortium. **2022**. *Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells*. **Viruses** 14(9):2069. doi: 10.3390/v14092069.
  35. Ezeonwumelu IJ, García-Vidal E, Felip E, Puertas MC, Oriol-Tordera B, Gutiérrez-Chamorro L, Gohr A, Ruiz-Riol M, Massanella M, Clotet B, Martinez-Picado J, Badia R, Riveira-Muñoz E, Ballana E. **2022**. *IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation*. **Frontiers in Immunology** 13: 1001068. doi: 10.3389/fimmu.2022.1001068
  36. Odeny TA, Lurain K, Strauss J, Fling SP, Sharon E, Wright A, Martinez-Picado J, Morán T, Gulley JL, Gonzalez-Cao M, Uldrick TS, Yarchoan R, Ramaswami R. **2022**. *Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer*. **Journal for ImmunoTherapy of Cancer** 10:e005128. doi:10.1136/jitc-2022-005128
  37. Gálvez C, Urrea V, Garcia-Guerrero MDC, Bernal S, Benet S, Mothe B, Bailón L, Dalmau J, Martinez A, Nieto A, Leal L, García F, Clotet B, Martinez-Picado J\*, Salgado M\*. **2022**. *Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA*. **Journal of Internal Medicine** 292(2):308-320. doi: 10.1111/joim.13484.
  38. Izquierdo-Pujol J, Moron-Lopez S, Dalmau J, Gonzalez-Aumatell A, Carreras-Abad C, Mendez M, Rodrigo C, Martinez-Picado J. **2022**. *Post COVID-19 condition in children and adolescents: an emerging problem*. **Frontiers in Pediatrics** 10:894204. doi: 10.3389/fped.2022.894204
  39. Bastard P, Vazquez SE, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon P, Kenney H, Fekkar A, Salaggianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo-Sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A, Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui-Lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif-Askari NS, Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Keles S, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailhoaie O, Antolí A, Jeziorski E, Rocamora-Blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan-Hammarström Q, Abolhassani H, Bompoil T, Dorgham K; COVID HGE Consortium; French COVID Study Group; COMET Consortium; Gorochov G, Laouenan C, Rodríguez-Gallego C, Ng LFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martinez-Picado J, Ozcelik T, Imberti L, Notarangelo LD, Troya J, Solanich X, Zhang SY, Puel A, Wilson MR, Trouillet-Assant S, Abel L, Jouanguy E, Ye CJ, Cobat A, Thompson LM, Andreakos E, Zhang Q, Anderson MS, Casanova JL, DeRisi JL. **2022**. *Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs*. **Science Immunology** 8(90):eabp8966. doi:10.1126/sciimmunol.abp8966



40. Bengu N, Mchunu N, Mokhethi S, Fillis R, Cromhout G, Lobenstein JV, Graza Y, Kapongo C, Chinniah K, Bhoola R, Adland E, Puertas MC, Ndung'u T, Martinez-Picado J, Archary M, Goulder PJR. **2022**. *Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment*. **Medicine (Baltimore)** 101(27):e29228. doi: 10.1097/MD.00000000000029228
41. Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau J, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulangeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhahay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari FS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Erikstrup C, Condino-Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital, SARS CoV2 Interest Group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank Investigators; COVID Human Genetic Effort; CP-COVID-19 Group; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement Français du Sang Study group, Anderson MS, Boisson B, Béziat V, Zhang SY, Andreaskos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Burdet C, Bouadma L, Zins M, Soler-Palacin P, Colobran R, Gorochoy G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Casanova JL, Abel L, Cobat A. **2022**. *The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies*. **Proceedings of the National Academy of Sciences of the USA** 119(21):e2200413119. doi: 10.1073/pnas.2200413119.
42. Borgognone A, Noguera-Julian M, Oriol B, Noël-Romas L, Ruiz-Riol M, Guillén Y, Parera M, Casadellà M, Duran C, Puertas MC, Català-Moll F, De Leon M, Knodel S, Birse K, Manzardo C, Miró JM, Clotet B, Martinez-Picado J, Moltó J, Mothe B, Burgener A, Brander C, Paredes R; BCNo2 Study Group. **2022**. *Gut microbiome signatures linked to HIV-1 reservoir size and viremia control*. **Microbiome** 10(1):59. doi: 10.1186/s40168-022-01247-6.
43. Zhang Q, et al. (Martinez-Picado J is collaborator). **2022**. *Human genetic and immunological determinants of critical COVID-19 pneumonia*. **Nature** 603(7902):587-598. doi: 10.1038/s41586-022-04447-0.
44. Oriol-Tordera B, Esteve-Codina A, Berdasco M, Rosás-Umbert M, Gonçalves E, Duran-Castells C, Català-Moll F, Llano A, Cedeño S, Puertas MC, Tolstrup M, Søgaard OS, Clotet B, Martinez-Picado J, Hanke T, Combadiere B, Paredes R, Hartigan-O'Connor D, Esteller M, Meulbroek M, Calle ML, Sanchez-Pla A, Moltó J, Mothe B, Brander C, Ruiz-Riol M. **2022**. *Epigenetic landscape in the kick-and-kill therapeutic vaccine BCNo2 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome*. **EBioMedicine** 78:103956. doi: 10.1016/j.ebiom.2022.103956.
45. Moron-Lopez S, Bernal S, Wong JK, Martinez-Picado J\*, Yukl SA\*. **2022**. *ABX464 decreases the total HIV reservoir and HIV transcription initiation in CD4+ T cells from HIV-infected ART-suppressed individuals*. **Clinical Infectious Diseases** 74(11): 2044-2049. doi: 10.1093/cid/ciab733
46. Bouza E, Arribas JR, Alejos B, Bernardino JJ, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martinez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamecz D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E. **2022**. *Past and future of HIV infection. A document based on expert opinion*. **Revista Española de Quimioterapia** 35(2):131-156. doi: 10.37201/req/083.2021.
47. Colomer-Lluch M, Kilpelainen A, Pernas M, Peña R, Ouchi D, Jimenez-Moyano E, Dalmau J, Casado C, López-Galíndez C, Clotet B, Martinez-Picado J, Prado JG. **2022**. *Viral and Cellular factors leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors*. **Journal of Virology** 96(1):e0149921. doi: 10.1128/JVI.01499-21
48. Vieira VA, Millar J, Adland E, Muenchhoff M, Roider J, Guash CF, Peluso D, Thomé B, Garcia-Guerrero MC, Puertas MC, Bamford A, Brander C, Carrington M, Martinez-Picado J, Frater J, Tudor-Williams G, Goulder P. **2022**. *Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish the rare phenotype of elite control in adolescents living with HIV from viraemic non-progressors*. **AIDS** 36(1):95-105. doi: 10.1097/QAD.0000000000003078
49. Gálvez C, Grau-Expósito J, Urrea V, Clotet B, Falcó V, Buzón MJ, Martinez-Picado J. **2021**. *Atlas of the HIV-1 reservoir in peripheral CD4 T cells of individuals on successful antiretroviral therapy*. **mBio** 12(6):e03078-21. doi:10.1128/mBio.03078-21
50. Vieira VA, Adland E, Muenchhoff M, Garcia-Guerrero MC, Puertas, Claudia MC, Fortuny C, Martin MP, Brander C, Malone D, Groll A, Ansari A, Martinez-Picado J, Bamford A, Tudor-Williams G, Ndung'u T, Walker BD, Ramsuran V, Frater J, Jooste P, Peppia D, Carrington M, PLoS Pathog 2021, **PJR**. **2021**. *An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults*. **PLoS Pathogens** 17(11):e1010090. doi: 10.1371/journal.ppat.1010090
51. Perez-Zsolt D, Muñoz-Basagoiti J, Rodon J, Elosua-Bayes M, Raich-Regué D, Risco C, Sachse M, Pino M,

- Gumber S, Paiardini M, Chojnacki J, Erkizia I, Muñiz-Trabudua X, Ballana E, Riveira-Muñoz E, Noguera-Julian M, Paredes R, Trinité B, Tarrés-Freixas F, Blanco I, Guallar V, Carrillo J, Blanco J, Telenti A, Heyn H, Segalés J, Clotet B, Martínez-Picado J\*, Vergara-Alert J\*, Izquierdo-Useros N\*. **2021. SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cellular and Molecular Immunology** 18(12):2676-2678. doi: 10.1038/s41423-021-00794-6
52. Lempp FA, Soriaga L, Montiel-Ruiz M, Benigni F, Noack J, Park YJ, Bianchi S, Walls AC, Bowen JE, Zhou J, Kaiser H, Joshi A, Agostini M, Meury M, Dellota E Jr, Jaconi S, Camerani E, Martínez-Picado J, Vergara-Alert J, Izquierdo-Useros N, Virgin HW, Lanzavecchia A, Vesler D, Purcell L, Telenti A, Corti D. **2021. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature** 598(7880):342-347. doi: 10.1038/s41586-021-03925-1
53. Puertas MC, Bayón-Gil Á, García-Guerrero MC, Salgado M, Urrea V, Morón-López S, Peña R, Jiménez-Moyano E, Clotet B, Prado JG, Martínez-Picado J\*. **2021. VIP-SPOT: an innovative assay to quantify the productive HIV-1 reservoir in the monitoring of cure strategies. mBio.** 12(3):e0056021. doi: 10.1128/mBio.00560-21
54. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, García-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekanu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrell S, Duffy D, Quintana-Murci L, Klopperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulangeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group, Anderson MS, Boisson B, Béziat V, Zhang SY, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martínez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova JL. **2021. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology** 6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340
55. Asano T, et al. (Martínez-Picado J is collaborator). **2021. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology** 6(62), eabl4348. doi: 10.1126/sciimmunol.abl4348.
56. Vigón L, Martínez-Román P, Rodríguez-Mora S, Torres M, Puertas MC, Mateos E, Salgado M, Navarro A, Sánchez-Conde M, Ambrosioni J, Cervero M, Wyen C, Hoffmann C, Miró JM, Alcamí J, Podzameczer D, García-Gutiérrez V, Martínez-Picado J, Briz V, Rosa López-Huertas M, Planelles V, Coiras M.; Multidisciplinary Group of Study of HIV-1 Reservoir MGS-HIVRES. **2021. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology** 192:114666. doi: 10.1016/j.bcp.2021.114666
57. Rokx C, Prins HAB, Vandekerckhove L, Fidler SJ, Frater J, Bracchi M, Søgaard OS, Tolstrup M, Rasmussen TA, Salgado M, Blanco J, Martínez-Picado J, Clotet B, Tambussi G, Groenendijk A, Verbon A, Boucher CAB. **2021. Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium. Journal of Virus Eradication** 7(2):100045. doi: 10.1016/j.jve.2021.100045
58. Millar JR, Bengu N, Vieira VA, Adland E, Roeder J, Muenchhoff M, Fillis R, Sprenger K, Ntantsana V, Fatti I, Archary M, Groll A, Ismail N, García-Guerrero MC, Matthews PC, Ndung'u T, Puertas MC, Martínez-Picado J\*, Goulder P\*. **2021. Early initiation of antiretroviral therapy following in utero HIV infection is associated with low viral reservoirs but other factors determine subsequent plasma viral rebound. Journal of Infectious Diseases** 224(11):1925-1934. doi: 10.1093/infdis/jiab223.
59. Benet S, Gálvez C, Drobniowski F, Kontsevaya I, Arias L, Monguió-Tortajada M, Erkizia I, Urrea V, Ong R-Y, Luquin M, Dupont M, Chojnacki J, Dalmau J, Cardona P, Neyrolles O, Lugo-Villarino G, Vérolet C, Julián E, Furrer H, Günthard HF, Crocker PR, Tapia G, Borràs FE, Fellay J, McLaren PJ, Telenti A, Cardona P-J, Clotet B, Vilaplana C\*, Martínez-Picado J\*, Izquierdo-Useros N\*. **2021. Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles** 10:e12046. doi: 10.1002/jev2.12046.
60. Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzameczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martínez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). **2021. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Journal of Immunotherapy of Cancer** 9(3):e001664. doi: 10.1136/jitc-2020-001664.

61. De Scheerder MA, van Bilsen WHP, Dullaers M, [Martinez-Picado J](#), Davidovich U, Vandekerckhove L. **2021**. *Motivations, barriers and experiences of participants in an HIV reservoir trial*. **Journal of Virus Eradication** 7(1):100029. doi: 10.1016/j.jve.2021.100029.
62. Moltó J, Rosás-Umbert M, Miranda C, Manzardo C, Puertas MC, Ruiz-Riol M, López M, Miró JM, [Martinez-Picado J](#), Clotet B, Brander C, Mothe B\*, Valle M\*. **2021**. *Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent*. **Journal of Antimicrobial Chemotherapy** 76(4):1032-1040. doi: 10.1093/jac/dkaa523.
63. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, [Martinez-Picado J](#), Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. **2020**. *Autoantibodies against type I IFNs in patients with life-threatening COVID-19*. **Science** 370(6515): eabd4585. doi: 10.1126/science.abd4585
64. Zhang Q, *et al.* ([Martinez-Picado J](#) is collaborator). **2020**. *Inborn errors of type I IFN immunity in patients with life-threatening COVID-19*. **Science** 370(6515): eabd4570. doi: 10.1126/science.abd4570
65. Oriol-Tordera B, Olvera A, Duran-Castells C, Llano A, Mothe B, Massanella M, Dalmau J, Ganoza C, Sanchez J, Calle ML, Clotet B, [Martinez-Picado J](#), Negredo E, Blanco J, Hartigan-O'Connor D, Brander C, Ruiz-Riol M. **2020**. *TL1A-DR3 plasma levels are predictive of HIV-1 disease control, and DR3 costimulation boosts HIV-1-specific T cell responses*. **Journal of Immunology** 205(12):3348-3357. doi: 10.4049/jimmunol.2000933
66. Imaz A, Tiraboschi JM, Niubó J, [Martinez-Picado J](#), Cottrell ML, Domingo P, Chivite I, Negredo E, Schauer A, Van Horne B, Morenilla S, Urrea V, Silva-Klug A, Scevola S, Garcia B, Kashuba ADM, Podzamczar D. **2020**. *Dynamics of the decay of HIV RNA and distribution of bictegrovir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegrovir/emtricitabine/tenofovir alafenamide*. **Clinical Infectious Diseases** 73(7): 1991-1999. doi: 10.1093/cid/ciaa1416.
67. Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, [Martinez-Picado J](#), Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcamí J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ; BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection. **2020**. *Recommendations for measuring HIV reservoir size in cure-directed clinical trials*. **Nature Medicine**. 26(9):1339-50. doi: 10.1038/s41591-020-1022-1.
68. Gonzalez-Cao M, [Martinez-Picado J](#), Rosell R. **2020**. *Safety of anti-PD-L1 inhibition in HIV-1-infected patients with cancer - Reply*. **JAMA Oncology** doi: 10.1001/jamaoncol.2020.3400.
69. Oriol-Tordera B, Berdasco M, Llano A, Mothe B, Gálvez C, [Martinez-Picado J](#), Carrillo J, Blanco J, Duran-Castells C, Ganoza C, Sanchez J, Clotet B, Calle ML, Sánchez-Pla A, Esteller M, Brander C, Ruiz-Riol M. **2020**. *Methylation regulation of antiviral host factors, interferon stimulated genes (ISGs) and T-cell responses associated with natural HIV control*. **PLoS Pathogens** 16(8):e1008678. doi: 10.1371/journal.ppat.1008678.
70. Moron-Lopez S, Urrea V, Dalmau J, Lopez M, Puertas MC, Ouchi D, Gómez A, Passaes C, Mothe B, Brander C, Saez-Cirion A, Clotet B, Esteller M, Berdasco M, [Martinez-Picado J](#). **2020**. *The genome-wide methylation profile of CD4+ T cells from HIV-infected individuals identifies distinct patterns associated with disease progression*. **Clinical Infectious Diseases** 72(9):e256-e264. doi: 10.1093/cid/ciaa1047.
71. Gálvez C, Urrea V, Dalmau J, Jimenez M, Clotet B, Monceaux V, Huot N, Leal L, González-Soler V, González-Cao M, Müller-Trutwin M, Sáez-Cirion A, García F, Blanco J, [Martinez-Picado J](#)\*, Salgado M\*. **2020**. *Extremely Low Viral Reservoir in Treated Chronically HIV-1-infected individuals*. **EBioMedicine** 57: 102830. doi: 10.1016/j.ebiom.2020.102830
72. Puertas MC, Ploumidis G; Ploumidis M, Fumero E, Clotet B, Walworth CM, Petropoulos CJ, [Martinez-Picado J](#). **2020**. *Pan-resistant HIV-1 emergence in the INSTI era: a case study*. **Lancet Microbe** 1(3): e130-e135, doi: 10.1016/S2666-5247(20)30006-9.
73. Eberhard JM, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopheit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball JHE, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín JL, Nijhui A, [Martinez-Picado J](#), Schulze zur Wiesch J, Sáez-Cirion A. **2020**. *Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1*. **Science Translational Medicine** 12(542): eaay9355. doi: 10.1126/scitranslmed.aay9355
74. Toda H, Diaz-Varela M, Segui-Barber J, Roobsoong W, Baro B, Garcia-Silva S, Galiano A, Gualdrón-López M, Almeida ACG, Brito MAM, Cardoso de Melo G, Aparici-Herraiz I, Castro-Cavada C, Monteiro WM, Borrás E, Sabido E, Almeida IC, Chojnacki J, [Martinez-Picado J](#), Calvo M, Armengol P, Carmona-Fonseca J, Yasnot MF, Lauzurica R, Marcilla A, Peinado H, Galinski MR, Lacerda MVG, Sattabongkot J, Fernandez-Becerra C, del Portillo HA. **2020**. *Plasma-derived extracellular vesicles from Plasmodium vivax patients signal spleen fibroblasts via NF-κB facilitating parasite cytoadherence*.



75. Bayón-Gil A, Puertas MC, Urrea V, Bailón L, Morón-López S, Cobarsí P, Brander C, Mothe B, Martínez-Picado J. 2020. HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. **Journal of Antimicrobial Chemotherapy** 75(8):2258-63. doi: 10.1093/jac/dkaa139.
76. Mothe B, Rosás-Umbert M, Coll P, Manzardo C, Puertas MC, Morón-López S, Llano A, Miranda C, Cedeño S, López M, Alarcón Soto Y, Gómez Melis G, Langohr K, Barriocanal AM, Toro J, Ruiz I, Rovira C, Carrillo A, Meulbroek M, Crook A, Wee EG, Miró EG, Clotet B, Valle M, Martínez-Picado J, Hanke T, Brander C, Moltó J. 2020. HIVconsv vaccines and romidepsin in early-treated HIV-1 infected individuals: Safety, immunogenicity and effect on the viral reservoir (study BCNo2). **Frontiers in Immunology** 11:823. doi: 10.3389/fimmu.2020.00823.
77. García M, López-Fernández L, Mínguez P, Morón-López S, Restrepo C, Navarrete-Muñoz MA, López-Bernaldo JC; Benguría A, García MI, Cabello A, Fernández Guerrero M, De la Hera FJ, Estrada V, Barros C, Martínez-Picado J, Górgolas M, Benito JM, Rallón N. 2020. Transcriptional signature of resting-memory CD4 T-cells differentiates spontaneous from treatment-induced HIV control. **Journal of Molecular Medicine** 98:1093-105. doi: 10.1007/s00109-020-01930-x.
78. Millar JR, Bengu N, Fillis R, Sprenger K, Ntlantsana V, Vieira VA, Khambati N, Archary M, Muenchhoff M, Groll A, Grayson N, Adamson J, Govender K, Dong K, Kiepiela P, Walker BD, Bonsall D, Connor T, Bull MJ, Nxele N, Roeder J, Ismail N, Adland E, Puertas MC, Martínez-Picado J, Matthews PC, Ndung'u T, Goulder P; Ucwangingo Lwabantwana Consortium. 2020. High-frequency failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal non-adherence. **EclinicalMedicine** 22:100344. doi: 10.1016/j.eclinm.2020.100344.
79. Gonzalez-Cao M, Moran T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, Juan O, de Castro J, Blanco R, Drozdowskyj A, Argilagué J, Meyerhans A, Blanco J, Prado JG, Carrillo J, Clotet B, Massuti B, Provencio M, Molina-Vila MA, Mayo de las Casas C, Garzon M, Cao P, Huang C-Y, Martínez-Picado J\*, Rosell R\*, for the Spanish Lung Cancer Group. 2020. *Durvalumab in HIV-1-infected patients with solid tumors*. **JAMA Oncology** 6(7):1063-1067. doi: 10.1001/jamaoncol.2020.0465.
80. Adland E, Millar J, Bengu N, Muenchhoff M, Fillis R, Sprenger K, Ntlantsana V, Roeder J, Vieira V, Govender K, Adamson J, Nxele N, Ochsensbauer C, Kappes J, Mori L, van Lobenstein J, Graza Y, Chinniah K, Kapongo C, Bhoola R, Krishna M, Matthews PC, Poderos RP, Lluch MC, Puertas MC, Prado JG, McKerrow N, Archary M, Ndung'u T, Groll A, Jooste P, Martínez-Picado J, Altfeld M, Goulder P. 2020. Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. **Nature Communications** 11(1):1767. doi: 10.1038/s41467-020-15632-y.
81. Andrade VM, Mavian C, Babic D, Cordeiro T, Sharkey M, Barrios L, Brander C, Martínez-Picado J, Dalmau J, Llano A, Li JZ, Jacobson J, Lavine CL, Seaman MS, Salemi M, Stevenson M. 2020. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. **Proceedings of the National Academy of Sciences of the USA** 117(18): 9981-9990. doi: 10.1073/pnas.1917034117.
82. Dupont M, Souriant S, Balboa L, Vu Manh TP, Pingris K, Rousset S, Cougoule C, Rombouts Y, Poincloux R, Ben Neji M, Allers C, Kaushal D, Kuroda MJ, Benet S, Martínez-Picado J, Izquierdo-Useros N, Sasiain MDC, Maridonneau-Parini I, Neyrolles O, Vérolet C, Lugo-Villarino G. 2020. Tuberculosis-associated type I interferon induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages. **eLife** pii: e52535. doi: 10.7554/eLife.52535.
83. Gupta RK, Peppas D, Hill AL, Gálvez C, Salgado M, Pace M, McCoy LE, Griffith SA, Thornhill J, Alrubayyi A, Huyvenerers LEP, Nastouli, Grant P, Edwards SG, Innes A, Frater J, Nijhuis M, Wensing AMJ, Martínez-Picado J, Olavarria E. 2020. Evidence for HIV-1 cure in The London Patient: a case report. **The Lancet HIV**, pii: S2352-3018(20)30069-2. doi: 10.1016/S2352-3018(20)30069-2.
84. Casado C, Gálvez C, Pernas M, Tarancón-Diez L, Rodríguez C, Sánchez-Merino V, Vera M, Olivares I, De Pablo-Bernal R, Merino-Mansilla A, Del Romero J, Lorenzo-Redondo R, Ruiz-Mateos E, Salgado M, Martínez-Picado J\*, Lopez-Galindez C\*. 2020. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. **Scientific Reports** 10:1902. Doi: 10.1038/s41598-020-58696-y.
85. Perez-Zsolt D, Martínez-Picado J\*, Izquierdo-Useros N\*. 2020. *When DCs Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses*. **Viruses** 12(1):8. doi: 10.3390/v12010008.
86. Salgado M, Martínez-Picado J, Gálvez, Rodríguez-Mora S, Rivaya B, Urrea V, Mateos E, Alcamí J, Coiras M. 2020. Dasatinib protects humanized mice from acute HIV-1 infection. **Biochemical Pharmacology** 174:113625 doi: 10.1016/j.bcp.2019.113625.
87. Blanch-Lombarte O, Gálvez C, Revollo B, Jiménez-Moyano E, Llibre JM, Manzano JL, Boada A, Dalmau J, Speiser DE, Clotet B, Prado JG, Martínez-Picado J. 2019. Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1-infected subject treated with pembrolizumab. **Journal of Clinical Medicine**. 8(12). pii:E2089. doi: 10.3390/jcm8122089.
88. Jong W, Leal L, Buyze J, Pannus P, Guardo A, Salgado M, Mothe B, Moltó J, Moron-López S, Gálvez C, Florence E, Vanham G, van Gorp E, Brander C, Allard S, Thielemans K, Martínez-Picado J, Plana M, García F, Gruters R. 2019. Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase IIa trial with HTI-TriMix. **Vaccines** 7(4). pii:E209. doi: 10.3390/vaccines7040209.
89. Perez-Zsolt D, Erkizia I, Pino M, García-Gallo M, Martín MT, Benet S, Chojnacki J, Fernández-Figueras MT, Guerrero D, Urrea V, Muñoz-Trabudua X, Kremer L, Martínez-Picado J\*, Izquierdo-Useros N\*. 2019. Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. **Nature Microbiology** 4(9):1558-70. doi: 10.1038/s41564-019-0453-2.
90. Perez-Zsolt D, Cantero-Pérez J, Erkizia I, Benet S, Pino M, Serra-Peinado C, Hernández-Gallego A, Castellví J, Tapia G, Arnau-Saz V, Garrido J, Tarrats A, Buzón MJ, Martínez-Picado J, Izquierdo-Useros N,



- Genescà M. **2019.** *Dendritic cells from the cervical mucosa capture and transfer HIV-1 via Siglec-1.* **Frontiers in Immunology** 10:825. doi: 10.3389/fimmu.2019.00825.
91. Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T, for theBCN01 study group. **2019.** *Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).* **EClinicalMedicine** 11:65-80. doi: 10.1016/j.eclinm.2019.05.009. 10.1016/j.eclinm.2019.05.009.
92. Millar JR, Mvo Z, Bengu N, Fillis R, Sprenger K, Matthews PC, Archary M, Ndung'u T, Adland E, Puertas MC, Martinez-Picado J, Goulder P. **2019.** *Increasing diagnostic uncertainties in children with in utero HIV infection. The Pediatric Infectious Disease Journal* 38(8):e166-e168. doi: 10.1097/INF.0000000000002315.
93. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. **2019.** *Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.* **The Lancet HIV** 6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9.
94. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppia D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E. **2019.** *HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.* **Nature** 568(7751):244-8. doi: 10.1038/s41586-019-1027-4.
95. Moron-Lopez S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, Torrella A, Clercq L, Ribas BP, Gálvez C, Salgado M, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J. **2019.** *Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals.* **Clinical Infectious Diseases** 69(8):1320-1328. doi: 10.1093/cid/ciy1095.
96. Ruiz A, Blanch-Lombarte O, Jimenez-Moyano E, Ouchi D, Mothe B, Peña R, Galvez C, Genescà M, Martinez-Picado J, Goulder P, Barnard R, Howell B, Clotet B, Prado JG. **2019.** *Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells.* **Frontiers in Immunology** 9:3162. doi: 10.3389/fimmu.2018.03162.
97. Muncunill J, Baptista MJ, Hernandez-Rodríguez Á, Dalmau J, García O, Tapia G, Moreno M, Sancho JM, Martinez-Picado J, Feliu E, Mate JL, Ribera JM, Navarro JT. **2019.** *Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas.* **Clinical Infectious Diseases** 68(5):834-43. doi: 10.1093/cid/ciy542.
98. Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. **2019.** *Cancer immunotherapy of patients with HIV infection.* **Clinical and Translational Oncology** 21(6):713-720. doi: 10.1007/s12094-018-1981-6. Review
99. Salgado M, Kwon M, Gálvez C, Badiola J, Nijhuis M, Bandera A, Balsalobre P, Miralles P, Buño I, Martinez-Laperche C, Vilaplana C, Jurado M, Clotet B, Wensing A, Martinez-Picado J\*, Diez-Martin JL\*. **2018.** *Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant.* **Annals of Internal Medicine** 169(10):674-683. doi:10.7326/M18-0759. (J.M-P. is co-senior and corresponding author)
100. Bejarano DA, Puertas MC, Börner K, Martinez-Picado J, Müller B, Kräusslich H-G. **2018.** *Detailed characterization of early HIV-1 replication dynamics in primary human macrophages.* **Viruses** 10(11), 620.
101. Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, Ham HJVD, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martinez-Picado J, Plana M, García F; iHIVARNA consortium. **2018.** *Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infection.* **AIDS** 32(17):2533-45.
102. Díaz-Varela M, de Menezes-Neto A, Perez-Zsolt D, Gámez-Valero A, Seguí-Barber J, Izquierdo-Useros N, Martinez-Picado J, Fernández-Becerra C, Del Portillo HA. **2018.** *Proteomics study of human cord blood reticulocyte-derived exosomes.* **Scientific Reports** 8(1):14046
103. Salgado M, Garcia-Minambres A, Dalmau J, Jiménez-Moyano E, Viciano P, Alejos B, Clotet B, Prado JG, Martinez-Picado J. **2018.** *Control of HIV-1 pathogenesis in viremic nonprogressors is independent of virus-Gag-specific CTL responses.* **Journal of Virology** 92(12). pii: e00346-18.
104. Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu S, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, G Reyes-Terán, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ. **2018.** *CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.* **Science Translational Medicine.** 10(437). pii: eaar6759.
105. Puertas MC, Gómez-Mora E, Santos JR, Moltó, J, Urrea, V, Morón-López S, Hernández-Rodríguez, A, Marfil S, Martínez-Bonet M, Mata L, Muñoz-Fernández MA, Clotet B, Blanco J, Martinez-Picado J. **2018.** *Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted protease inhibitors.* **Journal of Antimicrobial Chemotherapy** 73(7):1940-1948. doi: 10.1093/jac/dky106.
106. Martinez-Picado J, Zurakowski R, Buzón, MJ, Stevenson M. **2018.** *Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.* **Retrovirology** 15(1):15.

107. Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska J, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferoth K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Reyes-Teran S, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker BD, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P. **2018**. *Differential immunodominance hierarchy of CD8+ T-cell responses in HLA-B\*27:05 and B\*27:02-mediated control of HIV-1 infection*. **Journal of Virology** 92(4): e01685-17.
108. Martinez-Picado J, McLaren PJ, Telenti A, Izquierdo-Useros N. **2017**. *Retroviruses as myeloid cell riders; what natural human Siglec-1 "knockouts" tell us about pathogenesis*. **Frontiers in Immunology** 8:1593.
109. Rosás-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobarsi P, Gomez CE, Esteban M, Jimenez JL, García F, Blanco J, Martinez-Picado J, Paredes R, Brander C. **2017**. *Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B*. **PLoS One** 12(9):e184929.
110. Morón-López S, Puertas MC, Gálvez C, Navarro J, Carrasco A, Esteve M, Manyé J, Crespo M, Salgado M, Martinez-Picado J. **2017**. *Sensitive Quantification of the HIV-1 Reservoir in Gut-Associated Lymphoid Tissue*. **PLoS One** 12(4):e0175899.
111. Ruiz-Riol M, Berdnik D, Llano A, Mothe B, Gálvez C, Pérez-Álvarez S, Oriol-Tordera B, Olvera A, Silva-Arrieta S, Meulbroek M, Pujol F, Coll J, Martinez-Picado J, Ganoza C, Sanchez J, Gomez L, Wyss-Coray T, Brander C. **2017**. *Identification of IL-27/IL-27RA as a critical immune axis for in vivo HIV control*. **Journal of Virology** 91(16):e00441-17.
112. Hancock G, Morón-López S, Kopycinski J, Puertas MC, Giannoulatou E, Rose A, Salgado M, Hayton E-J, Crook A, Morgan C, Angus B, Chen F, Yang H, Martinez-Picado J, Hanke T, Dorrell L. **2017**. *Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsV, in antiretroviral therapy-treated subjects*. **Journal of the International AIDS Society** 20(1): 21171.
113. Codoñer FM, Peña R, Blanch-Lombarte O, Jimenez-Moyano E, Pino M, Vollbrecht T, Clotet B, Martinez-Picado J, Draenert R, Prado JG. **2017**. *Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to protease inhibitor*. **Scientific Reports** 7(1):3717.
114. Martínez-Bonet M, González-Serna A, Clemente MI, Morón-López S, Diaz L, Navarro M, Puertas MC, Leal M, Ruiz-Mateos E, Martinez-Picado J, Muñoz-Fernández MA. **2017**. *Relationship between CCR5(Δ32/WT) Heterozygosity and HIV-1 Reservoir Size in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection*. **Clinical Microbiology and Infection** 23(5):318-24.
115. Molinos-Albert LM, Bilbao E, Agulló L, Marfil S, García E, Rodríguez de la Concepción ML, Izquierdo-Useros N, Vilaplana C, Nieto-Garai JA, Contreras FX, Floor M, Cardona PJ, Martinez-Picado J, Clotet B, Villà-Freixa J, Lorzate M, Carrillo J, Blanco J. **2017**. *Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif*. **Scientific Reports** 7:40800.
116. Minuesa G, Albert C, Pastor-Anglada M, Martinez-Picado J, Koepsell H. **2017**. *Response to the Letter of H. Shen, W.Li, W.G. Humphreys and Y. Lai with the Title: Tenofovir Disoproxil Fumarate (TDF) is not an Inhibitor of Human Organic Cation Transporter 1 (OCT1)*. **The Journal of Pharmacology and Experimental Therapeutics** 360:343–5. (J.M-P. is corresponding author)
117. Baptista MJ, Hernandez-Rodriguez, A, Martinez-Caceres E, Morgades M, Martinez-Picado J, Sirera G, Sancho JM, Feliu E, Ribera JM, Navarro JT. **2017**. *Epstein-Barr viral loads and serum free light chains levels are potential follow up markers of HIV-related lymphomas*. **Leukemia & Lymphoma** 58(1):211-213.
118. Martinez-Picado J, McLaren PJ, Erkizia I, Martin M, Benet S, Rotger M, Dalmau J, Ouchi D, Wolinsky SM, Penugonda S, Günthard HF, Fellay J, Carrington M, Izquierdo-Useros N, Telenti A. **2016**. *Identification of Siglec-1 null individuals infected with HIV-1*. **Nature Communications** 7:12412.
119. Arkaitz I, Martinez-Picado J, Niubó J, Kashuba ADM, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczar D. **2016**. *HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen*. **Journal of Infectious Diseases** 214(10):1512-9.
120. Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzón MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J. **2016**. *Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART*. **Retrovirology** 13(1):51.
121. Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M. **2016**. *Role of human Organic Cation Transporter 1 (hOCT1) polymorphisms in lamivudine (3TC) uptake and drug-drug interactions*. **Frontiers in Pharmacology** 7:175.
122. Minuesa G, Arimany-Nardi C, Erkizia I, Cedeño S, Moltó J, Clotet B, Pastor-Anglada M, Martinez-Picado J. **2016**. *P-glycoprotein (ABCB1) Activity Decreases Raltegravir Disposition in Primary CD4+ P-gp<sup>high</sup> cells and correlates with HIV-1 viral load*. **Journal of Antimicrobial Chemotherapy** 71(10):2782-92.
123. Martinez-Picado J, Deeks SG. **2016**. *Persistent HIV-1 replication during antiretroviral therapy*. **Current Opinion on HIV/AIDS** 11(4):417–23.
124. Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG; ANRS CO21 Cohort. **2016**. *Long-term spontaneous control of HIV-1 relates to low frequency of infected cells and inefficient viral reactivation*. **Journal of Virology** 90(13):6148-58.
125. Morón-López S, Gómez-Mora E, Salgado M, Ouchi D, Puertas MC, Urrea V, Navarro J, Jou A, Pérez M,

- Tural C, Clotet B, Montaner LJ, Blanco J, Crespo M, Martinez-Picado J. 2016. *Short-term treatment with IFN $\alpha$  diminishes expression of HIV-1 and reduces CD4+ T-cell activation in HIV/HCV-coinfected patients on antiretroviral therapy.* **Journal of Infectious Diseases** 213(6):1008-12.
126. McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu M, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob A, Winkler C, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PIW, Zagury J-F, Fellay J. 2015. *Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.* **Proceedings of the National Academy of Sciences of the United States of America** 112(47):14658-63
127. Erikson E, Wrtil PR, Frank M, Ambiel I, Klingeberg K, Pino Claveria M, Azadi P, Izquierdo-Useros N, Martinez-Picado J, Meier C, Schnaar RL, Crocker PR, Reutter W, Keppler OT. 2015. *Mouse Siglec-1 Mediates Trans-Infection of Surface-Bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side Chain-Dependent Manner.* **Journal of Biological Chemistry** 290(45):27345-59.
128. Martínez-Bonet M, Puertas MC, Fortuny C, Ouchi D, Mellado J, Rojo P, Noguera-Julian A, Muñoz-Fernández MA, Martinez-Picado J. 2015. *Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy.* **Clinical Infectious Diseases** 61(7):1169-78. doi: 10.1093/cid/ciu456
129. Jarrín I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Bouffasa F, Costagliola D, Porter K, Blanco J, del Amo J, Martinez-Picado J, for CASCADE Collaboration in EuroCoord. 2015. *Does rapid HIV disease progression prior to cART initiation hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?* **AIDS** 29(17):2323-33.
130. Doyle T, Dunn D, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, Fearnhill E, Marcelin AG, Martinez-Picado J, Kaiser R, Geretti AM on behalf of the CORONET study group. 2015. *Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades.* **Journal of Antimicrobial Chemotherapy** 70(11):3080-6.
131. Duarte RF, Salgado M, Sánchez-Ortega I, Arnan M, Canals C, Domingo-Domenech E, Fernández-de-Sevilla A, González-Barca E, Morón-López S, Nogues N, Patiño B, Puertas MC, Clotet B, Petz LD, Querol S, Martinez-Picado J. 2015. *CCR5  $\Delta$ 32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.* **The Lancet HIV** 2(6):e236-e242.
132. Pino M, Erkizia I, Benet S, Erikson E, Fernández-Figueroas MT, Guerrero D, Dalmau J, Ouchi D, Rausell A, Ciuffi A, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J\*, Izquierdo-Useros N\*. 2015. *HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.* **Retrovirology** 12:37. \*Corresponding authors.
133. Mothe B, Climent N, Plana M, Rosas M, Jimenez JL, Muñoz-Fernandez MA, Puertas MC, Carrillo J, Gonzalez N, Leon A, Pich J, Arnaiz J, Gatell J, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernandez C, Sanchez-Palomino S, Guardo A, Peña J, Benito J, Rallón N, Gomez C, Perdiguero B, Garcia-Arraiza J, Esteban M, López J, Brander C, Garcia F. 2015. *Safety and immunogenicity of a MVA-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.* **Journal of Antimicrobial Chemotherapy**,70(6):1833-42. PMID:25724985.
134. Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso C, Prats A, Ferrer E, Rozas N, Maso M, Martinez-Picado J, Podzamczar D. 2015. *Viral and Inflammatory markers in Cerebrospinal Fluid of Patients with HIV-1-associated Neurocognitive Impairment During Antiretroviral Treatment Switch.* **HIV Medicine** 16(6):388-92.
135. Surdo M, Alteri C, Puertas MC, Saccomandi P, Parrotta L, Swenson L, Chapman D, Costa G, Artese A, Balestra E, Aquaro S, Alcaro S, Lewis M, Clotet B, Harrigan R, Valdez H, Svicher V, Perno CF, Martinez-Picado J, Ceccherini-Silberstein F. 2015. *Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIB study A4001029.* **Clinical Microbiology and Infection** 21:103.e1-6. PMID:25636934.
136. Massanella M, Ouchi D, Marfil S, Llibre JM, Puertas MC, Buzón MJ, Richman DD, Orna E, Stevenson M, Gatell JM, Domingo P, Negro E, Martinez-Picado J, Clotet B, Blanco J. 2014. *Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.* **PLoS One** 9(12):e114142.
137. Izquierdo-Useros N, Lorizate M, McLaren PJ, Telenti A, Kräusslich H-G, Martinez-Picado J. 2014. *HIV-1 Capture and Transmission by Dendritic Cells: the Role of Viral Glycolipids and the Cellular Receptor Siglec-1.* **PLoS Pathogens** 10(7): e1004146.
138. Puertas MC, Salgado M, Morón-López S, Ouchi D, Muñoz-Moreno JA, Moltó J, Clotet B, Martinez-Picado J. 2014. *Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of ART-suppressed patients.* **AIDS** 28(14):2157-9.
139. Buzon M, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li J, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. 2014. *Long-term Antiretroviral Treatment Initiated in Primary HIV-1 Infection Affects the Size, Composition and Decay Kinetics of the Reservoir of HIV-1 Infected CD4 T Cells.* **Journal of Virology** 88(17):10056-65.
140. Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, Martinez-Picado J, Gorboulev V, Koepsell H, Pastor-Anglada M. 2014. *Nucleoside Transporters (NTs) and Human Organic Cation Transporter 1 (hOCT1) Determine the Cellular Handling of DNA-Methyltransferase Inhibitors.* **British Journal of Pharmacology** 171(16):3868-80.
141. Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P, Pino M, Esteve A, Palou E, Brander C, Paredes R, Phung P, Clotet B, Telenti A\*, Martinez-Picado J\*



- Prado JG\*: The CoRP Study Group. **2014.** *Highly Pathogenic Adapted HIV-1 Strains Limit Host Immunity and Dictate Rapid Disease Progression.* **AIDS** 28(9):1261-72. (\*joint senior authorship & corresponding authors)
142. Kawana-Tachikawa A, Llibre JM, Bravo I, Escriu R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST investigators. **2014.** *Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals.* **PLoS One** 9(1):e87334.
  143. Puertas MC, Massanella M, Llibre JM, Ballesteros M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J, and the MaraviBoost Collaborative Group. **2014.** *Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.* **AIDS** 28(3):325-34.
  144. Bartha I, Carlson J, Brumme C, McLaren P, Brumme Z, John M, Haas D, Martinez-Picado J, Dalmau J, López Galindez C, Casado C, Rauch A, Günthard H, Bernasconi E, Vernazza P, Klimkait T, Yerly S, O'Brien S, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen T, Müller V, Harrigan PR, Heckerman D, Telenti A, Fellay J. **2013.** *A Genome-to-Genome Analysis of Associations between Human Genetic Variation, HIV-1 Sequence Diversity, and Viral Control.* **eLIFE** 2:e01123.
  145. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. **2013.** *Barriers to a Cure: New concepts in targeting and eradicating HIV-1 reservoirs.* **The Lancet** 381(9883):2109-17.
  146. Gordón-Alonso M, Rocha-Perugini V, Alvarez S, Ursa A, Izquierdo-Useros N, Martinez-Picado J, Muñoz-Fernández MA, Sánchez-Madrid F. **2013.** *Actin-binding protein drebrin regulates HIV-1-triggered actin polymerization and viral infection.* **The Journal of Biological Chemistry** 288(39):28382-97.
  147. McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PI, Zagury JF, Fellay J. **2013.** *Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls.* **PLoS Pathogens** 9(7):e1003515.
  148. Pou C, Codoñer FM, Thielen A, Bellido R, Pérez-Álvarez S, Cabrera C, Dalmau J, Curriu M, Lie Y, Noguera-Julian M, Puig J, Martinez-Picado J, Blanco J, Coakley E, Däumer M, Clotet B, Paredes R. **2013.** *HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization.* **PLoS One.** 8(8):e67085.
  149. Martinez-Picado J. **2013.** *Curar la infección por el VIH: los avances logrados y las cuestiones pendientes para vencer de modo definitivo la enfermedad.* **Investigación y Ciencia** 442:70-5.
  150. Rodríguez-Plata MT, Puigdomènech I, Izquierdo-Useros N, Puertas MC, Carrillo J, Erkizia I, Clotet B, Blanco J, Martinez-Picado J. **2013.** *The infectious synapse formed between mature dendritic cells and CD4+ T cells is independent of the presence of the HIV-1 envelope glycoprotein.* **Retrovirology** 10(1):42.
  151. Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez-Picado J, Zurakowski R. **2013.** *Modeling HIV-1 2-LTR dynamics following raltegravir intensification.* **Journal of the Royal Society Interface** 10(84):20130186.
  152. Negro E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez Alvarez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martinez-Picado J, Clotet B, Blanco J. **2013.** *Early but limited effects of raltegravir intensification on CD4 T-cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.* **Journal of Antimicrobial Chemotherapy**, 68(10):2358-62.
  153. Massanella M, Curriu M, Carrillo J, Gómez E, Puig J, Navarro J, Dalmau J, Martinez-Picado J, Crespo M, Cabrera C, Negro E, Clotet B, Blanco J. **2013.** *Assessing main death pathways in T lymphocytes from HIV infected individuals.* **Cytometry A** 83(7):648-58.
  154. Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PHB, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J, for the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). **2013.** *A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.* **Human Molecular Genetics** 22(9):1903-10.
  155. Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; the IntegRal collaborative group. **2013.** *Dynamics of CD8 T-Cell Activation after Discontinuation of HIV Treatment Intensification.* **Journal of Acquired Immune Deficiency Syndromes** 63(2):152-160.
  156. García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson JD, Martinez Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T for DCV2/MANON07-ORVACS study group. **2013.** *A dendritic cell-based vaccine elicits T-cell responses associated with a significant control of HIV-1 replication.* **Science Translational Medicine** 5(166):166ra2.
  157. Massanella M, Martinez-Picado J, Blanco J. **2013.** *Attacking the HIV Reservoir from the Immune and Viral Perspective.* **Current HIV/AIDS Reports** 10(1):33-41.

158. Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E, Pino M, Erkizia I, Glass B, Clotet B, Keppler OT, Telenti A, Kräusslich H-G, [Martinez-Picado J](#). **2012**. *Siglec-1 is a Novel Dendritic Cell Receptor that Mediates HIV-1 Trans-infection Through Recognition of Viral Membrane Gangliosides*. **PLoS Biology** 10(12):e1001448.
159. Puertas MC, Buzón MJ, Ballesteros M, Van Den Eede P, Clotet B, Prado JG, [Martinez-Picado J](#). **2012**. *Novel two-round phenotypic assay for protease inhibitor susceptibility testing in recombinant and primary HIV-1 isolates*. **Journal of Clinical Microbiology** 50(12):3909-16.
160. Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, Pérez-Alvarez N, Carrillo J, Clotet B, [Martinez-Picado J](#), Blanco J. **2012**. *Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV infected HAART-suppressed individuals with poor CD4 T-cell recovery*. **AIDS** 26(18):2285-93.
161. Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elias MJ, de Mendoza C, Martínez MA, [Martinez-Picado J](#), Menéndez-Arias L; for the ResRIS. **2012**. *Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy*. **Retrovirology** 9(1):68.
162. Deeks S, Aufran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun T-W, Churchill M, Di Mascio M, Katlama C, Lefeuvre A, Landay A, Lederman M, Lewin S, Maldarelli F, Margolis D, Markowitz M, [Martinez-Picado J](#), Mullins J, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud M-C, Peterlin M, Poli G, Routy J-P, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barre-Sinoussi F. **2012**. *Towards an HIV cure: a global scientific strategy*. **Nature Reviews Immunology** 12(8):607-614. Review.
163. Blanco JL, [Martinez-Picado J](#). **2012**. *HIV integrase inhibitors in ART-experienced patients*. **Current Opinion in HIV & AIDS**. 7(5):415-421. Review.
164. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R. **2012**. *HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics*. **PLoS ONE** 7(7): e40198.
165. Rodriguez-Plata MT, Urrutia A, Cardinaud S, Buzón MJ, Izquierdo-Useros N, Prado JG, Puertas MC, Erkizia I, Coulon P-G, Cedeño S, Clotet B, Moris A, [Martinez-Picado J](#). **2012**. *HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-cell activation*. **The Journal of Immunology**, 188(12):6036-45.
166. Gordón-Alonso M, Rocha-Perugini V, Alvarez S, Moreno-Gonzalo O, Ursa A, López S, Izquierdo-Useros N, [Martinez-Picado J](#), Muñoz-Fernández MA, Yañez-Mo M, Sánchez-Madrid F. **2012**. *The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry*. **Molecular Biology of the Cell**, 23(12):2253-2263.
167. Izquierdo-Useros N, Lorizate M, Contreras F-X, Rodriguez-Plata MT, Glass B, Erkizia I, Prado JG, Casas J, Fabriás G, Kräusslich H-G, [Martinez-Picado J](#). **2012**. *Sialyllactose in Viral Membrane Gangliosides is a Novel Molecular Recognition Pattern for Mature Dendritic Cell Capture of HIV-1*. **PLoS Biology**, 10(4): e1001315.
168. Dalmau J, Codoñer FM, Erkizia I, Pino M, Pou C, Paredes R, Clotet B, [Martinez-Picado J](#), Prado JG. **2012**. *In-Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection*. **PLoS ONE**, 7(2):e32714.
169. Bastos-Amador P, Pérez-Cabezas B, Naranjo-Gómez M, Izquierdo-Useros N, Puertas MC, [Martinez-Picado J](#), Pujol-Borrell R, Borràs FE. **2012**. *Capture of cell-derived microvesicles (exosomes and apoptotic bodies) by Human Plasmacytoid Dendritic Cells*. **Journal of Leukocyte Biology** 91(5):751-8.
170. Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutiérrez M, Palmer S, Stevenson M, Blanco J, [Martinez-Picado J](#), Clotet B. **2012**. *Treatment intensification with raltegravir in subjects with sustained HIV-1 viremia suppression: a randomized 48 weeks study*. **Antiviral Therapy** 17(2):355-64.
171. Buzón MJ, Erkizia I, Pou C, Minuesa G, Puertas MC, Esteve A, Castelló A, Santos JR, Prado JG, Izquierdo-Useros N, Pattery T, Van Houtte M, Carrasco L, Clotet B, Ruiz L, [Martinez-Picado J](#). **2012**. *Journal of A Non-infectious Cell-based Phenotypic Assay for the Assessment of HIV-1 Susceptibility to Protease Inhibitors*. **Antimicrobial Chemotherapy** 67(1):32-8.
172. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreno J, Bach V, Zuniga R, Perez-Alvarez S, Berger CT, Puertas MC, [Martinez-Picado J](#), Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gomez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C. **2011**. *Definition of the viral targets of protective HIV-1-specific T cell responses*. **Journal of Translational Medicine** 9(1):208.
173. Buzón MJ, Codoñer FM, Frost SDW, Pou C, Puertas MC, Massanella M, Dalmau J, Llibre JM, Stevenson M, Blanco J, Clotet B, Paredes R, [Martinez-Picado J](#). **2011**. *Deep molecular characterization of HIV-1 dynamics under suppressive HAART*. **PLoS Pathogens**, 7(10):e1002314.
174. Luo R, Piovoso MJ, [Martinez-Picado J](#), Zurakowski R. **2011**. *Optimal antiviral switching to minimize resistance risk in HIV therapy*. **PLoS ONE** 6(11):e27047.
175. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, Ge D, De Luca A, [Martinez-Picado J](#), Wolinsky SM, Martinson JJ, Jamieson BD, Bream JH, Martin MP, Borrow P, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Carrington M, Goldstein DB, Alter G, on behalf of NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). **2011**. *Copy Number Variation of KIR Genes Influences HIV-1 Control*. **PLoS Biology** 9(11): e1001208.
176. Izquierdo-Useros N, Esteban O, Rodriguez-Plata MT, Erkizia I, Prado JG, Blanco J, Garcia-Parajo MF, [Martinez-Picado J](#). **2011**. *Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells*. **Traffic** 12(12):1702-1713.

177. Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, [Martinez-Picado J](#). **2011**. *Drug uptake transporters in antiretroviral therapy*. **Pharmacology & Therapeutics** 132:268-79. Review.
178. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger S, Martinez R, Sandler NG, Roque A, Liebner J, Bategay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miró JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard HF, de Bakker P, Douek DC, Silvestri G, [Martinez-Picado J](#)\*, Telenti A\*. **2011**. *Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and sooty mangabey and rhesus macaque models of SIV infection*. **The Journal of Clinical Investigation**, 121(6):2391-400 (\*co-senior & corresponding author).
179. Gil C, Climent N, García F, Hurtado C, Nieto-Márquez S, León A, García MT, Rovira C, Miralles L, Dalmau J, Pumarola T, Almela M, [Martinez-Picado J](#), Lifson J, Zamora L, Miró JM, Brander C, Clotet B, Gallart T, Gatell JM. **2011**. *Ex-Vivo Production of Autologous Whole Inactivated HIV-1 for Clinical Use in Therapeutic Vaccines*. **Vaccine**, 29(34):5711-24.
180. Kisic M, Matamoros T, Nevot M, Mendieta J, [Martinez-Picado J](#), Martínez MA, Menéndez-Arias L. **2011**. *Thymidine analogue excision and discrimination modulated by mutational complexes including single-amino-acid deletions of Asp67 or Thr69 in HIV-1 reverse transcriptase*. **The Journal of Biological Chemistry**, 286(23):20615-24.
181. Buzón MJ, Wrin T, Codoñer FM, Dalmau J, Phung P, Bonjoch A, Coakley E, Clotet B, [Martinez-Picado J](#). **2011**. *Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes*. **Journal of Acquired Immune Deficiency Syndromes**, 57(2):109-17.
182. Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, [Martinez-Picado J](#), and The EuroSIDA Study Group. **2011**. *A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy*. **The Journal of Infectious Diseases**, 204(5):741-52.
183. Evangelou E, Fellay J, Colombo S, [Martinez-Picado J](#), Obel N, Goldstein DB, Ioannidis JPA, Telenti A. **2011**. *Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection*. **American Journal of Epidemiology** 173(11):1336-42.
184. Vigneault F, Woods M, Buzon MJ, Li C, Pereyra F, Church G, [Martinez-Picado J](#), Rosenberg ES, Telenti A, Yu XG, Lichterfeld M. **2011**. *Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers*. **Journal of Virology** 85(6):3015-9.
185. Izquierdo-Useros N, Puertas MC, Borràs FE, Blanco J, [Martinez-Picado J](#). **2011**. *Exosomes and retroviruses: the chicken or the egg?* **Cellular Microbiology**. 13(1):10-17. Review.
186. García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, [Martinez-Picado J](#), Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T, for DCV2/MANON07-ORVACS study group. **2011**. *A Therapeutic Dendritic Cell-based Vaccine for HIV-1 Infection*. **The Journal of Infectious Diseases** 203(4):473-8.
187. Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Santos JR, Buzón MJ, [Martinez-Picado J](#), Álvarez-Tejado M, Clotet B, Lidia Ruiz L, Paredes R. **2010**. *Dynamic Escape of Pre-Existing Raltegravir-Resistant HIV-1 from Raltegravir Selection Pressure*. **Antiviral Research**. 88(3):281-286.
188. Betancor G, Puertas MC, Nevot M, Garriga C, Martínez MA, [Martinez-Picado J](#), Luis Menendez-Arias L. **2010**. *Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure*. **Antimicrobial Agents and Chemotherapy** 54(11):4799-4811.
189. Vieira CR, Muñoz-Olaya JM, Sot J, Jiménez-Baranda S, Izquierdo-Useros N, Abad JL, Apellániz B, Delgado R, [Martinez-Picado J](#), Alonso A, Casas J, Nieva JL, Fabriás G, Mañes S, Goñi FM. **2010**. *Dihydro sphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains*. **Chemistry & Biology** 17:766-75.
190. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J & [Martinez-Picado J](#). **2010**. *HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Subjects*. **Nature Medicine** 16(4):460-5.
191. Izquierdo-Useros N, Naranjo-Gómez M, Erkizia I, Blanco J, Borràs FE, Puertas MC, & [Martinez-Picado J](#). **2010**. *HIV and Mature Dendritic cells: Trojan exosomes riding the Trojan horse?* **PLoS Pathogens** 6:e1000740. Review.
192. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, [Martinez-Picado J](#), Addo MM, Walker BD. **2010**. *Infrequent recovery of HIV from, but robust exogenous infection of activated CD4+ T-cells from HIV elite controllers*. **Clinical Infectious Diseases** 51:233-8.
193. Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, & [Martinez-Picado J](#). **2010**. *The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates*. **AIDS** 24:17-25.
194. Izquierdo-Useros N, Naranjo-Gómez M, Archer J, Hatch SC, Erkizia I, Blanco J, Borràs FE, Puertas MC, Connor JH, Fernández-Figueras MT, Moore L, Clotet B, Gummuluru S, & [Martinez-Picado J](#). **2009**. *Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway*. **Blood** 113:2732-2741.
195. Dalmau J, Puertas MC, Azuara M, Mariño A, Frahm N, Mothe B, Izquierdo-Useros N, Buzón MJ, Paredes R, Matas L, Allen TM, Brander C, Rodrigo C, Clotet B, [Martinez-Picado J](#). **2009**. *Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection*. **Clinical Infectious Diseases** 48:229-238.
196. Cozzi-Lepri A, Phillips AN, [Martinez-Picado J](#), Monforte A, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study



- Group. **2009.** *Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.* **The Journal of Infectious Diseases** 200:687-697.
197. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J. **2009.** *Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.* **Journal of Pharmacology and Experimental Therapeutics** 329:252-261.
198. Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez-Picado J, Goulder PJ. **2009.** *Functional consequences of human immunodeficiency virus escape from an HLA-B\*13-restricted CD8+ T-cell epitope in p1 Gag protein.* **Journal of Virology** 83:1018-1025.
199. Puertas MC, Buzón MJ, Artese A, Alcaro S, Menendez-Arias L, Perno CF, Clotet B, Ceccherini-Silberstein F, Martinez-Picado J. **2009.** *Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.* **Journal of Virology** 83:7434-7439.
200. Rusconi S, Lo Cicero M, Viganò O, Sirianni F, Bulgheroni E, Ferramosca S, Bencini A, Bianchi A, Ruiz L, Cabrera C, Martinez-Picado J, Supuran CT, & Galli M. **2009.** *New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.* **Molecules** 14:1927-1937.
201. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB, & NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). **2009.** *Common genetic variation and the control of HIV-1 in humans.* **PLoS Genetics** 5:e1000791.
202. Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, Cabrera C, Romeu J, Bofill M, Clotet B, & Martinez-Picado J. **2008.** *Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.* **AIDS Research and Human Retroviruses** 24:725-732.
203. Buzón MJ, Marfil S, Puertas MC, García E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J,\*, & Cabrera C. **2008.** *Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.* **Antiviral Therapy** 13:881-893. (\*co-senior & corresponding author)
204. Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, & Martinez-Picado J. **2008.** *Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.* **Antiviral Therapy** 13:945-951.
205. Llibre JM & Martinez-Picado J. **2008.** *[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].* **Enfermedades Infecciosas y Microbiología Clínica** 26 Suppl 12:17-22. **Review.**
206. Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, Pérez-Alvarez N, Videla S, Martinez-Picado J, & Clotet B. **2008.** *Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.* **HIV Clinical Trials** 9:387-398.
207. Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, & HIV Conference Call Study Group. **2008.** *Targeting only reverse transcriptase with zidovudine /lamivudine /abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.* **HIV Medicine** 9:508-513.
208. Darwich L, Cabrera C, Romeu J, Martinez-Picado J, Esté JA, Tural C, Bellido R, Angulo A, Ruiz L, & Bofill M. **2008.** *The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression.* **Journal of Acquired Immune Deficiency Syndromes** 49:507-512.
209. Kisic M, Mendieta J, Puertas MC, Parera M, Martínez MA, Martinez-Picado J, & Menéndez-Arias L. **2008.** *Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.* **Journal of Molecular Biology** 382:327-341.
210. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, & Martinez-Picado J. **2008.** *Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.* **The Journal of Pharmacology and Experimental Therapeutics** 324:558-567.
211. Puigdomènech I, Massanella M, Izquierdo-Useros N, Ruiz-Hernandez R, Curriu M, Bofill M, Martinez-Picado J, Juan M, Clotet B, & Blanco J. **2008.** *HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.* **Retrovirology** 5:32.
212. Martinez-Picado J & Martínez MA. **2008.** *HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.* **Virus Research** 134:104-123. **Review.**
213. Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martinez-Picado J, Vidal F, Fumaz CR, Clotet B, & TIBET Study Group. **2007.** *Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.* **AIDS** 21:169-178.
214. Serrano-Gómez D, Martínez-Nuñez RT, Sierra-Filardi E, Izquierdo N, Colmenares M, Pla J, Rivas L, Martinez-Picado J, Jimenez-Barbero J, Alonso-Lebrero JL, González S, & Corbí AL. **2007.** *AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN.* **Antimicrobial Agents and Chemotherapy** 51:2313-2323.
215. Martinez-Picado J & Wai Yan Tam L. **2007.** *Risk of selecting resistance mutations during treatment interruption.* **Current Opinion in HIV and AIDS** 2:6-13. **Review.**

216. Villena C, Prado JG, Puertas MC, Martínez MA, Clotet B, Ruiz L, Parkin NT, Menéndez-Arias L, & Martínez-Picado J. **2007**. *Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region*. **Journal of Virology** 81:4713-4721.
217. Izquierdo-Useros N, Blanco J, Erkizia I, Fernández-Figueras MT, Borràs FE, Naranjo-Gómez M, Bofill M, Ruiz L, Clotet B, & Martínez-Picado J. **2007**. *Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission*. **Journal of Virology** 81:7559-7570.
218. Yu XG, Lichterfeld M, Williams KL, Martínez-Picado J, & Walker BD. **2007**. *Random T-cell receptor recruitment in human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells from genetically identical twins infected with the same HIV-1 strain*. **Journal of Virology** 81:12666-12669.
219. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martínez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, & Goldstein DB. **2007**. *A whole-genome association study of major determinants for host control of HIV-1*. **Science** 317:944-947.
220. Cabrera C, Marfil S, García E, Martínez-Picado J, Bonjoch A, Bofill M, Moreno S, Ribera E, Domingo P, Clotet B, & Ruiz L. **2006**. *Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen*. **AIDS** 20:2075-2080.
221. Bofill M, Martínez-Picado J, Ruiz-Hernandez R, Cabrera C, Marfil S, Erkizia I, Bellido R, Romeu J, Clotet B, & Ruiz L. **2006**. *Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance*. **AIDS Research and Human Retroviruses** 22:893-896.
222. Moltó J, Ruiz L, Valle M, Martínez-Picado J, Bonjoch A, Bravo I, Negro E, Heilek-Sneider GM, & Clotet B. **2006**. *Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naïve, HIV-infected patients*. **Antiviral Therapy** 11:47-51.
223. Purcet S, Minuesa G, Molina-Arcas M, Erkizia I, Casado FJ, Clotet B, Martínez-Picado J, & Pastor-Anglada M. **2006**. *3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes*. **Antiviral Therapy** 11:803-811.
224. Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, Verrill CL, Sirera G, Eldridge RL, Lahaie MP, Ruiz L, Clotet B, Petropoulos CJ, Walker BD, & Martínez-Picado J. **2006**. *Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus*. **The Journal of Experimental Medicine** 203:529-539.
225. Martínez-Picado J, Prado JG, Fry EE, Pfaffert K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, & Goulder P. **2006**. *Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1*. **Journal of Virology** 80:3617-3623.
226. Weber J, Weberova J, Carobene M, Mirza M, Martínez-Picado J, Kazanjian P, & Quiñones-Mateu ME. **2006**. *Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness*. **Journal of Virological Methods** 136:102-117.
227. Prado JG, Parkin NT, Clotet B, Ruiz L, & Martínez-Picado J. **2005**. *HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure*. **Clinical Infectious Diseases** 41:729-737.
228. Martínez-Picado J, Morales-Lopetegui K, Villena C, Gutiérrez C, Izquierdo N, Marfil S, Clotet B, & Ruiz L. **2005**. *Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification*. **Journal of Clinical Microbiology** 43:436-438.
229. Rodes B, García F, Gutierrez C, Martínez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, & Red de Investigación en SIDA. **2005**. *Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients*. **Journal of Medical Virology** 77:23-28.
230. Martínez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, Petropoulos CJ, & Parkin NT. **2005**. *Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1*. **Journal of Virology** 79:5907-5913.
231. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoiz I, Martínez-Picado J, & Casado FJ. **2005**. *Cell entry and export of nucleoside analogues*. **Virus Research** 107:151-164. Review.
232. Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negro E, Tural C, Sirera G, & Clotet B. **2004**. *Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects*. **AIDS Research and Human Retroviruses** 20:1283-1288.
233. Negro E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, Fumoz CR, Ruiz L, Abril V, Rodríguez de Castro E, Ochoa C, Martínez-Picado J, Montaner J, Rey-Joly C, Clotet B, & Swatch Study Team. **2004**. *Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study*. **Antiviral Therapy** 9:889-893.
234. Cano-Soldado P, Lorráyoiz IM, Molina-Arcas M, Casado FJ, Martínez-Picado J, Lostao MP, & Pastor-Anglada M. **2004**. *Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)*. **Antiviral Therapy** 9:993-1002.
235. Prado JG, Shintani A, Bofill M, Clotet B, Ruiz L, & Martínez-Picado J. **2004**. *Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic HIV infection during structured treatment interruptions*. **Journal of Clinical Microbiology** 42:1620-1625.



236. Draenert R, Le Gall S, Pfafferoth KJ, Leslie AJ, Chetty P, Brander C, Holmes EC, Chang SC, Feeney ME, Addo MM, Ruiz L, Ramduth D, Jeena P, Altfeld M, Thomas S, Tang Y, Verrill CL, Dixon C, Prado JG, Kiepiela P, [Martinez-Picado J](#), Walker BD, & Goulder PJ. **2004**. *Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection*. **The Journal of Experimental Medicine** 199:905-915.
237. Leslie AJ, Pfafferoth KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, [Martinez-Picado J](#), Kiepiela P, Walker BD, & Goulder PJ. **2004**. *HIV evolution: CTL escape mutation and reversion after transmission*. **Nature Medicine** 10:282-289.
238. Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, & [Martinez-Picado J](#). **2004**. *Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215*. **Virology** 326:103-112.
239. [Martinez-Picado J](#), Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciano P, Hertogs K, Boucher C, D'Aquila RT, Clotet B, & SWATCH Study Team. **2003**. *Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial*. **Annals of Internal Medicine** 139:81-89.
240. Menéndez-Arias L, Martínez MA, Quiñones-Mateu ME, & [Martinez-Picado J](#). **2003**. *Fitness variations and their impact on the evolution of antiretroviral drug resistance*. **Current Drug Targets. Infectious Disorders** 3:355-371. Review.
241. Weber J, Rangel HR, Chakraborty B, Tadele M, Martínez MA, [Martinez-Picado J](#), Marotta ML, Mirza M, Ruiz L, Clotet B, Wrin T, Petropoulos CJ, & Quiñones-Mateu ME. **2003**. *A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy*. **The Journal of General Virology** 84:2217-2228.
242. Ruiz L, Ribera E, Bonjoch A, Romeu J, [Martinez-Picado J](#), Paredes R, Diaz M, Marfil S, Negredo E, García-Prado J, Tural C, Sirera G, & Clotet B. **2003**. *Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study*. **The Journal of Infectious Diseases** 188:977-985.
243. Izquierdo N, Naranjo M, Fernández MA, Cos J, Massuet L, [Martinez-Picado J](#), & Borràs FE. **2003**. *Leukocyte Reduction Filters: an alternative source of Peripheral Blood Mononuclear Cells*. **Immunología** 22:255-62.
244. [Martinez-Picado J](#), Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, Clotet B, & Ruiz L. **2002**. *Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions*. **AIDS** 16:895-899.
245. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, & [Martinez-Picado J](#). **2002**. *Ampronavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity*. **AIDS** 16:1009-1017.
246. Clotet B, Ruiz L, [Martinez-Picado J](#), Negredo E, Hill A, & Popescu M. **2002**. *Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts*. **HIV Clinical Trials** 3:316-323.
247. Frost SD, [Martinez-Picado J](#), Ruiz L, Clotet B, & Brown AJ. **2002**. *Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection*. **Journal of Virology** 76:968-979.
248. [Martinez-Picado J](#), Frost SD, Izquierdo N, Morales-Lopetegi K, Marfil S, Puig T, Cabrera C, Clotet B, & Ruiz L. **2002**. *Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals*. **Journal of Virology** 76:12344-12348.
249. Ruiz L, Carcelain G, [Martinez-Picado J](#), Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, Morales-Lopetegi K, Autran B, & Clotet B. **2001**. *HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection*. **AIDS** 15:F19-F27.
250. Clotet B, Martínez-Picado J, Arrizabalaga J, & Ruiz L. **2001**. *[Resistance to protease inhibitors]. Enfermedades Infecciosas y Microbiología Clínica* 19:34-41. Review.
251. Ruiz L, [Martinez-Picado J](#), Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E, Sirera G, Tural C, & Clotet B. **2000**. *Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression*. **AIDS** 14:397-403.
252. Miller V, Sabin C, Hertogs K, Bloor S, [Martinez-Picado J](#), D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, & Staszewski S. **2000**. *Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure*. **AIDS** 14:2857-2867.
253. Gilbert PB, Hanna GJ, De Gruttola V, [Martinez-Picado J](#), Kuritzkes DR, Johnson VA, Richman DD, & D'Aquila RT. **2000**. *Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens*. **AIDS Research and Human Retroviruses** 16:1325-1336.
254. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, [Martinez-Picado J](#), Sutton L, Hazelwood JD, & D'Aquila RT. **2000**. *Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase*. **Journal of Clinical Microbiology** 38:2715-2721.
255. [Martinez-Picado J](#), DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E, Gunthard HF, Sutton L, Savara A, Petropoulos CJ, Hellmann N, Walker BD, Richman DD, Siliciano R, & D'Aquila RT. **2000**. *Antiretroviral resistance during successful therapy of HIV type 1 infection*. **Proceedings of the National Academy of Sciences of the United States of America** 97:10948-10953.
256. [Martinez-Picado J](#), Savara AV, Shi L, Sutton L, & D'Aquila RT. **2000**. *Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants*. **Virology** 275:318-322.
257. [Martinez-Picado J](#), Sutton L, De Pasquale MP, Savara AV, & D'Aquila RT. **1999**. *Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing*. **Journal of Clinical Microbiology** 37:2943-2951.
258. Merrill DP, [Martinez-Picado J](#), Tremblay C, Sax PE, Boswell SL, Wong JT, D'Aquila RT, Walker BD, &

- Hirsch MS. 1999. *Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy*. **The Journal of Infectious Diseases** 179:345-351.
259. Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martinez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, & Clotet B. 1999. *Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with  $\leq 250/\mu\text{mL}$  CD4 T cells and undetectable plasma virus load*. **The Journal of Infectious Diseases** 180:56-60.
260. Martinez-Picado J, Savara AV, Sutton L, & D'Aquila RT. 1999. *Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1*. **Journal of Virology** 73:3744-3752.
261. Martinez-Picado J & D'Aquila R. 1998. *HIV-1 drug resistance assays in clinical management*. **AIDS Clinical Care** 10:81-88. Review.
262. Schmit J-C, Martinez-Picado J, Ruiz L, Tural C, Laethem KV, Cabrera C, Ibanez A, Puig T, Witvrouw M, Desmyter J, DeClercq E, Clotet B, & Vandamme A-M. 1998. *Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine- experienced patients receiving lamivudine-containing combination therapy*. **Antiviral Therapy** 3:81-8.
263. Ruiz L, Nijhuis M, Boucher C, Puig T, Bonjoch A, Martinez-Picado J, Marfil S, de Jong D, Burger D, Arnó A, Balagué M, & Clotet B. 1998. *Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients*. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology** 19:19-28.
264. Ruiz L, Romeu J, Clotet B, Balagué M, Cabrera C, Sirera G, Ibáñez A, Martinez-Picado J, Raventós A, Tural C, Segura A, & Foz M. 1996. *Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of  $300 \times 10^6/\text{l}$* . **AIDS** 10:F39-F44.
265. Ruiz L, Romeu J, Martinez-Picado J, Schmit JC, Vandamme AM, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E, & Clotet B. 1996. *Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC*. **AIDS** 10:F61-F66.
266. Martinez-Picado J, Alsina M, Blanch AR, Cerda M, & Jofre J. 1996. *Species-Specific Detection of Vibrio anguillarum in marine aquaculture environments by selective culture and DNA hybridization*. **Applied and Environmental Microbiology** 62:443-449.
267. Martinez-Picado J, Blanch AR, & Jofre J. 1994. *Rapid detection and identification of Vibrio anguillarum by using a specific oligonucleotide probe complementary to 16S rRNA*. **Applied and Environmental Microbiology** 60:732-737.
268. Alsina M, Martinez-Picado J, Jofre J, & Blanch AR. 1994. *A medium for presumptive identification of Vibrio anguillarum*. **Applied and Environmental Microbiology** 60:1681-1683.
269. Martinez-Picado J, Blanch AR, & Jofre J. 1993. *Iridovirus-like particles associated with nodular skin lesions and vesicles in Parapocryptes serperaster*. **Journal of Aquatic Animal Health** 5:148-51.

---

## BOOKS AND MONOGRAPHS

Martinez-Picado J\*. **2024.** *La infecció pel virus de la immunodeficiència humana (VIH): una pandèmia que ha marcat el canvi de mil·lenni.* Memòria de la Reial Acadèmia de Ciències i Arts de Barcelona 1079, 70(3):1-63. ISSN: 2462-3334.

Pérez-Zsolt D, Martinez-Picado J\*, Izquierdo-Useros N\*. **2022.** *Receptors on primary phagocytes as therapeutic targets against highly pathogenic emerging viruses (Chapter 11).* In: **Drug Discovery Series**, Antiviral Discovery for Highly Pathogenic Emerging Viruses, *Edited by:* C Muñoz-Fontela and R Delgado. **The Royal Society of Chemistry.**

Various authors. **2016.** *The HIV & Hepatitis Drug Resistance and PK Guide (15<sup>th</sup> edition).*

Fundació de Lluita contra la SIDA. Barcelona. ISBN: 978-84-608-8503-0.

Co-editor and contributing to the following sections:

*Chapter 7: Drug resistance-associated mutations and their effects on viral fitness*

*Chapter 8: Prevalence of HIV-1 drug resistance mutations in antiretroviral naïve patients*

*Chapter 12: Current antiretroviral drugs: approved and in development*

Various authors. **2015.** *The HIV & Hepatitis Drug Resistance and PK Guide (14<sup>th</sup> edition).*

Fundació de Lluita contra la SIDA. Barcelona. ISBN: 978-84-606-5580-0.

Co-editor and contributing to the following sections:

*Chapter 1: Drug resistance. Definitions and concepts*

*Chapter 7: Drug resistance-associated mutations and their effects on viral fitness*

*Chapter 8: Prevalence of HIV-1 drug resistance mutations in antiretroviral naïve patients*

*Chapter 12: Current antiretroviral drugs: approved and in development*

Various authors. **2014.** *The HIV & Hepatitis Drug Resistance and PK Guide (13<sup>th</sup> edition).*

Fundació de Lluita contra la SIDA. Barcelona. ISBN: 978-84-616-7448-0.

Co-editor and contributing to the following sections:

*Chapter 1: Drug resistance. Definitions and concepts*

*Chapter 7: Drug resistance-associated mutations and their effects on viral fitness*

*Chapter 8: Prevalence of HIV-1 drug resistance mutations in antiretroviral naïve patients*

*Chapter 12: Current antiretroviral drugs: approved and in development*

Various authors. **2012.** *The HIV & Hepatitis Drug Resistance and PK Guide (12<sup>th</sup> edition).*

Fundació de Lluita contra la SIDA. Barcelona. ISBN: 978-84-695-4357-3.

Co-editor and contributing to the following sections:

*Chapter 1: Drug resistance. Definitions and concepts*

*Chapter 7: Drug resistance-associated mutations and their effects on viral fitness*

*Chapter 8: Prevalence of HIV-1 drug resistance mutations in antiretroviral naïve patients*

*Chapter 12: Current antiretroviral drugs: approved and in development*

Various authors. **2011.** *The HIV & Hepatitis Drug Resistance and PK Guide (11<sup>th</sup> edition).*

Fundació de Lluita contra la SIDA. Barcelona. ISBN: 978-84-694-7149-4.

Co-editor and contributing to the following sections:

*Chapter 1: Drug resistance. Definitions and concepts*

*Chapter 7: Drug resistance-associated mutations and their effects on viral fitness*

*Chapter 8: Prevalence of HIV-1 drug resistance mutations in antiretroviral naïve patients*

*Chapter 12: Current antiretroviral drugs: approved and in development*

Red de Investigación en SIDA –RIS–. **2011.** *Guía de resistencias a los antirretrovirales 2011.*

Publicaciones Permanyer. Barcelona. ISBN: 978-84-9926-257-4.

Clotet B, Llibre JM, Paredes R, Martinez-Picado J. **2011.** *Resistencia del VIH a los antirretrovirales.* En:

**Guía práctica del SIDA: clínica, diagnóstico y tratamiento (11<sup>a</sup> edición).** Editorial Antares.

Barcelona. ISBN: 978-84-88825-06-3.

Clotet B, Llibre JM, Paredes R, Martinez-Picado J. **2010**. *Resistencia del VIH a los antirretrovirales*. En: **Guía práctica del SIDA: clínica, diagnóstico y tratamiento (10ª edición)**. Editorial Antares. Barcelona. ISBN: 978-84-88825-03-2.

**Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected patients.** In B Clotet *et al.* (ed.), TAISA, S.L., Barcelona.  
**1<sup>st</sup> edition (2000), 2<sup>nd</sup> edition (2002), 3<sup>rd</sup> edition (2003), 4<sup>th</sup> edition (2004), 5<sup>th</sup> edition (2005), 6<sup>th</sup> edition (2006), 7<sup>th</sup> edition (2007), 8<sup>th</sup> edition (2008), 9<sup>th</sup> edition (2009), 10<sup>th</sup> edition (2010)**

De Mendoza *et al.* **(2010)**. *Guía de resistencias a los antirretrovirales*. Red de Investigación en SIDA (RIS). **Publicaciones Permanyer**.

De Mendoza *et al.* **(2009)**. *Guía de resistencias a los antirretrovirales*. Interpretación de genotipos de resistencia de la Red de Investigación en SIDA (RIS). **Publicaciones Permanyer**.

Clotet B, Llibre JM, Martinez-Picado J, Paredes R. **(2007)**. *Resistencia del VIH a los antirretrovirales*. En: **Guía práctica del SIDA: clínica, diagnóstico y tratamiento (9ª edición)**. Editorial Elsevier/Masson. Barcelona. ISBN: 978-84-458-1791-9.

Varios autores **(2007)**. *Guía de resistencias a los antirretrovirales*. Interpretación de genotipos de resistencia de la Red de Investigación en SIDA (RIS). (2007). **Publicaciones Permanyer**.

Prado JG and Martinez-Picado J. **(2005)**. *Estudio del fitness viral, ¿tiene utilidad en la práctica clínica? Inhibidores de Fusión* 7:3-5.

Prado JG and Martinez-Picado J. **(2005)**. «Fitness» del VIH-1 e implicaciones en la patogénesis de la infección. **Infecciones e Inmunología** 4(2):29-38.

Martinez-Picado J. **(2001)**. *Técnicas de virología para laboratorios de VIH: macrocultivo cualitativo de PBMCs*. **Timely Topics in Medicine**.

Martinez-Picado J. **(2001)**. *Técnicas de virología para laboratorios de VIH: capacidad replicativa viral*. **Timely Topics in Medicine**.

Martinez-Picado J. **2001**. *Capacidad replicativa del VIH-1*. **AIDS Cyber Journal** 4.

Clotet B, Martinez-Picado J, Ruiz L, Tural C. **2000**. *Resistencias a los fármacos antirretrovirales*, Ed. P. Permanyer SL, Barcelona.

Martinez-Picado J., and Clotet B. **2000**. *Tratamiento de la infección por VIH: más allá de la carga viral*. **JANO** 58:64-66.

Martinez-Picado J., B. Clotet. **1999**. *Mutaciones de resistencia seleccionadas durante tratamiento antirretroviral*, p. 57-133. In B. Clotet and L. Ruiz and J. Martinez-Picado and J. M. Gatell and D. D. Richman (ed.), **Guía práctica en el manejo de las resistencias al VIH**. Grupo E. Entheos, Madrid.

---

## PATENTS AND UTILITY MODELS

**TITLE:** Antibodies and uses thereof for the treatment of infections caused by enveloped viruses  
**INVENTORS:** (by order of signature): J Martinez-Picado, P Resa-Infante, I Erkizia, N Izquierdo-Useros, B Clotet

**PATENT APPLICATION No.** P23548EP00

**PRIORITY COUNTRY:** EU

**FILLING DATE:** 27 January 2023

**ENTITY:** IrsiCaixa AIDS Research Institute

**EXTENDED TO COUNTRIES:**

**COMPANIES EXPLOITING IT:**

**TITLE:** Method for detecting and quantifying inducible HIV reservoirs

**INVENTORS:** (by order of signature): MC Puertas, J Martinez-Picado

**PATENT APPLICATION No.** Provisional application N° US 63/193,261

**PRIORITY COUNTRY:** US

**FILLING DATE:** 26 May 2021

**ENTITY:** IrsiCaixa AIDS Research Institute

**EXTENDED TO COUNTRIES:**

**COMPANIES EXPLOITING IT:**

**TITLE:** Siglec-1 inhibitors for preventing, inhibiting the progression or treating Coronavirus infections

**INVENTORS:** (by order of signature): N Izquierdo-Useros, J Martinez-Picado, B Clotet

**PATENT APPLICATION No.** Provisional application N° US 63/152,346

**PRIORITY COUNTRY:** US

**FILLING DATE:** 23 February 2021

**ENTITY:** IrsiCaixa AIDS Research Institute

**EXTENDED TO COUNTRIES:**

**COMPANIES EXPLOITING IT:**

**TITLE:** Siglec-1 monoclonal antibodies for treating and preventing HIV-1 and Ebola virus infections

**INVENTORS:** (by order of signature): N Izquierdo-Useros, J Martinez-Picado, M Pino, D Perez-Zsolt, L Kremer

**PATENT APPLICATION No.** US 62/828,195

**PRIORITY COUNTRY:** US

**FILLING DATE:** 02 Apr 2019

**ENTITY:** IrsiCaixa AIDS Research Institute

**EXTENDED TO COUNTRIES:**

**COMPANIES EXPLOITING IT:**

**TITLE:** Microbicide compositions comprising Siglec-1 monoclonal antibodies for HIV-1 prevention and treatment

**INVENTORS:** (by order of signature): D Perez- Zsolt, N Izquierdo-Useros, J Martinez-Picado

**PATENT APPLICATION No.** US 62/832,054

**PRIORITY COUNTRY:** US

**FILLING DATE:** 02 Apr 2019

**ENTITY:** IrsiCaixa AIDS Research Institute

**EXTENDED TO COUNTRIES:**

**COMPANIES EXPLOITING IT:**

**TITLE:** HIV-1 Integrase deficient immunogens and methods for loading dendritic cells with said immunogens



INVENTORS: (by order of signature): MJ Buzón & J Martinez-Picado  
PATENT APPLICATION No. EP 12382016.9  
PRIORITY COUNTRY: Europe  
FILLING DATE: 20/01/2012  
ENTITY: IrsiCaixa AIDS Research Institute  
EXTENDED TO COUNTRIES:  
COMPANIES EXPLOITING IT:

TITLE: CD169 receptor inhibition method  
INVENTORS: (by order of signature): N Izquierdo-Useros, M Lorizate, H-G Kräusslich & J Martinez-Picado  
PATENT APPLICATION No. EP 11382392.6 and US 61/579242  
PRIORITY COUNTRY: Europe, Japan, China, and USA  
FILLING DATE: 22/12/2011  
ENTITY: IrsiCaixa AIDS Research Institute, and University of Heidelberg  
EXTENDED TO COUNTRIES:  
COMPANIES EXPLOITING IT:

TITLE: Methods and compositions for the treatment of AIDS  
INVENTORS: (by order of signature): G Fabriàs, F Goñi, N Izquierdo-Useros, A Llebaria, S Mañes, J Martinez-Picado  
PATENT APPLICATION No. PCT/EP2011/051237  
PRIORITY COUNTRY: USA, Japan, China  
FILLING DATE: 28/01/2011  
ENTITY: IrsiCaixa AIDS Research Institute, and CSIC  
EXTENDED TO COUNTRIES:  
COMPANIES EXPLOITING IT:

TITLE: HIV-1 primers for uracil-D-glycosylase-based cloning  
INVENTORS: (by order of signature): Richard T. D'Aquila, Lorraine Sutton, Maria Pia de Pasquale and Javier Martinez-Picado  
REQUEST NO. 44,210 (DOCKET:00786/41900)  
PRIORITY COUNTRY: USA  
PRIORITY DATE: 1999  
ENTITY: Massachusetts General Hospital  
EXTENDED TO COUNTRIES:  
COMPANIES EXPLOITING IT:

---

## INVITED TALKS

(since 2007)

### ***New Strategies for Curing HIV***

Plenary Opening presentation  
15<sup>th</sup> Spanish Conference on AIDS – GeSIDA  
Zaragoza (Spain), November 24<sup>th</sup> 2024.

### ***HIV reservoir size: smaller is better?***

Invited Lecture  
Pediatric Adolescent Virus Elimination (PAVE). A NIH-NIAID-sponsored Martin Delaney Collaboratory  
–virtual– October 29, 2024

### ***Allogeneic stem cell transplantation for hematologic malignancies in people with HIV: a path to cure HIV?***

Invited Lecture  
CRYOSTEM Scientific Day 202; under the aegis of SFGM-TC  
Paris (France), October 16, 2024

### ***Pediatric HIV infection as a model for curing HIV***

Invited Lecture  
Special populations with HIV: Children and adolescents, women and migrants  
Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) - AIDS Study Group (GeSIDA)  
Madrid (Spain), October 4, 2024

### ***HIV reservoir: an update for clinicians***

Invited Lecture  
10<sup>th</sup> HIV Workshop on HIV –virtual–  
Instituto de Investigación Sanitaria Gregorio Marañón  
Madrid (Spain), September 17, 2024

### ***Allogeneic stem cell transplantation to cure HIV: the IciStem experience***

Invited Lecture  
Aarhus HIV Cure symposium  
Aarhus (Denmark), September 12, 2024

### ***HIV Cure and Remission Strategies***

Invited Lecture  
“Stratégies antirétrovirales, comorbidités et immunothérapie de l’infection VIH”  
ANRS Emerging Infectious Diseases  
Paris Sante Campus (Paris), June 5, 2024

### ***RNA vaccines: a symphony of tenacity and chance in the Nobel Prize in Medicine***

Invited Lecture  
BioSciences Day  
Vic (Barcelona), April 24, 2024

### ***HIV Cure Research CROI 2024***

Invited Lecture  
Update on the 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)  
La Pedrera (Barcelona), March 14, 2024

### ***Challenging the frontiers of HIV research: from spontaneous cure to allogeneic transplants***

Invited Lecture  
Workshop “Reservoir measures in HIV cure strategies”  
Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) - AIDS Study Group (GeSIDA)  
Madrid, February 20<sup>th</sup>, 2024

### ***Vacunes d’ARN: uns simfonia de tenacitat i atzar en el Nobel de Medicina***

Invited Lecture  
Cicle Premis Nobel 2023  
Espai Ciència, Octubre Centre de Cultura Contemporània,  
Valencia, January 29<sup>th</sup>, 2024

### ***Allogeneic stem cell transplantation in HIV cure research***

Invited Lecture  
Biotechnology: undergraduate seminar  
University of Vic, December 4<sup>th</sup>, 2023

### ***Allogeneic stem cell transplantation in HIV cure research***

Invited Lecture  
Living with HIV, organized by HispanoSIDA  
CaixaForum, Barcelona, November 22<sup>nd</sup>, 2023

### ***HIV: challenging the immune system***

Invited Lecture  
Master Mundus Life II  
Autonomous University of Barcelona, October 19<sup>th</sup>, 2023

### ***Clinical, host and virological factors associated with a reduction of HIV latent reservoirs in the RID HIV cohorts***

Invited Lecture  
Emory University  
Atlanta, October 16<sup>th</sup>, 2023

### ***HIV eradication and cure***

Invited Lecture  
2<sup>nd</sup> edition HIV from A to Z: training a new generation of HIV physicians  
Virtual (Spain), July 18, 2023

### ***Biomedical research against viral pandemics***

Invited Lecture  
Universitat Internacional de Catalunya  
Barcelona, July 8<sup>th</sup>, 2023

### ***Allogeneic stem cell transplantation to cure HIV: so close yet so far***

Invited Lecture  
Hospital de Bellvitge  
Barcelona, June 13<sup>th</sup>, 2023

### ***Allogeneic stem cell transplantation to cure HIV: so close yet so far***

Invited Lecture  
Spring Meeting of the Catalan Society of Immunology on “Leukocyte differentiation and adult immuno-deficiencies”  
Barcelona, May 18<sup>th</sup>, 2023

### ***HIV-1 vs. SARS-CoV-2: similarities and differences***

Invited Lecture  
Update on HIV infection and the COVID-19 pandemic  
University of Vic-UCC, April 20<sup>th</sup>, 2023

### ***Can We Cure HIV? where oncology and virology meet***

Invited Lecture  
Catalan Institute of Oncology  
Barcelona, April 7<sup>th</sup>, 2023

### ***Basic and Translational Science CROI 2023***

Invited Lecture  
European update on the 30<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2023)  
Online, March 9, 2023

### ***Basic and Translational Science CROI 2023***

Invited Lecture  
Update on the 30<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2023)  
La Pedrera (Barcelona), March 2, 2023

### ***40 years of HIV: defying the toughest!***

Invited Lecture  
VIR Biotec  
San Diego (CA, USA), November 29, 2022

***RID-HIV: clinical cohorts and assays definition***

Invited Lecture  
NIH meeting  
Palm Springs (CA, USA), October 10, 2022

***The multitask efforts of measuring viral persistence***

Invited Lecture  
8<sup>th</sup> HIV Cure Symposium  
Ghent (Belgium), September 12, 2022

***Reservoirs & Persistence - Assays***

Invited Lecture  
Viral Infections & Inflammation 2022  
Washington (USA), September 9, 2022

***Exceptional HIV Elite Controllers***

Invited Lecture  
HIV Cure Symposium of the International AIDS Society  
24<sup>th</sup> International AIDS Conference  
Montreal (Canada), July 28, 2022

***Should we be working towards larger international collaborations in HIV cure?***

Invited Lecture  
2022 Danish HIV cure symposium.  
The search for a cure for HIV – challenges and future perspectives  
Aarhus University (Denmark), June 17, 2022

***HIV-1 vs. SARS-CoV-2: Similarities and Differences***

Invited Lecture  
Update on HIV infection and the COVID-19 pandemic: HIV and SARS-CoV-2: Similarities and Difference between two Pandemics  
Manresa (Barcelona), May 25, 2022

***HIV cure***

Invited Lecture  
Update on the 29<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2022)  
La Pedrera (Barcelona), March 3, 2022

***40 Years of HIV: Can We Cure It?***

Invited Lecture  
Universidad Miguel Hernandez y Hospital General Universitario de Elche  
Alicante (Spain), February 24, 2022

***HIV eradication and cure***

Invited Lecture  
HIV from A to Z: training a new generation of HIV physicians  
Virtual (Spain), January 12, 2022

***New HIV-1 Cure Strategies***

Plenary lecture  
12<sup>th</sup> Spanish Meeting on AIDS – GeSIDA  
Málaga, December 1, 2021

***Genetic factors and severity of COVID-19***

Update on HIV infection and the COVID-19 pandemic  
University of Vic-Central University of Catalonia (UVic-UCC)  
Virtual, June 1, 2021

***Update on HIV Cure Progress***

Closing Plenary Lecture  
European Meeting on HIV & Hepatitis: Treatment Strategies & Antiviral Drug Resistance  
Virtual, May 28, 2021

***VIHsión de futuro: la erradicación del VIH***

Invited Lecture  
Punto de encuentro VIH 2021  
Virtual, April 21, 2021

***Basic research: HIV cure and neutralizing antibodies***

Invited Lecture  
Update on the 28<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2021)  
Virtual, March 16, 2021

***HIV cure strategies***

Invited Lecture  
Conference on Pathogenesis of HIV Infection @ Universidad de Alcalá de Henares  
Virtual, February 24, 2021

***Does the size matter? Learning from cases with low-level viral reservoirs***

Invited Lecture  
BEAT-HIV Annual Meeting (adapted online due to Covid-19 restrictions)  
Philadelphia, June 9, 2020

***COVID-19: Encontrar la cura***

Invited [debate](#) with Núria Montserrat (ICREA-IBEC), and Javier Martínez-Picado (ICREA-IrsiCaixa). Chaired by the journalist Cristina Sáez  
Centre de Cultura Contemporània de Barcelona (CCCB)  
Barcelona, June 3, 2020

***aPD-1/aPD-L1 monoclonal antibodies on HIV-1 reservoirs***

Invited Lecture  
Workshop on cancer Treatment in Chronic infections and immunosuppression  
Barcelona, January 24, 2020

***Cell & Gene therapies to eliminate HIV***

Invited Lecture  
Katholieke Universiteit Leuven  
Leuven (Belgium), January 17, 2020

***Cell & Gene therapies to eliminate HIV***

Invited Lecture  
Sant Pau Hospital  
Barcelona, January 08, 2020

***HIV cure: Is it possible?***

Invited Lecture  
Vall d'Hebron Hospital  
Barcelona, December 16, 2019

***What is an HIV cure and how is it documented?***

Invited Lecture  
Foundation for Health Sciences  
Madrid, November 21, 2019

***Can HIV-1 infection be cured?***

Invited Lecture  
Interhospital sessions in infectious diseases @ the Miguel Servet Hospital  
Zaragoza, November 20, 2019

***Advances in HIV cure: Bone Marrow Transplant***

Invited Lecture  
VIH2019@unidades.es  
Madrid, October 25, 2019

***The IciStem experience: learning from allogeneic stem cell transplantation to cure HIV***

Invited Lecture  
European Society of Gene and Cell Therapy (ESGCT) Conference  
Barcelona, October 24, 2019

***Stem cell transplantation to cure HIV: so close yet so far***

Invited Lecture  
Lectures in Life Sciences; Northwestern University



Chicago, October 01, 2019

***Towards an HIV Cure***

Invited Lecture  
Int'l AIDS Society Pre-Conference  
Mexico DF, July 21, 2019

***Stem cell therapy to cure HIV: so close, so far***

Plenary invited Lecture  
23<sup>rd</sup> IFCC-EFLM European Congress of Clinical Chemistry  
and Laboratory Medicine  
Barcelona, May 22, 2019

***Hematological stem cell therapy to cure HIV infection: so close, so far***

Invited Lecture  
Sant Pau Hospital  
Barcelona, May 17, 2019

***Hematological stem cell therapy to cure HIV infection: so close, so far***

Invited Lecture  
Vall d'Hebron Institut de Recerca  
Barcelona, April 30, 2019

***Stem cell therapy to get rid of HIV: so close, so far***

Invited Lecture  
HIV cure research on the European level – Vision 2020-2025. German Center for Infectious Diseases Research (DZIF) Strategic Meeting.  
Hamburg (Germany), April 2, 2019

***Top 5 basic research breakthroughs in HIV***

Invited Lecture  
Museo Reina Sofia  
Madrid, March 15, 2019

***Top basic research breakthroughs in HIV cure***

Invited Lecture  
La Pedrera-Casa Milà  
Barcelona (Spain), March 14, 2019

***Hematological stem cell therapy to cure HIV infection: so close, so far***

Invited Lecture  
52<sup>nd</sup> Miami Winter Symposium: Evolving Concepts in HIV and Emerging Viral Infections.  
Miami (USA), January 28-30, 2019

***Trasplantament amb cèl·lules mare: Tan a prop i alhora tan lluny de la curació del VIH***

Invited Lecture  
XV Jornada de promoció de la salut i qualitat de vida per a persones amb VIH/SIDA  
CaixaForum, Barcelona, November 15, 2018

***Allogeneic stem cell transplantation***

Invited Keynote Speaker  
L'approccio multidisciplinare nella cura dei linfomi HIV-associati  
Milan (Italy), November 9, 2018

***Remission and cure efforts***

Invited Lecture  
22<sup>nd</sup> International AIDS Conference (AIDS 2018)  
Amsterdam, Netherlands, July 23, 2018

***Making HIV cure a reality: what separates us from a cure?***

Invited Keynote Speaker  
HIV Standalone 2018  
Amsterdam (Netherlands), June 7, 2018

***HIV persistence and approaches to cure***

Mauro Moroni Memorial Lecture  
10<sup>th</sup> Italian Conference on AIDS and Antiviral Research  
Rome (Italy), May 22, 2018

***Functional cure vs. eradication: will it be feasible?***

Invited Lecture  
28<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases  
Madrid (Spain), April 21, 2018

***New therapeutic strategies to cure HIV: so close, so far***

Invited Lecture  
8<sup>th</sup> International Workshop on HIV Persistence during Therapy  
Miami, FL (USA), December 15, 2017

***Treatment Intensification: much better?***

Invited Lecture  
HIV Intensification Workshop  
Philadelphia, PA (USA), December 5, 2017

***Allogeneic Stem Cell Transplantation in HIV-1 infected individuals: the IciStem Consortium***

Invited Lecture  
4<sup>th</sup> Utrecht HIV Cure Symposium  
Utrecht (Netherlands), November 20, 2017

***The HIV/AIDS pandemic from molecules to populations: basic research and public health challenges***

Invited Lecture  
ICREA Simposium  
Barcelona (Spain), October 31, 2017

***Allogeneic transplantation of hematopoietic progenitors and the cure of HIV infection***

Invited Lecture  
Hospital General Universitario Gregorio Marañón  
Madrid (Spain), October 17, 2017

***HIV Immunopathogenesis***

Invited Lecture  
Hot topics in HIV: Vaccines, Immune recovery and Eradication  
Barcelona (Spain), October 5, 2017

***Stem cell transplantation in HIV-1-infected patients***

Invited Lecture  
HIV and Hepatitis Nordic Conference  
Stockholm (Sweden), September 28, 2017

***HIV-1 or the art of teasing the immune system***

Invited Lecture  
Heinrich Pette Institute - Leibniz Institute for Experimental Virology  
Hamburg (Germany), June 8, 2017

***Rapid HIV Disease Progression***

Invited Lecture  
UVic-UCC: Actualització sobre Sida i Metagenòmica  
Vic (Spain), May 23, 2017

***HIV Reservoir: Current Strategies for Eradication***

Invited Lecture  
I meeting HIV as a model for understanding immunology  
Barcelona (Spain), May 9, 2017

***Stem cell therapy to cure HIV infection: so close, so far***

Invited Lecture  
Aarhus University  
Aarhus (Denmark), January 31, 2017

***Allogeneic Stem Cell Transplantation***

Invited Lecture  
Hot topics in HIV: vaccines, immune recovery and eradication  
Barcelona, November 3, 2016

**Residual Replication in HIV-1 suppressed patients: pros and cons**

Invited Lecture  
University Hospital Zurich (Universität Zürich Irchel)  
Zurich (Switzerland), October 13, 2016

**HIV cure: dream or reality?**

Invited Lecture  
Berlin Meeting 2016 on HIV & viral Hepatitis  
Berlin, Germany October 8, 2016

**HIV-1 Eradication Strategies**

Invited Lecture  
IN ACTION: Italian network Acute HIV Infection  
Monza, Italy October 5, 2016

**AIDS Research: a yet incomplete success story**

Invited Lecture  
Reference Network in Biotechnology  
Bellaterra (Barcelona), July 8, 2016

**Role of Residual Viral Replication**

Invited Lecture  
ASM (*American Society for Microbiology*) Microbe 2016  
Boston, MA (USA), June 16-20, 2016

**Diagnostic assays to guide HIV cure: the EpiStem experience**

Invited Lecture  
14<sup>th</sup> European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance  
Rome (Italy), May 27, 2016

**HIV disease progression rates**

Invited Lecture  
Instituto Nacional de Microbiología (Instituto de Salud Carlos III)  
Majadahonda (Madrid), May 4, 2016

**HIV-1 or the art of teasing the immune system**

Invited Lecture  
Instituto de Biomedicina de Sevilla (IBIS)  
Sevilla, March 10, 2016

**New frontiers in HIV research: a translational view**

Invited Lecture  
Post CROI 2016  
Zaragoza, March 9, 2016

**Basic research and HIV-1 cure**

Invited Lecture  
Post CROI 2016 La Pedrera  
Barcelona, March 1, 2016

**Allogeneic stem-cell transplantation in HIV-1-infection: as close to cure**

Invited Lecture  
Josep Carreras Leukaemia Research Institute  
Barcelona, January 20, 2016

**Obstacles and opportunities to cure HIV-1**

Invited Lecture  
Department of Pharmacy  
University Hospital Germans Trias i Pujol  
Barcelona, January 12, 2016

**Allogeneic stem-cell transplantation**

Invited Lecture  
15<sup>th</sup> European AIDS Conference (EACS)  
Barcelona, October 23, 2015

**Impact of Integrase Inhibitors on the viral reservoir**

Invited Lecture  
1<sup>st</sup> HIV Forum: Integrase Inhibitors  
Barcelona, October 20, 2015

**Allogeneic stem-cell transplantation in HIV-1-infection**

Invited Lecture  
STEPS: A community initiative to design the pathway to a long-term remission of HIV infection  
Barcelona, October 20, 2015

**HIV Cure**

Invited Lecture  
29<sup>th</sup> IUSTI European Conference on Sexually Transmitted Infections  
Sitges (Spain), September 24-26, 2015

**Cure for HIV: a biomedical challenge**

Invited Lecture  
Polish AIDS Conference  
Łódź (Poland), June 19, 2015

**HIV-1 eradication: a translational perspective**

Invited Lecture  
Curs: Actualització sobre Sida i Malalties Relacionades i el seu tractament (UVic-UCC)  
Manresa (Spain), May 12, 2015

**HIV Cure**

Invited Lecture  
XIII CURSO DE ACTUALIZACIÓN EN ENFERMEDADES INFECCIOSAS. Universidad Rey Juan Carlos  
Alcorcón (Spain), May 05, 2015

**HIV-1 eradication: a translational perspective**

Invited Lecture  
Current Challenges in HIV-1 Infection  
Madrid (Spain), January 19, 2015

**HIV-1 eradication strategies**

Invited Lecture  
Cell Therapy Consortium: from stem cells to patient welfare  
Madrid (Spain), January 16, 2015

**HIV-1 Remission Strategies**

Invited Lecture  
Pasteur Institute  
Paris (France), December 12, 2014

**Allogeneic stem cell transplant in HIV-1-infected individuals**

Invited Lecture  
6<sup>th</sup> Spanish Meeting on AIDS - GeSIDA  
Malaga (Spain), November 26, 2014

**HIV-1 eradication strategies**

Invited Lecture  
56<sup>th</sup> National Meeting of the Spanish Society for Hematology and Hemotherapy  
Madrid (Spain), November 7, 2014

**Host-virus interactions in HIV-1 disease progression: contribution of the -omics to clinical observations**

Invited Lecture  
BCN Virology Meeting 2014 (SCB)  
Barcelona (Spain), November 3, 2014

**Past, present and future of AIDS**

Invited Lecture  
3<sup>rd</sup> Innovation Workshop  
Badalona City Hospital  
Badalona (Spain), October 30, 2014

**\*Immunopathogenesis**

Invited Lecture  
Hot topics in HIV: Vaccines, Immune Recovery and Eradication  
Barcelona (Spain), October 9, 2014

***El virus de la SIDA: nou mecanisme per envair el sistema immunitari***

Invited Lecture  
50<sup>è</sup> Aniversari Càtedra de Microbiologia Universitat de Barcelona  
Barcelona (Spain), May 30, 2014

***Host-virus interactions that determine clinical progression in HIV-1 infection***

Invited Lecture  
European Consortium Entire-Net  
Institut Català de la Salut  
Barcelona (Spain), May 28, 2014

***Barriers to achieving a cure for HIV/AIDS***

Invited Lecture  
American Foundation for AIDS Research (amfAR)  
Munich (Germany), May 24, 2014

***Barriers to achieving a cure for HIV/AIDS***

Invited Lecture  
Hospital Universitari de Bellvitge  
Barcelona (Spain), May 22, 2014

***One more trick that HIV-1 uses to subvert the human immune system***

Invited Lecture  
Ragon Institute of MGH, MIT and Harvard  
Cambridge (MA, USA), May 13, 2014

***The AIDS virus: new mechanism to invade the immune system***

Invited Opening Lecture  
3<sup>rd</sup> Madrid Meeting on Dendritic cells and Macrophages  
Madrid (Spain), April 28, 2014

***Cure in Chronic HIV-1 infection***

Department of Internal Medicine  
Invited Lecture  
University Hospital Germans Trias I Pujol  
Badalona (Spain), April 1, 2014

***Host-virus interactions in HIV-1 disease progression: learning from clinical observation***

Societat Catalana d'Immunologia  
Invited Lecture  
Hospital de la Santa Creu i Sant Pau  
Barcelona (Spain), February 6, 2014

***The AIDS virus: new mechanism to invade the immune system***

Invited Lecture  
Institut d'Estudis Catalans  
Barcelona (Spain), January 13, 2014

***Challenges in clinical research***

Invited Lecture  
1<sup>st</sup> European Roundtable on Future Management of HIV  
Barcelona (Spain), November 22, 2013

***Cure in Chronic HIV-1 infection***

Invited Lecture  
V GESIDA Spanish AIDS Conference  
Sitges (Spain), November 20, 2013

***The path towards a cure for HIV***

Invited plenary  
7<sup>th</sup> Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention & Treatment  
Royal Tropical Institute (KIT)  
Amsterdam (The Netherlands), 19 November 2013  
<http://www.nchiv.org/>

***One more trick that HIV-1 uses to subvert the human immune system***

Invited lecture  
Amsterdam Medical Center (AMC)

Amsterdam (The Netherlands), 18 November 2013

***Is HIV cure achievable?***

Invited Lecture  
British HIV Association Autumn Conference  
Queen Elizabeth II Conference Centre  
London (UK), 15 November 2013  
<http://www.bhiva.org/BHIVAHIVHep2013.aspx>

***Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection***

Invited Lecture  
Hot topics in HIV: Vaccines, Immune Recovery and Eradication  
Hotel AC Forum  
Barcelona (Spain), October 10, 2013

***Host-Virus Interactions in HIV-1 Rapid Disease Progression***

Invited Lecture S05.01  
Symposium on New Targets from Acute Infection  
AIDS Vaccine 2013 Conference  
Barcelona (Spain), October 9, 2013

***La Recerca Científica del VIH/SIDA***

Invited Lecture  
Acte de Lliurament de Beques per a Màsters d'Excel·lència  
La Pedrera, Barcelona (Spain), October 9, 2013

***Sugar sweet viruses: the scourge of the immune system***

Invited Lecture  
University of Ghent  
Ghent (Belgium), August 27, 2013

***Past, present and future of AIDS***

Invited Lecture  
Major challenges in biomedicine  
Debats ICREA-CCCB  
Barcelona (Spain), June 12, 2013

***Host-virus interactions in HIV-1 disease progression: learning from clinical observation***

Invited Lecture  
Centro de Investigación Biomédica de La Rioja (CIBIR)  
Logroño (Spain), April 16, 2013

***Virological Challenges in monitoring HIV Eradication***

11<sup>th</sup> European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance  
Invited Lecture  
Trevi Fountain Conference Centre  
Rome (Italy), March 20–22, 2013

***Host-virus interactions in HIV-1 disease progression: learning from clinical observation***

Symposium: *Emerging Infectious Diseases: the New Pandemics in the 21<sup>st</sup> Century*  
Invited Lecture  
Organized by [Nature Publishing Group](#) and chaired by the Editor in-chief of Nature Medicine  
Fundación Ramón Areces  
Madrid (Spain), February 7, 2013

***Host-virus interactions: how do retroviruses establish and maintain latency?***

Workshop: HIV cure and eradication: a feasible option?  
Invited Lecture  
Palazzo delle Stelline  
Milan (Italy), January 24, 2013

***HIV cure: a scientific challenge underway***

Invited Opening Lecture  
IV GESIDA Spanish AIDS Conference  
Toledo (Spain), November 27, 2012

**Rapid HIV-1 disease progression**

Heidelberg University  
Heidelberg (Germany), November 20, 2012

**Why we cannot cure HIV infection?**

Vall d'Hebron University Hospital  
Barcelona, November 19, 2012

**Immunopathogenesis**

Hot topics in HIV: Vaccines, Immune Recovery and Eradication  
Hotel Granados, Barcelona, October 29, 2012

**Dulces virus: la pérdida del sistema inmunitario**

Centro Biología Molecular CSIC-UAM  
Madrid (Spain), October 25, 2012

**VIH y Células Dendríticas: una relación agrí dulce**

Respuesta inmune en el control de las enfermedades virales  
IV Jornadas Monográficas de la Sociedad Española de Virología  
Chinchón, Madrid (Spain), October 19, 2012

**The role of antiretroviral therapy in immune modulation: treatment intensification studies**

amfAR Think Tank: Research toward a cure for AIDS: The role of the immune system and immune-based therapies  
NH Caransa Hotel, Amsterdam, September 24-25, 2012

**Viral Eradication: the Cure Agenda**

Invited Plenary Session  
XIX International AIDS Conference  
Washington DC (USA), July 24, 2012

**HIV Reservoirs**

Plenary Session  
Joint annual meeting (Swiss Society of Infectious Diseases SSI, Swiss Society for Hospital Hygiene SSHH, Swiss Society for Microbiology SSM, Swiss Society for Tropical Medicine and Parasitology SSTMP)  
Olma Messen St. Gallen, (Switzerland), June 22, 2012.

**HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse?**

Section Plenary  
Meeting on Dendritic cells and Macrophages  
Centro Nacional de Biotecnología/CSIC  
Madrid (Spain), May 28-29, 2012

**Erradicación Viral**

VIH: tratamiento, prevención, erradicación  
Fundación Valenciana de Estudios Avanzados  
Valencia (Spain), May 21, 2012

**Pushing the limits: unmasking residual HIV replication during HAART**

Section Plenary  
10<sup>th</sup> European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance  
Barcelona (Spain), March 29, 2012

**Residual HIV Replication on Antiretroviral Therapy**

Section Plenary  
5<sup>th</sup> International Workshop on HIV Persistence During Therapy  
St. Maarten (West Indies), December 6-9, 2011

**Progresión rápida en la infección por VIH-1**

Section Plenary  
III Congreso Nacional de GeSIDA  
Sevilla (Spain), November 7-10, 2011

**The best of basic science for HIV clinicians in the last year**

Closing Plenary  
The 13<sup>th</sup> European AIDS Conference / EACS

Belgrade (Serbia), October 15, 2011

**Eradicating HIV: Past and present attempts**

Towards an HIV Cure: Insight into residual viral replication, establishment of reservoirs and understanding mechanism of persistence  
6<sup>th</sup> International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention  
Rome (Italy), July 20, 2011

**New concepts in eradication of virus reservoirs**

New concepts in HIV immunopathogenesis, treatment and vaccine strategies; International AIDS Society  
Istituto Superiore di Sanità  
Rome (Italy), July 16, 2011

**Molecular mechanisms of HIV-1 uptake by dendritic cells**

Centro de Investigación Médica Avanzada  
Universidad de Navarra  
Pamplona (Spain), June 17, 2011

**Raltegravir intensification, the HIV reservoir and inflammation**

Conference on Inflammation and Mucosal Immunity in HIV  
McGill University  
Montreal (Canada), May 2, 2011

**Impact of raltegravir intensification of HAART-suppressed patients on HIV-1 replication and immune dynamics.**

Scientific Input Engagement  
Hyatt Regency DFW  
Dallas (TX, USA), December 6, 2010

**Residual HIV replication and therapy intensification**

NEW INSIGHTS INTO FUNDAMENTAL AND CLINICAL HIV/AIDS RESEARCH  
Pasteur Institute  
Paris (France), December 3, 2010  
(Invited by Françoise Barre-Sinoussi, Nobel Prize in Physiology or Medicine 2008)

**HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients**

X Jornada de Virologia (opening lecture)  
Institut d'Estudis Catalans  
Societat Catalana de Biologia  
Barcelona (Spain), November 23, 2010

**Molecular mechanisms of HIV-1 capture and antigen presentation by dendritic cells**

II Jornadas monográficas de la Sociedad Española de Virología: 25 años de tratamiento antirretroviral.  
Hotel NH La Habana.  
Madrid (Spain), October 30, 2010

**New factors involved in the prognosis of HIV infection**

14<sup>a</sup> Jornada de tratamiento antirretroviral en pediatría  
2<sup>o</sup> Curso de formación básica en infección VIH pediátrica  
CaixaForum  
Barcelona (Spain), October 22, 2010

**HIV reservoirs**

4<sup>th</sup> Teaching Meeting of the Spanish AIDS Research Network  
Hotel Estela  
Sitges (Spain), October 6, 2010

**Residual HIV Replication and Therapy Intensification**

Hamburger HIV-Strategieforum  
Universitätsklinikum Hamburg-Eppendorf  
Hamburg (Germany), June 12, 2010

**New evidence about HIV eradication**

Palau de la Música Catalana  
Barcelona, 6 May 2010

**Hosting HIV: From Intuitive to Sophisticated Genomics**

Hospital Sant Joan de Déu  
Barcelona, 6 April 2010

**Hosting HIV: From Intuitive to Sophisticated Genomics**

Centro de Investigación en Enfermedades Infecciosas (CieNI)  
Instituto Nacional de Enfermedades Respiratorias (INER)  
Mexico DF, 19 March 2010

**Capture and Transfer of HIV-1 Particles by Mature Dendritic Cells Converges with the Exosome Dissemination Pathway**

Instituto de Investigaciones Biomédicas  
Universidad Nacional Autónoma de México (UNAM)  
Mexico DF, 18 March 2010

**HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients**

HIV Biology and Pathogenesis  
Keystone Symposia on Molecular and Cellular Biology  
Santa Fe (New Mexico), USA, 15 January 2010

**Recent Progress in HIV Drug Resistance**

Update 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections  
Fundació de Lluita contra la SIDA (Hotel AC)  
Barcelona, 26 February 2010

**Genómica del huésped en la infección por el VIH-1**

Programa oficial de post-grado en Biociencias, Módulo de Microbiología Clínica, Grandes Síndromes en Patología Infecciosa  
Badalona, 22 January 2010.

**HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients**

HIV Biology and Pathogenesis  
Keystone Symposia on Molecular and Cellular Biology  
Santa Fe (New Mexico), USA, 12-17 January 2010

**HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients**

Fundació Lluita contra la SIDA  
Hotel Condes de Barcelona, Barcelona 26 November 2009

**Capture and Transfer of HIV-1 Particles by Mature Dendritic Cells Converges with the Exosome Dissemination Pathway**

Pasteur Institute  
Paris 13 November 2009  
(Invited by Françoise Barre-Sinoussi, Nobel Prize in Physiology or Medicine 2008)

**Progresión Rápida en la Infección por VIH-1**

I Congreso Nacional GeSIDA (Grupo de Estudio de SIDA – SEIMC)  
Palacio Municipal de Congresos  
Madrid 21-24 October 2009

**Rapid HIV-1 Disease Progression**

Invited presentation in the HIV Pathogenesis Symposium  
49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy of the American Society for Microbiology  
San Francisco (CA), 12-15 September 2009

**AIDS and HIV: 25 years of progress and pitfalls**

Cicle de Xerrades al Col.legi de Biòlegs de Catalunya

Col.legi de biòlegs de Catalunya  
Barcelona, 24 April 2009

**Effects of Treatment Intensification**

16<sup>th</sup> Scientific Board Meeting and EraMune Investigators Meeting  
ORVACS (Objectif Recherche VACCin Sida)  
Foundation Bettencourt Schueller  
Paris, 6-7 March 2009

**Recent Progress in Basic HIV Research**

Update 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections  
Sociedad Enfermedades Infecciosas del Norte (SEINORTE)  
Pamplona, 26 February 2009

**AIDS and HIV: 25 years of progress and pitfalls**

2<sup>nd</sup> Workshop on Research at the School of Pharmacy  
University of Barcelona  
Barcelona, 23 February 2009

**Recent Progress in HIV Drug Resistance**

Update 16<sup>th</sup> Conference on Retroviruses and Opportunistic Infections  
Fundació de Lluita contra la SIDA (Hotel AC)  
Barcelona, 20 February 2009

**Genómica del huésped en la infección por el VIH-1**

Programa oficial de post-grado en Biociencias, Módulo de Microbiología Clínica, Grandes Síndromes en Patología Infecciosa  
Badalona, 21 January 2009.

**Principios de la Farmacogenómica en el campo del VIH**

Workshop: Factores del huésped y del virus que afectan a la progresión de la enfermedad. Cohortes genéticas.  
Workshop Organizer and lecturer

1. Barcelona, 29 April 2008.
2. Madrid, 17 June 2008
3. Barcelona, 21 October 2008

**The evolving concept of HIV eradication**

Thinking about HIV eradication: is it possible now?  
Barcelona, 27 November 2008

**Genetic Correlates of Resistance to HIV-1 Infection in HIV-1 Exposed but Uninfected: Patients with Haemophilia**

Banc de Sang i Teixits  
Barcelona, 26 May 2008

**Host Genomics and Pharmacogenomics in HIV-1 Infection**

Fundació de Lluita contra la SIDA  
Badalona, 21 May 2008.

**SIDA, la malaltia – la investigació**

XXIII Jornades Culturals. Ciència i Món  
La Farga, Sant Cugat del Vallés, Barcelona, Spain  
Barcelona, 13 & 14 March 2008.

**Integración del screening genético del HLA-B\*5701 en la rutina habitual del laboratorio**

The Predict-1 Study  
Hotel Catalonia Plaza, Barcelona, Spain  
Barcelona, 5 March 2008.

**Selección de los datos más destacables de básica del 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections**

XIV Symposium “Por un Mundo sin VIH”  
Hotel Melià Gran Sitges  
Barcelona, 23 February 2008.

**Update in drug resistance**

Update 15<sup>th</sup> Conference on Retroviruses and Opportunistic

Infections  
Hotel AC  
Barcelona, 15 February 2008.

***Hosting HIV: from intuitive to sophisticated genomics***

Boston University Medical Center  
Boston, 7 February 2008

***Genómica del huésped en la infección por el VIH-1***

Programa oficial de post-grado en Biociencias, Módulo de Microbiología Clínica, Grandes Síndromes en Patología Infecciosa  
Badalona, 16 January 2008.

***Host Genomics and Pharmacogenomics in HIV-1 Infection***

Fundació de Lluita contra la SIDA  
Badalona, 10 January 2008.

***Host Genomics and Pharmacogenomics in HIV-1 Infection***

Fundació de Lluita contra la SIDA  
Badalona, 29 November 2007

***Molecular and cellular immunity in identical twins infected by the same Human Immunodeficiency Virus strain***

Acadèmia de Ciències Mèdiques i de la Salut -VIII Symposium La Marató de TV3-  
Barcelona, 27 June 2007

***Host Genomics and Pharmacogenomics in HIV-1 Infection***

Hotel La Romareda  
Zaragoza, 29 May 2007

***Constraints on HIV-1 evolution and immunodominance in monozygotic twins***

Pediatrics Unit, Hospital Universitari Germans Trias i Pujol  
Badalona, Barcelona, 17 May 2007

***Pharmacogenomics and its application on HIV-1 infection***

Hotel trip  
Oviedo, 26 April 2007

***Host Genomics in HIV-1 infection***

Barajas Business Center  
Madrid, 11 April 2007

***Update on HIV-1 drug resistance: highlights from the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, 2007)***

Hotel Fira Palace  
Barcelona, 12 March 2007

***HIV-1 Protease***

Institut de Biotecnologia i Biomedicina Vicent Villar i Palasi (Universitat Autònoma de Barcelona)  
Bellatera, Barcelona, 13 February 2007

***Host Genomics in HIV-1 infection***

Fundació de Lluita contra la SIDA  
Badalona, 9 February 2007

***Intravenous drug addition and viral evolution: HIV-1 acquired immunity***

Internal Medicine Unit, Hospital Universitari Germans Trias i Pujol  
Badalona, Barcelona, 24 January 2007

---

## RESEARCH ACTIVITIES IN INTERNATIONAL CENTERS

### Invited Researcher

CENTER: University of California, San Diego

TOWN: San Diego      COUNTRY: **USA**      YEAR: 2002

SUBJECT: HIV-1 Evolution during treatment interruptions

### Postdoctoral Stage

CENTER: Harvard University: Infectious Disease Unit, Massachusetts General Hospital

TOWN: Boston      COUNTRY: **USA**      YEARS: 1996-1999

SUBJECT: HIV-1 drug resistance and replicative capacity

### Predoctoral stage

CENTER: Department of Microbiology, University of Umeå

TOWN: Umeå      COUNTRY: **Sweden**      YEAR: 1992

SUBJECT: Molecular determination of *Vibrio* bacterium in waters

---

## CONFERENCE CONTRIBUTIONS

CONTRIBUTION: Poster Presentation PP1.17-00054  
TITLE: Optimizing detection of HIV-1 infected cells: a novel bioinformatics pipeline leveraging Kraken2 for single-cell multiomics datasets  
AUTHORS: Garrido-Sanz L, Soriaga LB, Wong E, Puertas MC, Dalmau J, Coll P, Mothe B, Clotet B, Telenti A, Martínez-Picado J, Morón-López S  
CONFERENCE: 11<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Fort Lauderdale (FL, USA), December 10-13, 2024**

CONTRIBUTION: Oral Presentation 07  
TITLE: Two decades of HIV in Spain: insights from the CORIS cohort  
AUTHORS: Jarrín I, Moreno C, Marco-Sánchez C, Gómez-García T, Ruiz Sancho A, Inciarte A, Martínez-Picado J, Capa L, Olalla J, Ruiz Seco P, de Zárraga Fernández MA, Dueñas Gutiérrez C, Montero-Alonso M, Moreno S and Cohorte CORIS  
CONFERENCE: 15<sup>th</sup> Spanish Conference on AIDS – GeSIDA  
CITY and YEAR: **Zaragoza (Spain), November 24-27, 2024**

CONTRIBUTION: Oral Presentation 14  
TITLE: HIV-1-infected individuals with extremely low reservoir on ART are characterized by reduced viral diversity and higher hypermutations levels in their viral reservoirs  
AUTHORS: González Navarro I, Lorenzo-Redondo R, Garrido-Sanz L, Urrea V, Gálvez C, Martínez-Picado J, Salgado M  
CONFERENCE: 15<sup>th</sup> Spanish Conference on AIDS – GeSIDA  
CITY and YEAR: **Zaragoza (Spain), November 24-27, 2024**

CONTRIBUTION: Poster Presentation 132  
TITLE: Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy  
AUTHORS: Resa-Infante P, Erkizia I, Muñoz-Trabudua X, Linty F, Bentlage A, Perez-Zsolt D, Muñoz-Basagoiti J, Raich-Regué D, Izquierdo-Useros N, Rispens T, Vidarsson G, Martínez-Picado J  
CONFERENCE: 15<sup>th</sup> Spanish Conference on AIDS – GeSIDA  
CITY and YEAR: **Zaragoza (Spain), November 24-27, 2024**

CONTRIBUTION: Poster Presentation 139  
TITLE: Optimizing detection of HIV-1 infected cells: a novel bioinformatics pipeline leveraging Kraken2 for single-cell multiomics datasets  
AUTHORS: Garrido-Sanz L, Soriaga LB, Wong E, Puertas MC, Dalmau J, Coll P, Mothe B, Clotet B, Telenti A, Martínez-Picado J, Morón-López S  
CONFERENCE: 15<sup>th</sup> Spanish Conference on AIDS – GeSIDA  
CITY and YEAR: **Zaragoza (Spain), November 24-27, 2024**

CONTRIBUTION: Oral Presentation 9  
TITLE: Plasma biomarkers in children and young people with long-COVID  
AUTHORS: Izquierdo-Pujol J, Urrea V, Puertas M, Dalmau J, Gonzalez-Aumatell A, Carreras-Abad C, Mendez M, Rodrigo C, Martínez-Picado J, Morón-López S  
CONFERENCE: Demystifying Long COVID International Conference 2024  
CITY and YEAR: **Barcelona (Spain), November 22-24, 2024**

CONTRIBUTION: Oral Presentation 13  
TITLE: Exploring the neurobiological underpinnings of long COVID-related cognitive impairment - NeuroCOVID study  
AUTHORS: Puertas M, Prats A, Grau-Rivera O, Lopez C, Minguillón C, Suárez-Calvet M, Muñoz-Moreno J, Mateu L, Navarro A, Martínez-Picado J, Massanella M  
CONFERENCE: Demystifying Long COVID International

Conference 2024  
CITY and YEAR: **Barcelona (Spain), November 22-24, 2024**

CONTRIBUTION: Oral Presentation  
TITLE: Modelling Post-acute COVID-19 Neuropathogenesis in Human Brain Organoids  
AUTHORS: Puertas MC, Martí-Sarrias A, García-González L, Turpin I, Bayón-Gil A, Piñol-Jurado P, Resa-Infante P, Acosta S, Martínez-Picado J  
CONFERENCE: Viral Infections & Inflammation Workshop 2024  
CITY and YEAR: **Virtual, September 26-27, 2024**

CONTRIBUTION: Oral Presentation  
TITLE: Exploring Endothelial Dysfunction Led by Proinflammatory Cytokines in COVID-19: Insights from 3D Lung Microvessels On-Chip  
AUTHORS: Fortea M\*, Puertas MC\*, Urrea V, Cherubini M, Bayón-Gil A, Resa-Infante P, Piñol-Jurado P, Bernabeu M\*, Haase K\*, Martínez-Picado J\*  
CONFERENCE: Viral Infections & Inflammation Workshop 2024  
CITY and YEAR: **Virtual, September 26-27, 2024**

CONTRIBUTION: Poster Presentation  
TITLE: Unravelling neurodegenerative effects of SARS-CoV-2 infection in Alzheimer's disease-brain organoids  
AUTHORS: Garcia-Gonzalez L, Martí-Sarrias A, Puertas MC, Turpin I, Bayón-Gil A, Resa-Infante P, Martínez-Picado J, Navarro A, Acosta S  
CONFERENCE: Alzheimer's Association International Conference 2024  
CITY and YEAR: **Philadelphia (USA), July 27 - August 1, 2024**

CONTRIBUTION: Poster Presentation  
TITLE: Exploring Endothelial Dysfunction in COVID-19: Insights from 3D Lung Microvessels On-Chip  
AUTHORS: Fortea M, Puertas MC, Urrea V, Cherubini M, Bayón-Gil A, Resa-Infante P, Piñol-Jurado P, Martínez-Picado J\*, Bernabeu M\*, Haase K\*  
CONFERENCE: International Vascular Biology Meeting 2024  
CITY and YEAR: **Amsterdam (The Netherlands), July 3, 2024**

CONTRIBUTION: Oral Presentation 3318  
TITLE: Sex-specific Innate Immune Selection in Vertical HIV Transmission and cART-free Aviraemia in Males  
AUTHORS:  
CONFERENCE: 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)  
CITY and YEAR: **Denver (CO, USA), March 3-6, 2024**

CONTRIBUTION: Poster Presentation 853  
TITLE: Long COVID in Children Is Associated with Lower Anti-RBD IgG/IgA and Neutralizing Antibody Levels  
AUTHORS: Izquierdo-Pujol J, Morón-López S, Pedreño N, Pidkova T, Dalmau J, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, Carrillo J, Blanco J, Trinité B, Martínez-Picado J  
CONFERENCE: 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)  
CITY and YEAR: **Denver (CO, USA), March 3-6, 2024**

CONTRIBUTION: Poster Presentation 647  
TITLE: Impact of DTG+3TC as First-Line ART on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.  
AUTHORS: Moltó J, García-Guerrero MC, Bailón L, Moraes-Cardoso I, Aparicio E, Coll P, Rivero A, Rosen EP, Estes JD, Blanco J, Olvera A, Puertas MC, Mothe B, Martínez-Picado J, on behalf of the DUALITY study group.  
CONFERENCE: 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)



CITY and YEAR: **Denver (CO, USA) March 3-6, 2024**

CONTRIBUTION: Poster Presentation 519  
TITLE: Taming the Viral Reservoir Over Three Decades of Advancements in HIV Treatment  
AUTHORS: González-Navarro I, Urrea V, Gálvez C, Mothe B, Bailón L, Martinez-Picado J, Salgado M  
CONFERENCE: 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)  
CITY and YEAR: **Denver (CO, USA), March 3-6, 2024**

CONTRIBUTION: Poster Presentation 305  
TITLE: Massive endocytosis mechanisms are involved in CD169-mediated uptake of HIV-1 by dendritic cells.  
AUTHORS: Laguía-Nueda F, Chojnacki J, Erkizia I, Rebollo E, Geli MI, Enrich C, Martinez-Picado J, Resa-Infante P  
CONFERENCE: 31<sup>st</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2024)  
CITY and YEAR: **Denver (CO, USA) March 3-6, 2024**

CONTRIBUTION: Poster Presentation 35 (session B)  
TITLE: Enveloped viruses take advantage of Massive Endocytosis mechanisms in CD169-mediated uptake in Dendritic Cells.  
AUTHORS: Laguía-Nueda F, Chojnacki J, Erkizia I, Rebollo E, Geli MI, Enrich C, Martinez-Picado J, Resa-Infante P  
CONFERENCE: Viruses 2024  
CITY and YEAR: **Barcelona (Spain) February 14-16, 2024**

CONTRIBUTION: Oral Presentation  
TITLE: PBMC Immunophenotyping, plasma inflammatory profile and antibody levels of children with Long COVID  
AUTHORS: Izquierdo-Pujol J, Morón-López S, Pedreño N, Pidkova T, Dalmau J, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, Carrillo J, Blanco J, Trinité B, Martinez-Picado J.  
CONFERENCE: Demystifying Long COVID-19 International Conference 2023  
CITY and YEAR: **Madrid (Spain), December 7-9, 2023**

CONTRIBUTION: Oral Presentation CO-16  
TITLE: Taming the viral reservoir over three decades of advancements in HIV treatment  
AUTHORS: González-Navarro I, Urrea V, Gálvez C, Mothe B, Bailón L, Martinez-Picado J, Salgado M  
CONFERENCE: 14<sup>th</sup> Spanish Meeting on AIDS – GeSIDA  
CITY and YEAR: **A Coruña (Spain), November 26-29, 2023**

CONTRIBUTION: Thematic Poster Presentation PT-05  
TITLE:  $\alpha$ CD4 CAR-T cells produce an *in vitro* effective cytotoxic effect against CD4<sup>+</sup> T cells  
AUTHORS: Campos-Gonzalez G, Tirado N, Martinez-Picado J, Velasco-Hernandez T, Salgado M  
CONFERENCE: 14<sup>th</sup> Spanish Meeting on AIDS – GeSIDA  
CITY AND YEAR: **A Coruña (Spain), November 26-29, 2023**

CONTRIBUTION: Oral presentation  
TITLE: Lack of HIV-associated pathogenicity in Viremic Non-Progressors is related with preserved TLR4 responsiveness  
AUTHORS: Bayón-Gil A, Dalmau J, Erkizia I, Martinez-Picado J, Puertas MC  
CONFERENCE: XVII Conference of the Catalan Society of Immunology  
CITY and YEAR: **Barcelona (Spain), November 2-3, 2023**

CONTRIBUTION: Poster presentation  
TITLE:  $\alpha$ CD4 CAR-T cells produce an *in vitro* effective cytotoxic effect against CD4<sup>+</sup> T cells  
AUTHORS: Campos-Gonzalez G, Tirado N, Martinez-Picado J, Velasco-Hernandez T, Salgado M  
CONFERENCE: XVII Congress of the Catalan Society of Immunology  
CITY and YEAR: **Barcelona (Spain), November 2-3, 2023**

CONTRIBUTION: Oral presentation

TITLE: Massive Endocytosis mechanisms are involved in CD169-mediated uptake of HIV-1 by dendritic cells  
AUTHORS: Laguía-Nueda F, Chojnacki J, Erkizia I, Rebollo E, Geli MI, Enrich C, Martinez-Picado J, Resa-Infante P  
CONFERENCE: XXII Jornades de Virologia  
CITY and YEAR: **Barcelona (Spain) October 27<sup>th</sup>, 2023**

CONTRIBUTION: Oral Presentation  
TITLE: Taming the viral reservoir over three decades of advancements in HIV treatment  
AUTHORS: González-Navarro I, Urrea V, Gálvez C, Mothe B, Bailón L, Martinez-Picado J\*, Salgado M\*  
CONFERENCE: 1<sup>st</sup> HIV Reservoirs and Immune Control Conference  
CITY and YEAR: **Malahide (Ireland), October 1-4, 2023**

CONTRIBUTION: Oral Presentation  
TITLE: PBMC Immunophenotyping, plasma inflammatory profile and antibody levels of children with Long COVID  
AUTHORS: Izquierdo-Pujol J, Morón-López S, Pedreño N, Pidkova T, Dalmau J, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, Carrillo J, Blanco J, Trinité B, Martinez-Picado J.  
CONFERENCE: Keystone Symposia on Long COVID and Post Acute Sequelae of SARS-CoV-2 (PASC): Pathogenesis and Treatment  
CITY and YEAR: **Santa Fe (USA), August 27-31, 2023**

CONTRIBUTION: Oral Presentation #OALBA0504  
TITLE: Absence of viral rebound for 20 months without antiretrovirals after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells to treat a biphenotypic sarcoma  
AUTHORS: A. Sáez-Cirión, A.-C. Mamez, V. Avettand-Fenoel, P. Thoueille, M. Nabergoj, M. Hentzien, E. Meresle Costa, M. Salgado, M. Nijhuis, A. Melard, E. Gardienet, V. Monceaux, C. Passaes, A. Chapel, F. Perdomo-Celis, A. Wensing, J. Martínez-Picado, S. Yerly, M. Rougemont, A. Calmy, ICISTEM study group  
CONFERENCE: 12<sup>th</sup> IAS Conference on HIV Science  
CITY and YEAR: **Brisbane (Australia) July 23-26, 2023**

CONTRIBUTION: Oral Presentation #OALBX0104  
TITLE: Sustained aviraemia in the absence of anti-retroviral therapy in male children following *in utero* vertical HIV transmission  
AUTHORS: Cromhout G, Bengu N, Adland E, Herbert N, Lim N, Govender K, Fillis R, Sprenger K, Vieira V, Kannie S, van Lobenstein J, Chinniah K, Kapongo C, Bhoola R, Krishna M, Mchunu N, Puertas MC, Groll A, Reddy K, Ndung'u T, Oshenbauer C, Cotugno N, Palma P, Tagarro A, Roeder J, Giaquinto C, Rossi P, Kappes J, Martinez-Picado J, Archary M, Goulder P.  
CONFERENCE: 12<sup>th</sup> IAS Conference on HIV Science  
CITY and YEAR: **Brisbane (Australia) July 23-26, 2023**

CONTRIBUTION: Oral Presentation #OALBA0504  
TITLE: Low tryptophan catabolism marks immune preservation in HIV+ viremic non-progressors  
AUTHORS: Bayon-Gil A, Goldman A, Dalmau J, Ying Hong K, Koshy J, Giron L, Abdel-Mohsen M, Martinez Picado J, Puertas MC  
CONFERENCE: 12<sup>th</sup> IAS Conference on HIV Science  
CITY and YEAR: **Brisbane (Australia) July 23-26, 2023**

CONTRIBUTION: Oral Presentation  
TITLE: HIV-1 reservoir dynamics during hematopoietic stem cell transplantation  
AUTHORS: Cardozo-Ojeda EF, Salgado M, Duke E, Schiffer J, Martinez-Picado J  
CONFERENCE: Society for Mathematical Biology Annual Meeting - 2023  
CITY and YEAR: **Ohio (USA) July 16-21, 2023**

CONTRIBUTION: Invited Keynote/Talk  
TITLE: Immunophenotyping of Long COVID in children with a 37-color panel using full-spectrum cytometry  
AUTHORS: Izquierdo-Pujol J, Morón-López S, Dalmau J,

Puertas MC, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, [Martinez-Picado J](#).  
CONFERENCE: Cytek UGM Amsterdam 2023  
CITY and YEAR: **Amsterdam (Netherlands), June 20-21, 2023**

CONTRIBUTION: Poster Presentation 838  
TITLE: PBMC immunophenotyping and plasma inflammatory profile of children with long COVID  
AUTHORS: Izquierdo-Pujol J, Moron-Lopez S, Dalmau J, Puertas MC, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, [Martinez Picado J](#)  
CONFERENCE: 30<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2023)  
CITY and YEAR: **Seattle (WA, USA), February 19-22, 2023**

CONTRIBUTION: Poster Presentation 385  
TITLE: Plasma CD33 level is a marker of virus control post-“kick and kill” cure intervention  
AUTHORS: Duran Castells C, Prats A, Oriol Tordera B, Llano A, Galvez C, [Martinez Picado J](#), Ballana E, García-Vidal E, Clotet B, Muñoz Moreno JA, Hanke T, Moltó J, Mothe Pujades B, Brander C, Ruiz Riol M  
CONFERENCE: 30<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2023)  
CITY and YEAR: **Seattle (WA, USA), February 19-22, 2023**

CONTRIBUTION: Poster presentation 246  
TITLE: Low Tryptophan Catabolism Marks Immune Preservation in HIV+ Viremic Non-Progressors  
AUTHORS: Bayón-Gil A, Goldman A, Dalmau J, Hong KY, Koshy J, Giron L, Abdel-Mohsen M, [Martinez-Picado J](#), Puertas MC  
CONFERENCE: 30<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2023)  
CITY and YEAR: **Seattle (USA), February 19-23, 2023**

CONTRIBUTION: Poster Presentation 246  
TITLE: Permanent control of HIV-1 pathogenesis in exceptional elite controllers  
AUTHORS: Gálvez C, Casado C, Pernas M, Tarancon-Diez L, Rodriguez C, Sánchez-Merino V, Vera M, De Pablo-Bernal RS, Merino-Mansilla A, Del Romero J, Lorenzo-Redondo R, Ruiz-Mateos E, Salgado M, [Martinez-Picado J](#), Lopez-Galindez C.  
CONFERENCE: 2023 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (WA, USA), February 19-22, 2023**

CONTRIBUTION: Oral Presentation #OP 7.5  
TITLE: Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR trial.  
AUTHORS: Puertas MC, Gunst JD, Pahus MH, Kinloch NN, Copertino DC, Ward AR, Brumme ZL, Jones RB, Tolstrup M, Fidler S, Søgaard OS, [Martinez-Picado J](#)  
CONFERENCE: 10<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA) December 13-16, 2022**

CONTRIBUTION: Poster Presentation #PP 1.19  
TITLE: Differential decay dynamics of the inducible pool of HIV-1 infected CD4+ T cells and proviral DNA upon ART initiation revealed by the novel VIP-SPOT assay  
AUTHORS: Puertas MC, Garcia-Guerrero MC, Bailón L, Mothe B, Coll P, Moltó J, [Martinez-Picado J](#)  
CONFERENCE: 10<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA) December 13-16, 2022**

CONTRIBUTION: Poster Presentation #PP 3.13  
TITLE: HIV-1-infected individuals with extremely low reservoir under ART are characterized by reduced viral diversity and higher levels of hypermutations in their viral reservoirs  
AUTHORS: Lorenzo-Redondo R, Gonzalez-Navarro I, Galvez C, Garrido L, Urrea V, [Martinez-Picado J](#), Salgado J  
CONFERENCE: 10<sup>th</sup> International Workshop on HIV

Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA) December 13-16, 2022**

CONTRIBUTION: Oral Presentation  
TITLE: PBMC immunophenotyping and plasma inflammatory profile of children with long COVID  
AUTHORS: Izquierdo-Pujol J, Morón-López S, Dalmau J, Puertas MC, Carreras-Abad C, Gonzalez-Aumatell A, Mendez M, Rodrigo C, [Martinez-Picado J](#).  
CONFERENCE: XXI Virology Meeting 2022 (Catalan Society of Biology)  
CITY and YEAR: **Barcelona (Spain), November 21, 2022**

CONTRIBUTION: Poster Presentation  
TITLE: Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs)  
AUTHORS: González-Navarro I, Gálvez C, Urrea V, Garcia-Guerrero MC, Bernal S, Benet S, Mothe B, Bailón L, Dalmau J, Martinez A, Nieto A, Leal L, García F, Clotet B, [Martinez-Picado J\\*](#), Salgado M\*  
CONFERENCE: 8<sup>th</sup> HIV Cure Symposium  
CITY and YEAR: **Ghent (Belgium) September 12-13, 2022**

CONTRIBUTION: Oral & Poster Presentation EPA011  
TITLE: Immune preservation in HIV+ Viremic Non-Progressors is associated with downregulation of type-I IFN pathway and reduced activation of cytotoxic compartments  
AUTHORS: Bayón-Gil A, Hernandez I, Dalmau J, Nieto JC, Urrea V, García-Guerrero MC, Gálvez C, Salgado M, Heyn H, [Martinez-Picado J](#), Puertas MC  
CONFERENCE: AIDS 2022 – The 24th International AIDS Conference  
CITY and YEAR: **Montreal (Canada) July 29 – August 2, 2022**

CONTRIBUTION: Oral Presentation  
TITLE: Proteomics characterization of circulating extracellular vesicles in COVID-19 patients with different clinical manifestations  
AUTHORS: Pinazo MJ, Cortes-Serra N, Ayllon-Hermida A, Gualdrón-López M, Resa- Infante P, Bech-Serra J, Montaner-Tarbés S, Aparici I, Nicolau-Fernandez M, Erkizia I, Ballana E, Marfil S, Pradenas E, Bauza Martinez J, Völlmy FL, Fraile L, Montoya M, Segales J, Carrillo J, Blanco J, Muelas M, Sotil R, Fernandez-Becerra C, de La Torre C, [Martinez-Picado J](#), del Portillo HA  
CONFERENCE: *ISEV 2022 Annual Meeting*  
CITY and YEAR: **Lyon (France) May 25-29, 2022**

CONTRIBUTION: Oral & Poster Presentation #1017  
TITLE: Assessing the impact of conditioning and graft-vs-host in reducing the HIV reservoir under allogeneic hematopoietic stem cell transplantation  
AUTHORS: Garba S, Duke ER, Krantz E, Salgado M, Gálvez C, Urrea-Gales V, Nijhuis M, Wensing A, [Martinez-Picado J](#), Schiffer J, Cardozo-Ojeda EF, on behalf of the IciStem Consortium  
CONFERENCE: Keystone Symposia - Next Generation HIV Vaccines & Therapies (C2)  
CITY and YEAR: **Banff (Canada) March 27-30, 2022**

CONTRIBUTION: Oral Presentation  
TITLE: Immune preservation in HIV+ Viremic Non-Progressors is associated with downregulation of IFN-type I pathway and reduced activation of cytotoxic compartments  
AUTHORS: Bayón-Gil A, Hernandez I, Dalmau J, Nieto JC, Urrea V, García-Guerrero MC, Gálvez C, Salgado M, Heyn H, [Martinez-Picado J](#), Puertas MC  
CONFERENCE: 12<sup>th</sup> Spanish Meeting on AIDS – GeSIDA  
CITY and YEAR: **Málaga (Spain), November 29-December 2, 2021**

CONTRIBUTION: Oral Presentation  
TITLE: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells  
AUTHORS: Muñoz-Basagoiti J, Rodon J, Elosua-Bayes M,

- Raich-Regué D, Risco C, Sachse M, Pino M, Gumber S, Paiardini M, Chojnacki J, Erkizia I, Muñoz-Trabudua X, Ballana E, Riveira-Muñoz E, Noguera M, Paredes R, Trinité B, Tarrés-Freixas F, Blanco I, Guallar V, Carrillo J, Blanco J, Telenti A, Heyn H, Segalés J, Clotet B, Martínez-Picado J\*, Vergara-Alert J\*, Izquierdo-Useros N\*
- CONFERENCE: Virology meeting 2021 – 3<sup>rd</sup> Symposium on Coronavirus Research  
CITY and YEAR: **Barcelona (Spain), November 5, 2021**
- CONTRIBUTION: Oral Presentation  
TITLE: Proteomics and immunological studies of circulating extracellular vesicles in COVID-19 patients  
AUTHORS: Pinazo MJ, Cortés N, Ayllón A, Montaner-Tarbés S, Gualdrón-López M, Resa Infante P, Bech JJ, Aparici I, Erkizia I, Ballana E, Marfil S, Pradenas Saavedra E, Bauza Martínez J, Segales J, Blanco J, Fernandez-Becerra C, de La Torre C, Martínez-Picado J, del Portillo HA.  
CONFERENCE: IGTP Scientific Retreat  
CITY and YEAR: **Badalona (Spain), June 14, 2021**
- CONTRIBUTION: Oral Presentation 300  
TITLE: The peripheral CD4+ T-cell reservoir atlas in cART-treated HIV-infected individuals  
AUTHORS: Gálvez C, Grau-Expósito J, Urrea V, Buzón MJ, Martínez-Picado J  
CONFERENCE: 2021 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Virtual, March 6-10, 2021**
- CONTRIBUTION: Oral Presentation 335  
TITLE: ABX464 decreases the total HIV reservoir and HIV transcription initiation *in vivo*  
AUTHORS: Moron-Lopez S, Bernal S, Steens J-M, Wong JK, Martínez-Picado J, Yukl SA  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 192  
TITLE: Permanent control of HIV-1 pathogenesis in exceptional elite controllers  
AUTHORS: Gálvez C, Casado C, Pernas M, Tarancon-Diez L, Rodriguez C, Sánchez-Merino V, Vera M, De Pablo-Bernal RS, Merino-Mansilla A, Del Romero J, Lorenzo-Redondo R, Ruiz-Mateos E, Salgado M, Martínez-Picado J, Lopez-Galindez C.  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 259  
TITLE: Uncoupled cellular and plasma markers of monocyte activation in early HIV infection  
AUTHORS: Jiménez M, Pastor Palomo L, Urrea V, Izquierdo-Useros N, Martínez-Picado J, Mandomando I, Jairoce C, Clotet B, Carrillo J, Naniche D, Blanco J  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 323  
TITLE: Presence of macrophage-tropic HIV-1 variants following analytical treatment interruption  
AUTHORS: Andrade VM, Mavian C, Babic D, Cordeiro Alvarado T, Sharkey M, Barrios L, Brander C, Dalmau J, Seaman MS, Salemi M, Martínez-Picado J, Stevenson M  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 339  
TITLE: HIV-specific T-cell responses in an HIV-positive cohort post-allogeneic hematological stem cell transplant  
AUTHORS: Eberhard JM, Angin M, Passaes CP, Salgado M, Monceaux V, Hütter G, Balsalobre P, Kwon M, Diez JL, Nijhuis M, Wensing A, Martínez-Picado J, Schulze Zur Wiesch J, Saez-Cirion A, for the IciStem Study Group  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 346LB  
TITLE: Sustained HIV remission in the London patient: the case for HIV cure  
AUTHORS: Gupta RK, Peppas D, Pace M, Thornhill JP, Nastouli E, Grant P, McCoy L, Innes A, Edwards S, Wensing A, Nijhuis M, Martínez-Picado J, Frater J, Olavarria E, for the CHERUB and IciStem Study Groups  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 348LB  
TITLE: CCR5Δ32SCT-induced HIV remission: trace of DNA but fading immune reactivity  
AUTHORS: Jensen BO, Häussinger D, Knops E, Wensing A, Martínez-Picado J, Nijhuis M, Salgado M, Estes JD, Lübke N, Kaiser R, Harrer T, Fischer J, Schulze zur Wiesch J, Eberhard JM, Kobbe G  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 464LB  
TITLE: Bictegrovir distribution and bictegrovir/FTC/TAF activity in genital tract and rectum  
AUTHORS: Imaz A, Tiraboschi JM, Niubo J, Martínez-Picado J, Cottrell ML, Domingo P, Chivite I, Negro E, Morenilla S, Urrea V, Scevola S, Garcia B, Kashuba A, Podzamczek D  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation 374  
TITLE: ART-treated subjects with low viral reservoir show unusual HIV latency distribution  
AUTHORS: Gálvez C, Urrea V, Benet S, Bailon L, Martínez A, Mothe B, Dalmau J, Leal L, Garcia F, Martínez-Picado J, Salgado M  
CONFERENCE: 2020 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), March 8-11, 2020**
- CONTRIBUTION: Poster Presentation  
TITLE: Novel methodology for the detection of enveloped viruses  
AUTHORS: Resa-Infante P, Erkizia I, Nieto-Garai JA, Lorizate M, Izquierdo-Useros N, Martínez-Picado J  
CONFERENCE: Viruses 2020  
CITY and YEAR: **Barcelona (Spain), February 5-7, 2020**
- CONTRIBUTION: Poster Presentation  
TITLE: Siglec-1 expressed on Dendritic cells is a new receptor implicated in arenavirus uptake  
AUTHORS: Muñoz-Trabudua X, Borio C, Erkizia I, Perez-Zsolt D, Benet S, Martínez-Picado J, Izquierdo-Useros N  
CONFERENCE: Viruses 2020  
CITY and YEAR: **Barcelona (Spain), February 5-7, 2020**
- CONTRIBUTION: Oral Presentation  
TITLE: Impact of Siglec-1 variant on disseminated tuberculosis during HIV-1 co-infection  
AUTHORS: Benet S, Gálvez C, Drobniewski F, Kontsevaya I, Arias L, Monguió-Tortajada M, Erkizia I, Urrea V, Ong RY, Luquin M, Dupont M, Chojnacki J, Dalmau J, Cardona P, Lugo G, Verollet C, Julián E, Furrer H, Günthard H, Crocker P, Tapia G, Borràs FE, Fellay J, McLaren PJ, Telenti A, Cardona PJ, Clotet B, Vilaplana\*, Izquierdo-Useros N\*, Martínez-Picado J\*  
CONFERENCE: Keystone Symposia Conference – Tuberculosis: Immunity and Immune Evasion  
CITY and YEAR: **Santa Fe (NM, USA), January 16-20, 2020**
- CONTRIBUTION: Oral Presentation

TITLE: ART-treated subjects with low viral reservoir show unusual HIV latency distribution  
AUTHORS: Gálvez C, Urrea V, Benet S, Bailón L, Mothe B, Martínez A, Dalmau J, Leal L, García F, Martínez-Picado J\*, Salgado M\*  
CONFERENCE: 9<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA), Dec 10-13, 2019**

CONTRIBUTION: Oral Presentation (OP 8.3)  
TITLE: Intensification of ART with ABX464 decreases the total HIV reservoir and HIV transcription initiation in CD4+ T cells from HIV-infected ART-suppressed individuals  
AUTHORS: Bernal S, Moron-Lopez S, Steens JM, Wong J, Martínez-Picado J, Yukl SA.  
CONFERENCE: 9<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA), Dec 10-13, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: The IciStem consortium: T-cell immunology in HIV-1 infected individuals after allogeneic stem cell transplantation  
AUTHORS: Eberhard J, Angin M, Passaes C, Salgado M, Díez-Martín JL, Nijhuis M, Wensing A, Martínez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A.  
CONFERENCE: 9<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA), Dec 10-13, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Permanent control of HIV-1 pathogenesis in exceptional elite controllers  
AUTHORS: Gálvez C, Casado C, Pernas M, Tarancón-Diez L, Rodríguez C, Lorenzo-Redondo R, Ruiz- Mateos E, Salgado M, López-Galindez C\*, Martínez-Picado J\*  
CONFERENCE: 9<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (FL, USA), Dec 10-13, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: Exploring the therapeutic potential of Fabs derived from novel anti-Siglec-1 mAbs with the ability to block HIV-1 capture  
AUTHORS: X Muñiz-Trabudua, I Erkizia, P Resa-Infante, J Chojnacki, D Perez-Zsolt, L Kremer, J Martínez-Picado N Izquierdo-Useros\*  
CONFERENCE: XI Spanish AIDS Conference - GeSIDA  
CITY and YEAR: **Toledo (Spain), Dec 10-13, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC-1 null variant that limits antigen exchange via trafficking extracellular vesicles  
AUTHORS: S Benet, C Gálvez, F Drobniewski, I Kontsevaya, L Arias, M Monguió-Tortajada, I Erkizia, V Urrea, Ruo-Yan Ong, M Luquin, M Dupont, J Dalmau, P Cardona, G Lugo, C Verollet, E Julián, H Furrer, H Günthard, P Crocker, G Tapia, F E. Borràs, J Fellay, PJ. McLaren, A Telenti, P J Cardona, B Clotet, C Vilaplana\*, J Martínez-Picado\*, N Izquierdo-Useros\*  
CONFERENCE: XI Spanish AIDS Conference - GeSIDA  
CITY and YEAR: **Toledo (Spain), Dec 10-13, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC-1 null variant that limits antigen exchange via trafficking extracellular vesicles  
AUTHORS: S Benet, C Gálvez, F Drobniewski, I Kontsevaya, L Arias, M Monguió-Tortajada, I Erkizia, V Urrea, Ruo-Yan Ong, M Luquin, M Dupont, J Dalmau, P Cardona, G Lugo, C Verollet, E Julián, H Furrer, H Günthard, P Crocker, G Tapia, F E. Borràs, J Fellay, PJ. McLaren, A Telenti, P J Cardona, B Clotet, C Vilaplana\*, J Martínez-Picado\*, N Izquierdo-Useros\*  
CONFERENCE: 5th Geivex Symposium  
CITY and YEAR: **Granada (Spain), Nov 6-8, 2019**

CONTRIBUTION: Oral Presentation WEPEA065  
TITLE: Allogeneic stem cell transplant in HIV-1 infected individuals; An update of the IciStem Consortium

AUTHORS: Wensing AMJ, Salgado M, Kwon M, Eberhard JM, Saez-Cirion A, Schulze zur Wiesch J, Hütter G, Badiola-González J, Bandera A, Barrett L, Gupta RK, Jensen BE, Kuball JHE, Martín Carbonero L, Nabergoj M, Raj K, Saldaña-Moreno R, Scarlatti G, Vandekerckhove L, Díez Martín JL, Nijhuis M, Martínez-Picado J  
CONFERENCE: 10<sup>th</sup> IAS Conference on HIV Science  
CITY and YEAR: **Mexico City (Mexico), Jul 21-24, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Basal actin cytoskeleton-dependent siglec-1 nanoclustering facilitates the formation of HIV-sac compartments in mature dendritic cells  
AUTHORS: Gutierrez Martinez, E.; Benet Garrabe, S.; Martínez Guillamon, C.; Borgman, K.; Mateos, N.; Manzo, C.; Izquierdo Useros, N.; Martínez Picado, J.; García Parajo, M  
CONFERENCE: Joint 12<sup>th</sup> EBSA European Biophysics Congress / 10<sup>th</sup> IUPAP International Conference on Biological Physics  
CITY and YEAR: **Madrid (Spain), Jul 20-24, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue  
AUTHORS: Morón-López S, Puertas MC, Gálvez C, Navarro J, Carrasco A, Esteve M, Manyé J, Crespo M, Salgado M, Martínez-Picado J  
CONFERENCE: iChem2019  
CITY and YEAR: **San Francisco (USA), Jul 1-3, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Reticulocyte-derived exosomes: a new vaccine approach against *Plasmodium vivax* malaria  
AUTHORS: Díaz-Varela M, Gualdrón-López M, Aparici-Herraiz I, Pedró-Cos L, Lauzurica-Valdemoros R, Izquierdo-Useros N, Martínez-Picado J, Fernández-Becerra C, del Portillo HA  
CONFERENCE: 7<sup>th</sup> International Conference on *Plasmodium vivax* Research  
CITY and YEAR: **Paris (France), Jun 26-28, 2019**

CONTRIBUTION: Poster  
TITLE: Dendritic cells from the cervical mucosa capture and transfer HIV-1 via Siglec-1  
AUTHORS: Perez-Zsolt D., Cantero-Pérez J., Erkizia I., Benet S., Pino M., Serra-Peinado C., Hernández-Gallego A., Castellví J., Tapia G., Arnau-Saz V., Garrido J., Tarrats A., Buzón M. J., Martínez-Picado J., Izquierdo-Useros N. and Genescà M  
CONFERENCE: 19<sup>th</sup> International Congress of Mucosal Immunology  
CITY and YEAR: **Brisbane (Australia), Jun 16-20, 2019**

CONTRIBUTION: Poster & FLASH Presentation  
TITLE: Dendritic cells from the cervical mucosa capture and transfer HIV-1 via Siglec-1  
AUTHORS: Perez-Zsolt D., Cantero-Pérez J., Erkizia I., Benet S., Pino M., Serra-Peinado C., Hernández-Gallego A., Castellví J., Tapia G., Arnau-Saz V., Garrido J., Tarrats A., Buzón M. J., Martínez-Picado J., Izquierdo-Useros N. and Genescà M  
CONFERENCE: XV Congress of the Spanish Society of Virology / 11<sup>th</sup> International Meeting GVN  
CITY and YEAR: **Barcelona (Spain), Jun 10-12, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Limited contribution of viral factors to the viremic nonprogressor phenotype in adult and pediatric HIV-1 infection  
AUTHORS: Colomer-Lluch M, Adland E, Dalmau J, Francés C, Peña R, Jiménez-Moyano E, Clotet B, Martínez-Picado J, Goulder P, Prado JG  
CONFERENCE: Retroviruses  
CITY and YEAR: **Cold Spring Harbor (USA), May 20-25, 2019**

CONTRIBUTION: Oral Presentation 2501  
TITLE: Phase II study of durvalumab (MEDI4736) in HIV-1-infected cancer patients  
AUTHORS: Gonzalez-Cao M, Moran T, Dalmau J, Garcia-Corbacho J, Bernabe R, Juan O, de Castro J, Blanco R, Meyerhans A, Blanco J, Prado J, Karachaliou N, Brander C,

Carrillo J, Clotet B, Massuti B, Provencio M, Molina MA, Martinez-Picado J, Rosell R  
CONFERENCE: American Society of Clinical Oncology (ASCO)  
CITY and YEAR: **Chicago (USA), Jun 1-4, 2019**

CONTRIBUTION: Oral Presentation  
TITLE: Reticulocyte-derived exosomes: a new antigen discovery and vaccine delivery platform against *Plasmodium vivax* malaria  
AUTHORS: Díaz-Varela M, Gualdrón-López M, Segui-Barber J, Lauzurica-Valdemoros R, Izquierdo-Useros N, Martinez-Picado J, Fernández-Becerra C, del Portillo HA  
CONFERENCE: Malaria Vaccines for the World 2019  
CITY and YEAR: **Oxford (UK), May 8-10, 2019**

CONTRIBUTION: Poster Presentation 3010  
TITLE: Allogeneic stem cell transplantation reduces HIV latent reservoir under cART independently of CCR5-mutated donor  
AUTHORS: Salgado M, Gálvez C, Nijhuis M, Kwon M, Badiola J, Bandera A, Jensen B, Vandekerckhove L, Jurado M, Raj K, Schulze zur Wiesch J, Nabergoj M, Hutter G, Saldaña-Moreno R, Barrett L, Kuball J, Saez-Cirión A, Diez-Martin JL, Wensing A, Martinez-Picado J.  
CONFERENCE: Keystone Symposium. Functional Cures and the Eradication of HIV  
CITY and YEAR: **Whistler (Canada), March 24-28, 2019**

CONTRIBUTION: Poster Presentation 394  
TITLE: Analytical Treatment interruption (ATI) after allogeneic CCR5Δ32 HSCT for AML in 2013  
AUTHORS: Jensen BEO, Knops E, Lübke N, Wensing A, Martinez-Picado J, Kaiser R, Nijhuis M, Salgado M, Harrer T, Heger E, Eberhard JM, Hauber I, Münk C, Häussinger D, Kobbe G  
CONFERENCE: 2019 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), March 4-7, 2019**

CONTRIBUTION: Poster Presentation 363  
TITLE: In vivo antiviral effect of dasatinib in humanized mice infected with HIV-1  
AUTHORS: Salgado M, Martinez-Picado J, Gálvez C, Rodriguez-Mora S, Urrea V, Mateos E, Alcamí J, Coiras M  
CONFERENCE: 2019 Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), March 4-7, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Early and late cART treatment initiation have an impact on SIRT2 plasma levels associated with HIV viral load and proviral levels at PBMC  
AUTHORS: Duran-Castells C, Kawana-Tachikawa A, Llano A, Mothe B, Oriol-Tordera B, Galvez C, Ganoza C, Sanchez J, Clotet B, Martinez-Picado J, Muñoz-Moreno J.A, Wyss-Coray T, Brander C, Ruiz-Riol M  
CONFERENCE: 14th World Immune Regulation Meeting  
CITY and YEAR: **Davos (Switzerland), March 4-7, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: TLI1A/DR3 axis plays a key role in HIV control intensifying HIV specific CTL responses  
AUTHORS: Oriol-Tordera B, Llano A, Mothe B, Duran-Castells C, Olvera A, Galvez C, Ganoza C, Sanchez J, Gómez G, Negro E, Clotet B, Martinez-Picado J, Blanco J, Wyss-Coray T, Brander C, Ruiz-Riol M  
CONFERENCE: 14th World Immune Regulation Meeting  
CITY and YEAR: **Davos (Switzerland), March 4-7, 2019**

CONTRIBUTION: Poster Presentation  
TITLE: Immunoreconstitution of the T- cell memory compartment and priming of de novo HIV-specific CD8 T-cell responses in HIV-1 infected individuals after HSCT  
AUTHORS: Eberhard JM, Angin M, Salgado M, Jensen B, Knops E, Christopheit M, Kröger N., Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Kwon M, Diez JL, Hütter G, Rocha V, Nijhuis M, Wensing A, Martinez-Picado J, Schulze zur Wiesch J, Sáez-Cirión A

CONFERENCE: “DZIF German Center for Infection Research” 2018 meeting  
CITY and YEAR: **Heidelberg (Germany), 3-4 December 2018**

CONTRIBUTION: Oral presentation (OR-11)  
TITLE: *In vivo* dynamics of HIV-1 reactivation in a combined HIVcons vaccine & romidepsin strategy  
AUTHORS: Puertas MC, Morón-López S, Miranda C, López M, Hanke T, Manzano C, Miró JM, Brander C, Mothe B, Moltó J, Martinez-Picado J.  
CONFERENCE: X Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), 6-9 November 2018**

CONTRIBUTION: Oral poster (PO-13)  
TITLE: Chronically treated HIV+ subjects can naturally harbor extremely low viral reservoir  
AUTHORS: Gálvez C, Dalmau J, Urrea V, Clotet B, Leal L, García F, Martinez-Picado J, Salgado M.  
CONFERENCE: X Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), 6-9 November 2018**

CONTRIBUTION: Oral poster (PO-22)  
TITLE: Phase I clinical trial of a mRNA-based therapeutic vaccine against HIV-1 infection  
AUTHORS: Leal L, Crespo A, Morón-López S, Salgado M, Mothe B, Heirman C, Thielemans K, Pannus P, Vanham G, Brander C, Gruters R, Andeweg A, Martinez-Picado J, Plana M, García F.  
CONFERENCE: X Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), 6-9 November 2018**

CONTRIBUTION: Oral poster (PO-41)  
TITLE: Dynamics of HIV-1- reservoir decay in early-treated individuals  
AUTHORS: Bayón-Gil A, Urrea V, Mothe B, Brander C, Puertas MC, Martinez-Picado J.  
CONFERENCE: X Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), 6-9 November 2018**

CONTRIBUTION: Oral poster (PO-48)  
TITLE: Characterization of viral factors in pediatric and adult HIV-1 viremic non-progressors  
AUTHORS: Colomer-Lluch M, Adland E, Dalmau J, Francés C, Peña R, Jiménez-Moyano E, Clotet B, Martinez-Picado J, Goulder P, Prado JG.  
CONFERENCE: X Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), 6-9 November 2018**

CONTRIBUTION: Poster Presentation  
TITLE: Dynamics of HIV-1- reservoir decay in early-treated individuals  
AUTHORS: Bayón-Gil A, Urrea V, Mothe B, Brander C, Puertas MC, Martinez-Picado J.  
CONFERENCE: XVII Jornada de Virologia (Societat Catalana de Biologia)  
CITY and YEAR: **Barcelona (Spain), 30 October 2018**

CONTRIBUTION: Poster presentation (#2028)  
TITLE: Novel anti-Siglec-1 monoclonal antibodies offer cross-protection against Ebola virus and HIV-1  
AUTHORS: Perez-Zsolt D, Erkizia I, Pino M, García-Gallo M, Martin MT, Benet S, Fernández-Figueras MT, Guerrero D, Urrea V, Kremer L, Martinez-Picado J, Izquierdo-Useros N.  
CONFERENCE: Framing the Response to Emerging Virus Infections (S2) Keystone Symposia  
CITY and YEAR: **Hong-Kong, 14-18 October 2018**

CONTRIBUTION: Oral presentation (TUAA0203)  
TITLE: Dominant HIV DNA populations present in different T-cell subsets before stem cell transplantation persist in tissues early after transplantation with CCR5Δ32 stem cells  
AUTHORS: Wensing A, Bosman K, Bruns A, Ellerbroek P, de Jong T, Tesselaar K, Stam A, Salgado M, Hutter G, Brosens L, Kwon M, Diez Martin J, Boelens J, Martinez-Picado J, Kuball J, Nijhuis M, IciStem Consortium  
CONFERENCE: 22<sup>nd</sup> International AIDS Conference  
CITY and YEAR: **Amsterdam (the Netherlands), 23-27**

## July 2018

CONTRIBUTION: Poster presentation #311  
TITLE: Phase I clinical trial of an mRNA-based therapeutic vaccine against HIV-1 infection  
AUTHORS: Leal L, Guardo AC, Moron-Lopez S, Salgado M, Mothe B, Heirman C, Thielemans K, Pannus P, Brander C, Gruters R, Andeweg A, Martinez-Picado J, Plana M, Garcia F  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (MA, USA), Mar 4-7, 2018**

CONTRIBUTION: Poster presentation #386  
TITLE: HIV-seroreversion dynamics after allogeneic stem cell transplantation  
AUTHORS: Salgado M, González V, Rivaya B, Gálvez C, Kwon M, Badiola J, Bandera A, Jensen B, Vandekerckhove L, Raj K, Nijhuis M, Diez JL, Wensing A, Martinez-Picado J  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (MA, USA), Mar 4-7, 2018**

CONTRIBUTION: Poster presentation #390  
TITLE: Productive HIV-1 infection upregulates CD32 *in vitro* and *in vivo*  
AUTHORS: Serra Peinado C, Grau-Expósito J, Genescà M, Luque-Ballesteros L, Gálvez C, Castellví J, Willekens R, Montaner L, Falcó V, Martinez-Picado J, Buzón MJ  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (MA, USA), Mar 4-7, 2018**

CONTRIBUTION: Poster presentation #501  
TITLE: Effect of switching to integrase inhibitor on the HIV reservoir in ileum biopsies  
AUTHORS: Moron-Lopez S, Urrea V, Navarro J, Puertas MC, Torrella A, Salgado M, Gálvez C, Planas B, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (MA, USA), Mar 4-7, 2018**

CONTRIBUTION: Plenary presentation  
TITLE: New therapeutic strategies to cure HIV: so close, so far  
AUTHORS: Martinez-Picado J  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Oral presentation (OP2.6)  
TITLE: CD32+ CD4+ T Cells are HIV transcriptionally active rather than a resting reservoir  
AUTHORS: Abdel-Mohsen M, Tomescu C, Vadrevu S, Spivak A, Kuri-Cervantes L, Wu G, Cox K, Vemula S, Fair M, Lynn K, Buzon MJ, Martinez-Picado J, Betts M, Planelles V, Mounzer K, Howell B, Hazuda D, Tebas P, Montaner LJ  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Oral presentation (OP4.2)  
TITLE: Productive HIV-1 infection upregulates CD32 *in vitro* and *in vivo*  
AUTHORS: Serra-Peinado C, Grau-Expósito J, Genescà M, Luque-Ballesteros L, Astorga A, Gálvez C, Castellví J, Willekens R, Ocaña I, Burgos J, Navarro J, Curran A, Ribera E, Montaner L, Falcó V, Martinez-Picado J, Buzon MJ  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Oral presentation (OP6.1)  
TITLE: ICISTEM – HIV-seroreversion dynamics after allogeneic stem cell transplantation  
AUTHORS: Salgado M, González V, Rivaya B, Gálvez C, Kwon M, Badiola J, Bandera A, Jensen B, Vandekerckhove L, Raj K, Nijhuis M, Jurado M, Schulze zur Wiesch J, Saez-Cirió A, Diez-Martin JL, Wensing A, Martinez-Picado J  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Oral presentation (OP8.2)  
TITLE: Oral ABX464 reduces the HIV DNA reservoir in CD4+ peripheral blood T cells  
AUTHORS: Steens J-M, Cranston R, Martinez-Picado J, Paredes R, Clotet B, Gineste P, Ehrlich H, McGowan I  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Oral presentation (OP8.6)  
TITLE: Chronically treated HIV-positive subjects can naturally harbor extremely low viral reservoir  
AUTHORS: Gálvez C, Dalmau J, Urrea V, Clotet B, Leal L, García F, Martinez-Picado J, Salgado M  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Poster presentation (PP2.2)  
TITLE: Activation of mature dendritic cells via PKC agonist induces HIV-1 reactivation of latently infected cells  
AUTHORS: Benet S, Erkizia I, Martinez-Picado J, Izquierdo-Useros N  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Poster presentation (PP6.8)  
TITLE: Effect of switching to integrase inhibitor on the HIV reservoir in ileum biopsies  
AUTHORS: Moron-Lopez S, Urrea V, Navarro J, Puertas MC, Torrella A, Salgado M, Gálvez C, Planas B, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J  
CONFERENCE: 8<sup>th</sup> HIV Persistence during Therapy Workshop  
CITY and YEAR: **Miami (FL, USA), Dec 12-15, 2017**

CONTRIBUTION: Poster presentation  
TITLE: Ebv-Mir-BART11-3p, Ebv-Mir-BART9 and Ebv-Mir-BART10 are present in the plasma of HIV-infected subjects with lymphoma and are potential lymphoma biomarkers  
AUTHORS: Muncunill J, Baptista MJ, Hernandez-Rodriguez A, Dalmau J, Tapia G, Garcia O, Moreno M, Sancho JM, Martinez-Picado J, Ribera JM, Feliu E, Mate JL, Navarro JT  
CONFERENCE: 59<sup>th</sup> American Society for Hematology (ASH) Annual Meeting  
CITY and YEAR: **Atlanta (GA, USA) Dec 11, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Towards a natural HIV sterilizing cure: super elite controllers  
AUTHORS: Gálvez C, Salgado M, Rodriguez C, del Romero J, Casado C, Pernas M, López-Galindez C, Martinez-Picado J  
CONFERENCE: IX Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Vigo (Spain), Nov 29-30, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Nuevas herramientas de Ingeniería Genómica para el tratamiento del SIDA  
AUTHORS: Martín JM, Vallejo S, Salgado M, Gálvez C, Martín V, Fleischer A, Palomino E, Martínez Picado J, Bachiller D  
CONFERENCE: IX Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Vigo (Spain), Nov 29-30, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Expression of the marker CD32a within the B cell follicle of lymph nodes is restrained to productively HIV-infected cells  
AUTHORS: Luque-Ballesteros L, Serra-Peinado C, Grau-Expósito J, Genescà M, Astorga A, Morales R, Navarro J, Curran A, Burgos J, Ocaña I, Torrella A, Planas B, Badía R, Ribera E, Castellví J, Martinez-Picado J, Falcó V, Buzón MJ  
CONFERENCE: IX Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Vigo (Spain), Nov 29-30, 2017**

CONTRIBUTION: Poster presentation  
TITLE: ICISTEM – Results of the international project on allogeneic stem cell transplantation in patients with HIV-1 infection  
AUTHORS: Hütter G, Wensing AMJ, Diez Martin JL, Kuball J,

Nijhuis M, Saez-Cirion A; Rocha V, Schulze zur Wiesch J, Martinez-Picado J  
CONFERENCE: 4<sup>th</sup> International Congress on Stem Cell Transplantation and Cellular Therapies  
CITY and YEAR: **Berlin (Germany), Oct 26-29, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Allogeneic stem cell transplantation in HIV-1 infected individuals: The role of lymphocyte populations  
AUTHORS: Eberhard JM, Körner C, Salgado M, Jensen B, Kwon M, Diez JL, Hütter G, Rocha V, Sáez-Cirión A, Nijhuis M, Schulze zur Wiesch J, Wensing A, Martinez-Picado J, for the IciStem Consortium  
CONFERENCE: The joint Annual Meeting of the German Society of Infectious Diseases (DGI) and the German Center for Infection Research (DZIF)  
CITY and YEAR: **Hamburg (Germany), Sept 28-30, 2017**

CONTRIBUTION: Poster presentation  
TITLE: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors  
AUTHORS: Gonzalez-Cao M, Martinez-Picado, J, Provencio Pulla M, Clotet B, Juan O, Dalmau J, Moran T, Mayerhans A, De Castro J, Blanco J, Blanco R, Bernabe Caro R, Karachaliou N, Garcia-Corbacho J, Molina MA, Brander C, Rosell  
CONFERENCE: European Society for Medical Oncology meeting (ESMO)  
CITY and YEAR: **Madrid (Spain), Sept 08-12, 2017**

CONTRIBUTION: Poster presentation (Abstract MOPEA0043)  
TITLE: Host factors associated to control of HIV-reservoir in elitecontroller patients  
AUTHORS: García M, López-Fernández L, Mínguez P, Morón-López S, López-Bernaldo JC, Benguría A, Górgolas M, Cabello A, Fernández M, De la Hera FJ, Estrada V, Barros C, Restrepo C, García MI, Martínez-Picado J, Benito JM, Rallón N  
CONFERENCE: 9<sup>th</sup> IAS Conference on HIV Science  
CITY and YEAR: **Paris (France), July 23-26, 2017**

CONTRIBUTION: Oral presentation (Abstract OA5-1)  
TITLE: Achievement of full donor chimerism with episodes of alloreactivity contributes to reduce the HIV reservoir after allogeneic stem cell transplantation  
AUTHORS: Salgado M, Kwon M, Gálvez C, Nijhuis M, Schulze zur Wiesch J, Bandera A, Knops E, Badiola J, Jensen J, Saez-Cirión A, Jurado M, Kaiser R, Hutter G, Rocha V, Kobbe G, Wensing A, Diez JL, Martinez-Picado J, for the IciStem Consortium  
CONFERENCE: IAS HIV Cure & Cancer Forum  
CITY and YEAR: **Paris (France), July 22-23, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Myeloid Cells from Human Cervical Tissue Express Siglec-1 and Capture HIV-1  
AUTHORS: Cantero-Pérez J, Perez-Zsolt D, Erkizia I, Pino Claveria M, Hernández-Gallego A, Pérez-Roca L, Lorencés I, Garrido J, Tarrats A, Martinez-Picado J, Izquierdo-Useros N, Genescà M  
CONFERENCE: 18<sup>th</sup> International Congress of Mucosal Immunology  
CITY and YEAR: **Washington (USA), July 19-22, 2017**

CONTRIBUTION: Poster presentation  
TITLE: Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas  
AUTHORS: Muncunill J, Baptista MJ, Hernandez-Rodriguez A, Dalmau J, Garcia O, Tapia G, Moreno M, Sancho JM, Martinez-Picado J, Ribera JM, Feliu E, Mate J, Navarro JT  
CONFERENCE: 22<sup>nd</sup> European Hematology Association Conference  
CITY and YEAR: **Madrid (Spain), June 22-25, 2017**

CONTRIBUTION: Poster presentation  
TITLE: Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas  
AUTHORS: Baptista MJ, Muncunill J, Hernandez-Rodriguez A,

Dalmau J, Garcia O, Tapia G, Moreno M, Sancho JM, Martinez-Picado J, Ribera JM, Feliu E, Mate J, Navarro JT  
CONFERENCE: International Conference on Malignant Lymphoma  
CITY and YEAR: **Lugano (Switzerland), June 14-17, 2017**

CONTRIBUTION: Poster presentation (Abstract 31)  
TITLE: Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors  
AUTHORS: Codoñer FM, Peña R, Blanch-Lombarte O, Jimenez-Moyano E, Pino M, Vollbrecht T, Clotet B, Martinez-Picado J, Draenert R, Prado JG  
CONFERENCE: 15<sup>th</sup> European Meeting on HIV & Hepatitis  
CITY and YEAR: **Rome (Italy), June 7-9, 2017**

CONTRIBUTION: Oral presentation  
TITLE: APC from human cervical mucosa express Siglec-1 and mediate viral capture via recognition of viral membrane gangliosides  
AUTHORS: Perez-Zsolt D, Cantero-Pérez J, Erkizia I, Pino M, Hernández-Gallego A, Pérez-Roca L, Lorencés I, Garrido J, Tarrats A, Martinez-Picado J, Genescà M, Izquierdo-Useros N  
CONFERENCE: CSH Retroviruses  
CITY and YEAR: **Cold Spring Harbour (USA), May 22-27, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Bryostatins action on mature dendritic cells promotes HIV-1 reactivation of latently infected cells  
AUTHORS: Benet S, Nieto-Garai JA, Erkizia I, Bilbao E, Prado JG, Martinez-Picado J, Lorizate M, Izquierdo-Useros N  
CONFERENCE: Madrid Meeting on Dendritic Cells and Macrophages  
CITY and YEAR: **Madrid (Spain), March 27-28, 2017**

CONTRIBUTION: Oral presentation (119LB)  
TITLE: Viral control induced by HIVCONSV vaccine & romidepsin in early treated individuals  
AUTHORS: Mothe B, Moltó J, Manzardo C, Coll J, Puertas MC, Martinez-Picado J, Hanke T, Clotet B, Brander C  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), February 13-16, 2017**

CONTRIBUTION: Poster presentation (Abstract 228)  
TITLE: Genome-wide methylation is associated with HIV-1 infection and disease progression  
AUTHORS: Moron-Lopez S, Dalmau J, Urrea V, Lopez M, Puertas MC, Mothe B, Brander C, Esteller M, Berdasco M, Martinez-Picado J  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), February 13-16, 2017**

CONTRIBUTION: Poster presentation (Abstract 306)  
TITLE: Murine model to predict viral rebound in HIV+ allotransplanted subjects  
AUTHORS: Salgado M, Kwon M, Galvez-Celada C, Nijhuis M, Vilaplana C, Bandera A, Wensing A, Diez JL, Martinez-Picado J  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), February 13-16, 2017**

CONTRIBUTION: Poster presentation (Abstract 320)  
TITLE: Persistence of HIV DNA in tissues early after transplantation with CCR5Δ32 stem cells  
AUTHORS: Bosman K, Nijhuis M, Bruns A, Salgado M, Hütter G, Brosens L, Martinez-Picado J, Kuball J, Wensing A  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), February 13-16, 2017**

CONTRIBUTION: Oral presentation  
TITLE: Genome-wide methylation patterns are associated with HIV-1 infection and disease progression in CD4+ T lymphocytes

from HIV-1 infected patients  
AUTHORS: Moron-Lopez S, Dalmau J, Urrea V, Lopez M, Puertas MC, Gomez A, Ouchi D, Mothe B, Brander C, Clotet B, Esteller M, Berdasco M, Martinez-Picado J  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Oral presentation  
TITLE: Myeloid cells from human cervical tissue express Siglec-1 and capture HIV-1  
AUTHORS: Perez-Zsolt D, Cantero-Pérez J, Tarrats A, Hernández-Gallego A, Pérez-Roca L, Lorencés I, Erkizia I, Víctor V, Javier Martínez-Picado J, Genescà M, Izquierdo-Useros N  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation  
TITLE: IFN $\alpha$  secretion by HIV-exposed pDCs results in an increased Siglec-1-mediated viral transmission by DCs overcoming IFN $\alpha$  antiviral effect  
AUTHORS: Pino M, Erkizia I, Benet S, Perez-Zsolt D, Martinez-Picado J, Izquierdo-Useros N  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation  
TITLE: Bryostatin-1 action on mature dendritic cells promotes HIV-1 reactivation of latently infected cells  
AUTHORS: Benet S, Ander Nieto-Garai J, Erkizia I, Bilbao E, Prado JG, Martinez-Picado J, Lorizate M, Izquierdo-Useros N  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation  
TITLE: A particular transcriptional profile in CD8 T cells from EC could be associated with the better control of reservoir size in these patients  
AUTHORS: García Alonso M, López L, Barros C, Restrepo C, Morón-Lopez S, López JC, Cabello A, Fernández M, Górgolas M, Álvarez B, García R, De La Hera FJ, Estrada V, García MI, Benguría A, Martínez-Picado J, Benito JM, Rallón N  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation  
TITLE: Host Factors associated to Low HIV-Reservoir in resting memory CD4 T cells of Elite Controller Patients  
AUTHORS: García Alonso M, López L, Barros C, Restrepo C, Morón-Lopez S, López JC, Cabello A, Fernández M, Górgolas M, Álvarez B, García R, De La Hera FJ, Estrada V, García MI, Benguría A, Martínez-Picado J, Benito JM, Rallón N  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation  
TITLE: Latency reversing agents induce HIV-1 protein expression in latently infected cells facilitating cytotoxic T-lymphocyte antiviral recognition and killing  
AUTHORS: Ruiz A, Jimenez E, Peña R, Gálvez C, Genescà M, Martínez-Picado J, Goulder P, Clotet B, García J  
CONFERENCE: VIII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **San Sebastián (Spain), November 29 – December 2, 2016.**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif  
AUTHORS: LM Molinos-Albert, E Bilbao, L Agulló, S Marfil, E García, ML Rodríguez de la Concepción, N Izquierdo-Useros, C

Vilaplana, F-X Contreras, M Floor, PJ Cardona, J Martínez-Picado, B Clotet, J Villà-Freixa, M Lorizate, J Carrillo, J Blanco  
CONFERENCE: HIV Research for Prevention (HIVR4P 2016)  
CITY and YEAR: **Chicago (USA), October 17-21, 2016**

CONTRIBUTION: Oral presentation  
TITLE: Allogeneic Stem Cell Transplantation in HIV-1 Infected Individuals; the EpiStem Consortium  
AUTHORS: Wensing AM, Diez-Martin JL, Huetter G, Kuball J, Kwon M, Nijhuis M, Saez-Cirion A, Rocha V, Salgado M, Schulze zur Wiesch J, Stam A, Martínez-Picado J, EpiStem Consortium  
CONFERENCE: 21<sup>st</sup> International AIDS Conference  
CITY and YEAR: **Durban (South Africa), July 18-22, 2016**

CONTRIBUTION: Poster presentation (Abstract 3012)  
TITLE: pDCs exposed to HIV-1 trigger Siglec-1 expression on DCs that mediates viral transmission and eludes IFN antiviral effect  
AUTHORS: Pino M, Erkizia I, Benet S, Pérez-Zsolt D, Izquierdo-Useros N, Martínez-Picado J  
CONFERENCE: Keystone Symposium on Myeloid cells  
CITY and YEAR: **Killarney (Ireland), April 10-14, 2016**

CONTRIBUTION: Poster presentation (Abstract 3009)  
TITLE: Identification of the plasma factors that promote HIV-1 transmission mediated by dendritic cells in viremic individuals  
AUTHORS: Perez-Zsolt D, Erkizia I, Benet S, Pino M, Dalmau J, Martínez-Picado J, Izquierdo-Useros N  
CONFERENCE: Keystone Symposium on Myeloid cells  
CITY and YEAR: **Killarney (Ireland), April 10-14, 2016**

CONTRIBUTION: Poster presentation (Abstract 3013)  
TITLE: A dendritic cell nanocarrier system to reactivate latent HIV-1  
AUTHORS: Benet S, Nieto-Garai JA, Pino M, Bilbao E, Erkizia I, Perez-Zsolt D, Prado JG, Martínez-Picado J, Lorizate M, Izquierdo-Useros N  
CONFERENCE: Keystone Symposium on Myeloid cells  
CITY and YEAR: **Killarney (Ireland), April 10-14, 2016**

CONTRIBUTION: Poster presentation (Abstract P670)  
TITLE: HIV-1 Reservoir Dynamics after Allogeneic Stem Cell Transplantation: Clues to eradicate HIV  
AUTHORS: Kwon M, Salgado M, Balsalobre P, Nijhuis M, Blanco J, Miralles P, Serrano D, Gayoso J, Anguita J, Buno I, Wensing AM, Martínez Picado J, Diez Martin JL on behalf of EPISTEM Consortium  
CONFERENCE: 42<sup>nd</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation  
CITY and YEAR: **Valencia (Spain), April 3-6, 2016**

CONTRIBUTION: Only-abstract (Abstract AB74)  
TITLE: Individualized stem cell donor requests: Not longer a search in a haystack  
AUTHORS: Hütter G, Wensing AM, Diez Martin JL, Kuball J, Nijhuis M, Saez-Cirion A, Rocha V, Schulze zur Wiesch J, Martínez-Picado J  
CONFERENCE: 42<sup>nd</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation  
CITY and YEAR: **Valencia (Spain), April 3-6, 2016**

CONTRIBUTION: Poster presentation (Abstract 4006)  
TITLE: A tale of two stem cell transplantations in HIV+ patients: Results from the EpiStem Cohort  
AUTHORS: Salgado M, Kwon M, Nijhuis M, Gálvez C, van Lunzen J, Blanco J, Schulze zur Wiesch J, Hutter G, Wensing AM, Díez JL, Martínez-Picado J  
CONFERENCE: Keystone Symposia on HIV Persistence: Pathogenesis and Eradication  
CITY and YEAR: **Olympic Valley (CA, USA), March 20-24, 2016**

CONTRIBUTION: Poster presentation (Abstract 3038)  
TITLE: T<sub>resting-memory</sub> Cell Transcriptome Reveals Host Factors Involved in Modulating HIV-reservoir Size  
AUTHORS: García Alonso M, López L, Barros C, Restrepo C, Morón-Lopez S, López JC, Cabello A, Fernández M, Górgolas M,



Álvarez B, García R, De La Hera FJ, Estrada V, García MI, Benguría A, Martínez-Picado J, Benito JM, Rallón N  
CONFERENCE: Keystone Symposia on HIV Persistence: Pathogenesis and Eradication  
CITY and YEAR: **Olympic Valley (CA, USA), March 20-24, 2016**

CONTRIBUTION: Poster presentation (abstract 366)  
TITLE: A Tale of Two Stem-Cell Transplantations in HIV+ Patients: Clues to Eradicate HIV  
AUTHORS: Salgado M, Kwon M, Nijhuis M, van Lunzen J, Blanco J, Schulze zur Wiesch J, Hutter G, Wensing AM, Diez JL, Martínez-Picado J  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), February 22-25, 2016**

CONTRIBUTION: Poster presentation (abstract 320)  
TITLE: Shaping CTL Immunodominance With Conserved HIV Vaccines After Early Treatment (BCN01)  
AUTHORS: Mothe B, Manzardo C, Coll P, Moron-Lopez S, Dorrell L, Clotet B, Martínez-Picado J, Brander C, Hanke TL, for the BCN01 Study Group  
CONFERENCE: 23<sup>rd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Boston (USA), February 22-25, 2016**

CONTRIBUTION: Oral presentation (abstract OP 9.3)  
TITLE: HIV conserved region vaccine in early cART-treated subjects (BCN01): impact on immunogenicity and the latent reservoir  
AUTHORS: Morón-López S, Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Puertas MC, Dorrell L, Miró JM, Clotet B, Brander C, Martínez-Picado J, Hanke T for the BCN01 Study Group  
CONFERENCE: 7<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (USA), December 1-4, 2015.**

CONTRIBUTION: Oral presentation (abstract OP 5.1)  
TITLE: Long-term spontaneous control of HIV-1 relates to low frequency of infected cells and inefficient viral reactivation  
AUTHORS: Prado JG, Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martínez-Picado J, Lambotte O, Sáez-Cirión A and for the ANRS CO21 Cohort  
CONFERENCE: 7<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (USA), December 1-4, 2015.**

CONTRIBUTION: Poster presentation (abstract PP 3.0)  
TITLE: Allogeneic stem cell transplantation in HIV-1 infected individuals  
AUTHORS: Wensing AMJ, Diez Martin JL, Hutter G, Kuball J, Nijhuis M, Saez-Cirion A, Rocha V, Schulze zur Wiesch J, Martínez-Picado J  
CONFERENCE: 7<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (USA), December 1-4, 2015.**

CONTRIBUTION: Poster presentation (abstract PP 3.10)  
TITLE: Low viral reservoir treated patients (LoViReT): clinical predictors of low HIV-1 DNA  
AUTHORS: Salgado M, Gálvez C, Dalmau J, Carrillo J, Urrea V, Clotet B, Blanco J, Martínez-Picado J  
CONFERENCE: 7<sup>th</sup> International Workshop on HIV Persistence during Therapy  
CITY and YEAR: **Miami (USA), December 1-4, 2015.**

CONTRIBUTION: Poster presentation (abstract PP 3.13)  
TITLE: Post-mortem analysis of HIV-1 reservoir after allogeneic transplantation using stem cells  
AUTHORS: Nijhuis M, Bruns A, Salgado M, Stam AJ, Ellerbroek PM, Tesselaar K, van Ham P, de Jong TCM, Hutter G, Zeerleder SS, van der Meer JT, Brosens LLA, Martínez-Picado J, Kuball J, Wensing AMJ for the EpiStem Consortium  
CONFERENCE: 7<sup>th</sup> International Workshop on HIV Persistence

during Therapy  
CITY and YEAR: **Miami (USA), December 1-4, 2015.**

CONTRIBUTION: Oral presentation (abstract CO-02)  
TITLE: HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen  
AUTHORS: Imaz A, Martínez-Picado J, Niubo J, Kashuba AD, Ferrer E, Rozas N, Acerete L, Vila A, Ouchi D, Sykes CS and Podzamczar D  
CONFERENCE: VII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), December 1-4, 2015.**

CONTRIBUTION: Oral presentation (abstract CO-14)  
TITLE: Nanoliposomes Targeting Myeloid Cells to Deliver HIV-1 Latency Reactivators to Lymphoid Tissues  
AUTHORS: Benet Garrabé S, Nieto Garai JA, Pino M, Bilbao E, Erkizia I, Fernández M, García J, Martínez-Picado J, Lorzate M and Izquierdo-Useros N  
CONFERENCE: VII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), December 1-4, 2015.**

CONTRIBUTION: Poster discussion (abstract PO-31)  
TITLE: Deciphering the Soluble Factors Present in the Plasma of HIV-1 Infected Individuals that Up-Regulate SIGLEC-1, the Key Receptor for HIV-1 Trans-Infection  
AUTHORS: Pérez-Zsolt D, Erkizia I, Benet S, Pino M, Martínez-Picado J and Izquierdo-Useros N  
CONFERENCE: VII Spanish AIDS Conference (GeSIDA)  
CITY and YEAR: **Madrid (Spain), December 1-4, 2015.**

CONTRIBUTION: Oral presentation (abstract PS9/5)  
TITLE: HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen  
AUTHORS: Imaz A, Martínez-Picado J, Niubó J, Kashuba ADM, Ferrer E, Rozas N, Acerete L, Vila A, Ouchi D, Sykes C, Podzamczar D  
CONFERENCE: 15<sup>th</sup> European AIDS Conference (EACS)  
CITY and YEAR: **Barcelona (Spain), October 23, 2015.**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Siglec-1 mediates HIV-1 trans-infection in myeloid cells isolated from lymphoid tissue  
AUTHORS: Pino M, Erkizia I, Benet S, Guerrero D, Rausell A, Ciuffi A, Telenti A, Martínez-Picado J, Izquierdo-Useros N.  
CONFERENCE: 5<sup>th</sup> annual International Workshop on Higher Education.  
CITY and YEAR: **Vic (Spain), June 11, 2015.**

CONTRIBUTION: Poster presentation  
TITLE: Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy  
AUTHORS: Martínez-Bonet M, Puertas MC, Fortuny C, Ouchi D, Mellado J, Rojo P, Noguera-Julian A, Muñoz-Fernández MA, Martínez-Picado J  
CONFERENCE: XIII Congreso Nacional de Virología  
CITY and YEAR: **Madrid (Spain), June 7-10, 2015.**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Nanocarrier system to efficiently deliver small therapeutic molecules to lymphoid tissues  
AUTHORS: Izquierdo-Useros N, Nieto-Garai JA, Benet S, Pino M, Bilbao E, Erkizia I, Fernández-Figueras MT, Prado JG, Martínez-Picado J, Lorzate M.  
CONFERENCE: Keystone symposium – Mechanism of HIV persistence: Implications for a cure  
CITY and YEAR: **Boston (USA), April 26- May 01, 2015.**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Impact of IFN $\alpha$ -2a on the Replication-Competent HIV-1 Reservoir in CD4+ T Cells  
AUTHORS: Morón-López S, Salgado M, Ouchi D, Puertas MC, Jou T, Tural C, Navarro J, Pérez M, Crespo M\*, Martínez-Picado J.  
CONFERENCE: 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY and YEAR: **Seattle (USA), February 23-26, 2015**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Rapid progression hinders the recovery of CD4 + T cells following initiation of cART  
AUTHORS: Jarrin I, Dalmau J, Pantazis N, Olson A, Mussini C, Phillips A, Boufassa F, Costagliola D, Porter K, Blanco J, Del Amo J and Martínez-Picado J for CASCADE Collaboration in EuroCoord  
CONFERENCE: 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Seattle (USA), February 23-26, 2015**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Siglec-1 on Monocytes from Untreated HIV-1-Infected Patients Enhances HIV-1 Transfer  
AUTHORS: Pino M, Benet S, Erkizia I, Dalmau J, Ouchi D, Martínez-Picado J, Izquierdo-Useros N  
CONFERENCE: 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Seattle (USA), February 23-26, 2015**

CONTRIBUTION: Poster presentation (abstract 2096792)  
TITLE: Allogeneic Transplantation with CCR5  $\Delta 32/\Delta 32$  Cord Blood Hematopoietic Cells in a HIV-1-Infected Patient  
AUTHORS: Duarte R, Salgado M\*, Martínez-Picado J.  
CONFERENCE: 22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Seattle (USA), February 23-26, 2015**

CONTRIBUTION: Poster presentation (abstract 1697)  
TITLE: Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients  
AUTHORS: Baptista MJ\*, Morgades M, Hernandez A, Briega A, Martinez E, Martínez-Picado J, Sirera G, Tapia G, Moreno M, Sancho JM, Ribera JM, Feliu E, Navarro JT  
CONFERENCE: 56<sup>th</sup> American Society for Haematology Annual Meeting and Exposition  
CITY AND YEAR: **San Francisco (USA), December 6-9, 2014**

CONTRIBUTION: Poster presentation (abstract 1261)  
TITLE: Allogeneic Transplantation with CCR5  $\Delta 32/\Delta 32$  Cord Blood Hematopoietic Cells in a HIV-Infected Patient  
AUTHORS: Duarte RF\*, Salgado M, Sánchez-Ortega I, Arnán M, Canals C, Domingo E, Fernández de Sevilla A, García-Pont X, González-Barca E, Morón-López S, Nogues N, Patiño B, Puertas MC, Clotet B, Petz LD, Querol S, Martínez-Picado J  
CONFERENCE: 56<sup>th</sup> American Society for Haematology Annual Meeting and Exposition  
CITY AND YEAR: **San Francisco (USA), December 6-9, 2014**

CONTRIBUTION: Oral presentation  
TITLE: Reservorio Viral en Pacientes Pediátricos Infeccionados por el VIH-1: Efecto del Tratamiento Antirretroviral Precoz y de la Interrupción de Tratamiento  
AUTHORS: M Martínez-Bonet, MC Puertas, C Fortuny, J Mellado, P Rojo, MA Muñoz-Fernández, J Martínez Picado  
CONFERENCE: VI Congreso Nacional de GeSIDA  
CITY AND YEAR: **Málaga, (Spain); November 25-28, 2014**

CONTRIBUTION: Oral presentation  
TITLE: Siglec-1 Receptor is Detected on Myeloid Cells from Inflamed Lymphoid Tissues  
AUTHORS: Pino M, Erikson E, Erkizia I, Benet S, Clotet B, Keppler OT, Martínez-Picado J, Izquierdo-Useros N  
CONFERENCE: VI Congreso Nacional de GeSIDA  
CITY AND YEAR: **Málaga, (Spain); November 25-28, 2014**

CONTRIBUTION: Poster presentation  
TITLE: Impacto del IFN $\alpha$ -2a en el reservorio de VIH-1 en linfocitos T CD4+ en pacientes co-infectados por VHC  
AUTHORS: Morón-López S, Salgado M, Puertas MC, Jou T, Puig J, Tural C, Navarro J, Pérez M, Clotet B, Crespo M, Martínez-Picado J.  
CONFERENCE: VI Congreso Nacional de GeSIDA

CITY AND YEAR: **Málaga, (Spain); November 25-28, 2014**

CONTRIBUTION: Poster presentation  
TITLE: Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV conserved region vaccine, MVA.HIVconsv, in HAART-treated subjects  
AUTHORS: Morón-López S, Hancock G, Puertas MC, Rose A, Hayton E, Morgan C, Angus B, Yang H, Salgado M, Hanke T, Dorrell L, Martínez-Picado J.  
CONFERENCE: HIV Research for Prevention  
CITY AND YEAR: **Cape Town, (South Africa); October 28-31, 2014**

CONTRIBUTION: Poster presentation  
TITLE: Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality  
AUTHORS: Guardo AC, Miralles L, Aerts JL, Thielemans K, Mothe B, Martínez-Picado J, Brander C, García F, Plana M.  
CONFERENCE: HIV Research for Prevention  
CITY AND YEAR: **Cape Town, (South Africa); October 28-31, 2014**

CONTRIBUTION: Poster presentation  
TITLE: In Vivo Viral Control in a HLA-B\*35:01 Homozygous Individual after the Vaccine-induced Response to a Well-defined, HIV Gag-derived HLA-B\*35 CTL Epitope.  
AUTHORS: Rosas M, Mothe B, Climent N, Puertas MC, Martínez-Picado J, García F, Brander C.  
CONFERENCE: HIV Research for Prevention  
CITY AND YEAR: **Cape Town, (South Africa); October 28-31, 2014**

CONTRIBUTION: Oral presentation  
TITLE: Targeting myeloid cells with liposomal nanocarriers for therapeutic purposes  
AUTHORS: \*Ander Nieto-Garai J, Benet S, Pino M, Bilbao E, Erkizia I, Prado JG, Martínez-Picado J, Izquierdo-Useros N, Lorizate M.  
CONFERENCE: 37<sup>th</sup> Spanish Society of Biochemistry and Molecular Biology  
CITY AND YEAR: **Granada (Spain), September 9-12, 2014**

CONTRIBUTION: Oral presentation  
TITLE: Myeloid cells from lymphoid tissue mediate HIV-1 transmission via Siglec-1  
AUTHORS: Pino M, Benet S, Erkizia I, Martínez-Picado J, Izquierdo-Useros N\*  
CONFERENCE: 3<sup>rd</sup> Madrid Meeting on Dendritic cells and Macrophages  
CITY AND YEAR: **Madrid (Spain), April 28-29, 2014**

CONTRIBUTION: Poster presentation  
TITLE: Does rapid progression before cART initiation predict poor CD4 T-cell recovery once HIV-1 suppressive response is achieved?  
AUTHORS: Jarrin I\*, Dalmau J, Blanco J, Pantazis N, Olson A, Mussini C, Phillips A, Boufassa F, Costagliola D, Porter K, Del Amo J and Martínez-Picado J for CASCADE Collaboration in EuroCoord  
CONFERENCE: 18<sup>th</sup> Workshop on HIV Observational Databases (IWHOD)  
CITY AND YEAR: **Sitges (Spain), March 27-29, 2014**

CONTRIBUTION: Poster presentation (abstract X4 3022)  
TITLE: Similar HIV-1 evolution in HIV-1-infected viremic non-progressors and standard progressors  
AUTHORS: Salgado M\*, García-Miñambres A, Viciano P, Monge S, Dalmau J, Martínez-Picado J.  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology: HIV Pathogenesis, virus vs. host.  
CITY AND YEAR: **Banff (AB, Canada); March 9-14, 2014**

CONTRIBUTION: Poster presentation (abstract X4 2020)  
TITLE: Targeting engineered nanoliposomes to mature dendritic cells for therapeutic purposes  
AUTHORS: Izquierdo-Useros N\*, Nieto JA, Benet S, Pino M,

Erkizia I, Prado JG, Lorizate M, Martinez-Picado J.  
CONFERENCE: Keystone Symposia on Molecular and Cellular  
Biology: HIV Pathogenesis, virus vs. host.  
CITY and YEAR: **Banff (AB, Canada); March 9-14, 2014**

CONTRIBUTION: Poster presentation (abstract 300)  
TITLE: Effect of Raltegravir Intensification in the Cytokine  
Profile of Treated HIV+ Individuals  
AUTHORS: Massanella M\*, Llibre JM, Marfil S, Puertas MC,  
Puig J, Negro E, Richman DD, Martinez-Picado J, Clotet B,  
Blanco J.  
CONFERENCE: 21<sup>st</sup> Conference on Retroviruses and  
Opportunistic Infections  
CITY and YEAR: **Boston, (MA, USA); March 3-6, 2014**

CONTRIBUTION: Poster presentation (abstract 492)  
TITLE: Cerebro Spinal Fluid Viremia and Inflammatory  
Markers in Patients with Neurocognitive Impairment on  
TDF/FTC/EFV and after Switch to ABC/3TC/MVC  
AUTHORS: Tiraboschi J\*, Muñoz-Moreno J, Puertas MC,  
Alonso C, Prats-Paris A, Ferrer E, Rozas N, Maso-Serra M,  
Martinez-Picado J, Podzamczar D.  
CONFERENCE: 21<sup>st</sup> Conference on Retroviruses and  
Opportunistic Infections  
CITY and YEAR: **Boston, (MA, USA); March 3-6, 2014**

CONTRIBUTION: Oral presentation  
TITLE: In Vivo Administration of Lithium Does Not Induce  
HIV-1 Reactivation or Changes in the Viral Reservoir.  
AUTHORS: MC Puertas\*, M Salgado, S Morón-López, J Muñoz-  
Moreno, J Moltó, B Clotet, and J Martinez-Picado  
CONFERENCE: 6<sup>th</sup> International Workshop on HIV Persistence  
during Therapy  
CITY AND YEAR: **Miami, (FL, USA); December 3-6, 2013**

CONTRIBUTION: Oral presentation  
TITLE: Siglec-1 expressed on activated monocytes captures and  
transfers HIV-1 through recognition of sialyllactose exposed on  
viral membrane gangliosides.  
AUTHORS: M Pino\*, I Erkizia, J Dalmau, E Erikson, B Clotet,  
OT Keppler, A Telenti, H-G Krausslich, J Martinez-Picado, N  
Izquierdo-Useros.  
CONFERENCE: V Congreso Nacional de GeSIDA  
CITY AND YEAR: **Sitges, (Spain); November 19-22, 2013**

CONTRIBUTION: Oral presentation  
TITLE: HIV-1 Gag evolution during dual selective pressure by  
drugs and HLA-class I immune responses in long-term treated  
patients.  
AUTHORS: E Jimenez, R Peña, FM Codoñer, S Santamaria, M  
Pino, T Vollbrecht, B Clotet, J Martinez-Picado, JG Prado.  
CONFERENCE: V Congreso Nacional de GeSIDA  
CITY AND YEAR: **Sitges, (Spain); November 19-22, 2013**

CONTRIBUTION: Oral presentation (abstract P05.13)  
TITLE: Siglec-1 expressed on activated monocytes captures and  
transfers HIV-1 through recognition of sialyllactose exposed on  
viral membrane gangliosides.  
AUTHORS: M Pino\*, I Erkizia, J Dalmau, E Erikson, B Clotet,  
OT Keppler, A Telenti, H-G Krausslich, J Martinez-Picado, N  
Izquierdo-Useros.  
CONFERENCE: AIDS Vaccine 2013 Conference  
CITY AND YEAR: **Barcelona, (Spain); October 7-10, 2013**

CONTRIBUTION: Oral presentation (abstract OA07.05)  
TITLE: Highly Pathogenic Adapted HIV-1 Strains Limit  
Immune Responses and Dictates Rapid Disease Progression in  
Early Infection.  
AUTHORS: J Dalmau, M Rotger, I Erkizia, A Rauch, P Reche, M  
Pino, Y Lie, R Bellido, A Esteve, E Coackley, E Palou, C Brander,  
R Paredes, T Wrin, B Clotet, A Telenti, J Martinez-Picado, JG  
Prado\*.  
CONFERENCE: AIDS Vaccine 2013 Conference  
CITY AND YEAR: **Barcelona, (Spain); October 7-10, 2013**

CONTRIBUTION: Poster presentation (abstract P05.20)  
TITLE: HIV-1 Gag evolution during dual selective pressure by

drugs and HLA- class I immune responses in long-term treated  
patients.

AUTHORS: E Jimenez\*, R Peña\*, FM Codoñer, S Santamaria, M  
Pino, T Vollbrecht, B Clotet, J Martinez-Picado,  
R Draenert, JG Prado.

CONFERENCE: AIDS Vaccine 2013 Conference  
CITY AND YEAR: **Barcelona, (Spain); October 7-10, 2013**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Siglec-1 is a novel dendritic cell receptor that mediates  
HIV-1 trans-infection through recognition of viral membrane  
gangliosides.

AUTHORS: N Izquierdo-Useros\*, M Lorizate, MC Puertas, MT  
Rodriguez-Plata, N Zangger, M Pino, I Erkizia, A Telenti, H-G  
Krausslich, J Martinez-Picado.

CONFERENCE: Keystone Symposium; Immune Activation in  
HIV Infection: Basic Mechanisms and Clinical Implications  
CITY AND YEAR: **Breckenridge, CO (USA); April 3-8,  
2013**

CONTRIBUTION: Poster presentation (abstract)  
TITLE: Presence of highly Adapted and Pathogenic HIV-1  
strains Limits host Immune Responses and Dictates Rapid  
Disease Progression.

AUTHORS: Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P,  
Pino M, Lie Y, Bellido R, Esteve A, Coackley E, Palou E,  
Brander C, Paredes R, Wrin T, Clotet B, Telenti A, Martinez-  
Picado J, Prado JG.

CONFERENCE: Keystone Symposium; Immune Activation in  
HIV Infection: Basic Mechanisms and Clinical Implications  
CITY AND YEAR: **Breckenridge, CO (USA); April 3-8,  
2013**

CONTRIBUTION: Oral presentation (abstract 134)  
TITLE: Siglec-1 is a novel dendritic cell receptor that mediates  
HIV-1 trans-infection through recognition of viral membrane  
gangliosides.

AUTHORS: N Izquierdo-Useros\*, M Lorizate, MC Puertas, MT  
Rodriguez-Plata, N Zangger, M Pino, I Erkizia, A Telenti, H-G  
Krausslich, J Martinez-Picado.

CONFERENCE: 20<sup>th</sup> Conference on Retroviruses and  
Opportunistic Infections  
CITY AND YEAR: **Atlanta, GA (USA); March 3-6, 2013**

CONTRIBUTION: Poster presentation (abstract 283)  
TITLE: The infectious synapses formed between mature  
dendritic cells and CD4+ T cells are independent of the presence  
of the HIV-1 envelope glycoprotein.

AUTHORS: MT Rodriguez-Plata\*, I Puigdomenech, N  
Izquierdo-Useros, MC Puertas, J Carrillo, I Erkizia, B Clotet, J  
Blanco, J Martinez-Picado.

CONFERENCE: 20<sup>th</sup> Conference on Retroviruses and  
Opportunistic Infections  
CITY AND YEAR: **Atlanta, GA (USA); March 3-6, 2013**

CONTRIBUTION: Poster presentation (abstract P01.02)  
TITLE: HIV-1 capture and antigen presentation by dendritic  
cells: enhanced viral capture does not correlate with better  
T-cell activation.

AUTHORS: MT Rodriguez-Plata, A Urrutia, S Cardinaud, MJ  
Buzón, N Izquierdo-Useros, JG Prado, MC Puertas, I Erkizia, P-  
G Coulon, S Cedeño, B Clotet, A Moris, J Martinez-Picado.

CONFERENCE: AIDS 2012 Vaccine  
CITY AND YEAR: **Boston, MA (USA); May 10-12, 2012**

CONTRIBUTION: Oral presentation (abstract 1)  
TITLE: Bitter-sweet interactions between HIV-1 and mature  
dendritic cells.

AUTHORS: N Izquierdo-Useros, M Lorizate, F-X Contreras, MT  
Rodriguez-Plata, B Glass, I Erkizia, JG Prado, J Casas, G Fabriás,  
H-G Krausslich, J Martinez-Picado.

CONFERENCE: 8<sup>th</sup> International Workshop on HIV, Cells of  
Macrophage/Dendritic Lineage, and Other Reservoirs:  
Pathogenic and Therapeutic Implications  
CITY AND YEAR: **Stresa (Italy); May 10-12, 2012**

CONTRIBUTION: Poster presentation (abstract 10)

TITLE: HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-cell activation.

AUTHORS: MT Rodriguez-Plata, A Urrutia, S Cardinaud, MJ Buzón, N Izquierdo-Useros, JG Prado, MC Puertas, I Erkizia, P-G Coulon, S Cedeño, B Clotet, A Moris, J Martínez-Picado.

CONFERENCE: 8<sup>th</sup> International Workshop on HIV, Cells of Macrophage/Dendritic Lineage, and Other Reservoirs: Pathogenic and Therapeutic Implications

CITY AND YEAR: **Stresa (Italy); May 10-12, 2012**

CONTRIBUTION: Poster presentation (abstract 297)

TITLE: Matrix residues S54 and S111 co-evolve with primary Protease drug resistance sites L90 and V82 in a Highly Protease Inhibitors-Expose HIV-1 Infected Patient

CONFERENCE: 10<sup>th</sup> European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance

CITY AND YEAR: **Barcelona (Spain), March 29, 2012**

CONTRIBUTION: Poster presentation (abstract 297)

TITLE: Differences in Cytokine Levels in HIV-1 Individuals Might Contribute to Natural Control of HIV Infection by Viremic Non-progressors.

CONFERENCE: 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Seattle (USA); March 5-8, 2012**

CONTRIBUTION: Poster presentation (abstract 338)

TITLE: Effect of Maraviroc Intensification on the Decay of HIV-1 DNA in PBMC and Residual Viremia of Recently Infected Patients Initiating Treatment with Raltegravir plus Tenofovir/Emtricitabine: A 48-Week Randomized Study.

CONFERENCE: 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Seattle (USA); March 5-8, 2012**

CONTRIBUTION: Poster presentation (abstract 351)

TITLE: 48-Week Raltegravir Intensification Shows Differing Effects on CD8 and CD4 T Cells in Treated HIV+ Individuals with Poor CD4 T Cell Recovery.

CONFERENCE: 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Seattle (USA); March 5-8, 2012**

CONTRIBUTION: Poster presentation (abstract 590)

TITLE: The intracellular disposition of raltegravir is dependent on P-glycoprotein (P-gp; ABCB1) activity and is significantly reduced in primary CD4+ P-gp<sup>high</sup> T cells.

CONFERENCE: 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Seattle (USA); March 5-8, 2012**

CONTRIBUTION: Oral Communication (41)

TITLE: Effect of Maraviroc Intensification on the Decay of HIV-1 DNA in PBMC of Recently Infected Patients Initiating Treatment with Raltegravir plus Tenofovir/Emtricitabine: a 48-week Randomized Study.

CONFERENCE: 5<sup>th</sup> International Workshop on HIV Persistence During Therapy

CITY AND YEAR: **St. Maarten (West Indies); December 6-9, 2011**

CONTRIBUTION: Oral Communication (42)

TITLE: Dynamics of Immune Activation and PD-1 Expression in Recently Infected HIV-1 Naïve Subjects Intensifying with Maraviroc a Raltegravir plus Tenofovir/Emtricitabine Regimen.

CONFERENCE: 5<sup>th</sup> International Workshop on HIV Persistence During Therapy

CITY AND YEAR: **St. Maarten (West Indies); December 6-9, 2011**

CONTRIBUTION: Oral Communication (OR-07)

TITLE: La Progression Rápida en individuos infectados por VIH-1 está marcada por la ausencia de respuestas específicas T CD8+ frente al virus.

CONFERENCE: III Congreso Nacional de GeSIDA

CITY AND YEAR: **Sevilla (Spain); November 7-10, 2011**

CONTRIBUTION: Oral Communication (OR-01)

TITLE: VIH-1 y células dendríticas: la captura viral no se correlaciona con la presentación antigénica y la activación inducida a células T.

CONFERENCE: III Congreso Nacional de GeSIDA

CITY AND YEAR: **Sevilla (Spain); November 7-10, 2011**

CONTRIBUTION: Poster presentation

TITLE: Nueva metodología para la evaluación fenotípica de la susceptibilidad a inhibidores de la proteasa aplicable a virus VIH-1 recombinantes y aislados virales primarios.

CONFERENCE: III Congreso Nacional de GeSIDA

CITY AND YEAR: **Sevilla (Spain); November 7-10, 2011**

CONTRIBUTION: Poster presentation (abstract MOPE226)

TITLE: HIV-1 dual/mixed-tropic viruses can be inhibited in vitro as in vivo by maraviroc: a refined analysis from patients enrolled in the phase-IIb study-A4001029.

CONFERENCE: 6<sup>th</sup> International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention

CITY AND YEAR: **Rome (Italy); July 17-20, 2011**

CONTRIBUTION: Poster presentation (abstract 57)

TITLE: Excision of AZT and d4T Modulated by Deletions in the  $\beta$ 3- $\beta$ 4 Hairpin Loop of HIV-1 Reverse Transcriptase.

CONFERENCE: 24<sup>th</sup> International Conference on Antiviral Research

CITY AND YEAR: **Sofia (Bulgaria); May 5-11, 2011**

CONTRIBUTION: Poster presentation (abstract 37)

TITLE: HIV-1 R5+/X4-tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: A refined analysis of patients enrolled in the phase-IIb study-A4001029.

CONFERENCE: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies

CITY AND YEAR: **Los Cabos (Mexico); June 7-11, 2011**

CONTRIBUTION: **Oral presentation** (abstract 247)

TITLE: Live cell imaging of cell-associated viral capture by mature dendritic cells

CONFERENCE: HIV evolution, genomics and pathogenesis; Keystone Symposia on Molecular and cellular Biology.

CITY AND YEAR: **Whistler (Canada); March 20-25, 2011**

CONTRIBUTION: Poster presentation (abstract 149)

TITLE: Cytokine profiles during primary HIV-1 infection may predict the clinical outcome and the rate of progression of HIV-infected individuals

CONFERENCE: HIV evolution, genomics and pathogenesis; Keystone Symposia on Molecular and Cellular Biology.

CITY AND YEAR: **Whistler (Canada); March 20-25, 2011**

CONTRIBUTION: Poster presentation (abstract 359)

TITLE: Rapid progression to AIDS is characterized by the absence of CD8+ T-cell HIV specific responses in HIV infected subject

CONFERENCE: HIV evolution, genomics and pathogenesis; Keystone Symposia on Molecular and cellular Biology.

CITY AND YEAR: **Whistler (Canada); March 20-25, 2011**

CONTRIBUTION: **Oral presentation** (abstract 21)

TITLE: Comparative Analysis of Genomic Features of Human HIV-1 Infection and Primate Models of SIV Infection

CONFERENCE: 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**

CONTRIBUTION: Poster presentation (abstract 277)

TITLE: Ultra-deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART.

CONFERENCE: 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**

- CONTRIBUTION: Poster presentation (abstract 281)  
 TITLE: Dynamics of CD8 T Cell Activation during RAL Intensification and after Its Discontinuation in HAART suppressed Subjects.  
 CONFERENCE: 18th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**
- CONTRIBUTION: Poster presentation (abstract 468)  
 TITLE: Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers.  
 CONFERENCE: 18th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**
- CONTRIBUTION: Poster presentation (abstract 545)  
 TITLE: Effect of RAL Intensification in HAART-suppressed Subjects without Proper CD4 T Cell Recovery.  
 CONFERENCE: 18th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**
- CONTRIBUTION: Poster presentation (abstract 547)  
 TITLE: Immunological Effects of Treatment Intensification with MVC in Recently Infected HIV-1-naïve Subjects Starting RAL + TDF/FTC: The Maraviboost Study.  
 CONFERENCE: 18th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **Boston (MA) USA; 27 February – March 2, 2011**
- CONTRIBUTION: Oral presentation (abstract)  
 TITLE: HIV and Mature Dendritic cells: Trojan exosomes riding the Trojan horse.  
 CONFERENCE: International Workshop on Exosomes (IWE) 2011  
 CITY AND YEAR: **Paris (France); January 19-12, 2011**
- CONTRIBUTION: Poster presentation (abstract 202)  
 TITLE: Imaging HIV-1 Viral Like Particle Capture Mediated by Mature Dendritic Cells.  
 CONFERENCE: Keystone Symposia: Immunological Mechanisms of Vaccination  
 CITY AND YEAR: **Seattle (WA) USA; 27 October – November 1, 2010**
- CONTRIBUTION: Poster presentation  
 TITLE: The Amino Acid Substitution A376S in the HIV-1 Reverse Transcriptase Connection Subdomain Confers Low-Level Phenotypic Resistance to Nevirapine.  
 CONFERENCE: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies  
 CITY AND YEAR: **Dubrovnik, Croatia; 8-12 June 2010**
- CONTRIBUTION: Poster presentation  
 TITLE: The integrase inhibitor raltegravir is a substrate but not an inhibitor of P-glycoprotein: potential therapeutic target to modulate drug disposition?.  
 CONFERENCE: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies  
 CITY AND YEAR: **Dubrovnik, Croatia; 8-12 June 2010**
- CONTRIBUTION: Poster presentation  
 TITLE: Mechanisms of Nucleoside Analogue Resistance Associated with the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms.  
 CONFERENCE: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies  
 CITY AND YEAR: **Dubrovnik, Croatia; 8-12 June 2010**
- CONTRIBUTION: Poster presentation  
 TITLE: Partial CD4 T-Cell Recovery in Virologically Suppressed Immunological Non-Responder HIV-Infected Subjects by Treatment Intensification with Raltegravir.  
 CONFERENCE: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies  
 CITY AND YEAR: **Dubrovnik, Croatia; 8-12 June 2010**
- CONTRIBUTION: Oral presentation  
 TITLE: HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients.  
 CONFERENCE: 17th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **San Francisco (CA), USA; 16-19 February 2010**
- CONTRIBUTION: Oral presentation  
 TITLE: HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients.  
 CONFERENCE: 17th Conference on Retroviruses and Opportunistic Infections  
 CITY AND YEAR: **San Francisco (CA), USA; 16-19 February 2010**
- CONTRIBUTION: Invited presentation  
 AUTHORS: MJ Buzon, M Massanella, J Llibre, A Esteve, MC Puertas, S Palmer, M Stevenson, B Clotet, J Blanco, Javier Martinez-Picado\*, and Integral Collaborative Group  
 TITLE: HIV-1 Replication and Immune Dynamics are Impacted by Raltegravir Intensification of HAART-Suppressed Patients  
 CONFERENCE: HIV Biology and Pathogenesis Keystone Symposia on Molecular and Cellular Biology  
 CITY AND YEAR: **Santa Fe (New Mexico), USA, 12-17 January 2010**
- CONTRIBUTION: Poster presentation  
 TITLE: Ex-vivo production of autologous HIV-1 obtained from infected subjects to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (Clinical trial DCV02).  
 CONFERENCE: AIDS Vaccine 2009  
 CITY AND YEAR: **Paris, France; 19-22 October 2009**
- CONTRIBUTION: Poster presentation  
 TITLE: Screening of the interaction and transportability of NRTIs and the integrase inhibitor Raltegravir with protein members from SLC22 and SLC29 gene families.  
 CONFERENCE: BioMedical Transporters 2009  
 CITY AND YEAR: **Thun, Switzerland; 9-13 August 2009**
- CONTRIBUTION: Poster presentation 81  
 TITLE: Effect of the HIV-1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility.  
 CONFERENCE: XVIII International HIV Drug Resistance Workshop: basic principles & clinical implications.  
 CITY AND YEAR: **Fort Myers (FL), USA; 9-13 June 2009**
- CONTRIBUTION: Poster presentation 53  
 TITLE: Effect of RT connection domain mutations on efavirenz and nevirapine phenotypic susceptibility in NNRTI-resistant clinical HIV-1 isolates.  
 CONFERENCE: XVIII International HIV Drug Resistance Workshop: basic principles & clinical implications.  
 CITY AND YEAR: **Fort Myers (FL), USA; 9-13 June 2009**
- CONTRIBUTION: Oral presentation O-05  
 TITLE: Screening of the interaction and transportability of NRTIs and the integrase inhibitor Raltegravir with protein members from SLC22 and SLC29 gene families.  
 CONFERENCE: 10th International Workshop on Clinical Pharmacology of HIV Therapy.  
 CITY AND YEAR: **Amsterdam, The Netherlands; 15-17**

## April 2009

CONTRIBUTION: Poster presentation 82  
TITLE: Co-receptor tropism prediction in chronically HIV-1-infected subjects with suppressed viremia  
CONFERENCE: 7th European HIV Drug Resistance Workshop.  
CITY AND YEAR: **Stockholm, Sweden; 25-27 March 2009**

CONTRIBUTION: Poster presentation 11  
TITLE: Low-level viremia, rate of emergence of mutations and decreased replicative capacity  
CONFERENCE: 7th European HIV Drug Resistance Workshop.  
CITY AND YEAR: **Stockholm, Sweden; 25-27 March 2009**

CONTRIBUTION: Poster presentation 340  
TITLE: Copy number variation of KIR genes influences HIV-1 control.  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology.  
CITY AND YEAR: **Keystone (CO), USA; 22-27 March 2009**

CONTRIBUTION: Poster presentation 257  
TITLE: Capture and Transfer of HIV-1 Particles by Mature Dendritic Cells Converges with the Exosome-Dissemination Pathway.  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology.  
CITY AND YEAR: **Keystone (CO), USA; 22-27 March 2009**

CONTRIBUTION: Poster presentation 206  
TITLE: Study of Viral Variability Evolution in Patients Submitted to a Therapeutic Vaccine Based on Autologous Dendritic Cells Pulsed with Autologous Inactivated HIV-1 (protocol DCV01).  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology.  
CITY AND YEAR: **Keystone (CO), USA; 22-27 March 2009**

CONTRIBUTION: Poster presentation 205  
TITLE: Ex-Vivo Production of Autologous HIV-1 obtained from Infected Subjects to be used as Immunogen in Autologous Dendritic Cell-Based Therapeutic Vaccine (Clinical trial DCV02).  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology.  
CITY AND YEAR: **Keystone (CO), USA; 22-27 March 2009**

CONTRIBUTION: Poster presentation 167  
TITLE: Immunological failure as a determinant factor in extremely severe primary HIV infection.  
CONFERENCE: Keystone Symposia on Molecular and Cellular Biology.  
CITY AND YEAR: **Keystone (CO), USA; 22-27 March 2009**

CONTRIBUTION: Poster presentation 651  
TITLE: Interaction between HIV-1 Pol-derived Proteins Modulate Viral Fitness without Changes on Raltegravir Susceptibility.  
CONFERENCE: 16th Conference on Retroviruses and Opportunistic Infections.  
CITY AND YEAR: **Montréal, Canada; 8-11 February 2009**

CONTRIBUTION: Oral & Poster presentation 423a  
TITLE: Transient Increase in Episomal Viral cDNA following Raltegravir Intensification of a Stable HAART Regimen.  
CONFERENCE: 16th Conference on Retroviruses and Opportunistic Infections.  
CITY AND YEAR: **Montréal, Canada; 8-11 February 2009**

CONTRIBUTION: Invited talk  
TITLE: The evolving concept of HIV eradication.  
CONFERENCE: Thinking about HIV eradication: is it possible now?  
CITY AND YEAR: **Barcelona, Spain; November 27, 2008**

CONTRIBUTION: Oral presentation

TITLE: Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway.  
CONFERENCE: Advanced Microscopy Techniques for Immunofluorescence.  
CITY AND YEAR: **Barcelona, Spain; October 15-16, 2008**

CONTRIBUTION: Poster presentation  
TITLE: Envelope glycoprotein-independent HIV-1 capture and transmission mediated by mature DCs.  
CONFERENCE: Advanced Microscopy Techniques for Immunofluorescence.  
CITY AND YEAR: **Barcelona, Spain; October 15-16, 2008**

CONTRIBUTION: Oral presentation  
TITLE: Aportación de la Farmacogenómica  
CONFERENCE: XI Congreso Nacional sobre el SIDA  
CITY AND YEAR: **Córdoba, Spain; October 8-10, 2008**

CONTRIBUTION: Poster presentation (abstract 54)  
TITLE: Identification of lamivudine (3TC) as a novel substrate for human Organic Cation Transporters 1, 2 and 3  
CONFERENCE: XVII International HIV Drug Resistance Workshop: basic principles & clinical implications  
CITY AND YEAR: **Sitges, Spain; June 10-14, 2008**

CONTRIBUTION: Poster presentation (abstract 76)  
TITLE: Fitness progression and phenotypic susceptibility to raltegravir of HIV-1 integrase are not restricted in long-term HAART-treated patients  
CONFERENCE: XVII International HIV Drug Resistance Workshop: basic principles & clinical implications  
CITY AND YEAR: **Sitges, Spain; June 10-14, 2008**

CONTRIBUTION: Poster presentation (abstract 75)  
TITLE: Spontaneous mutations in HIV-1 V3 envelope of slow and fast progressors are capable to influence the binding to CCR5 and CXCR4 co-receptors  
CONFERENCE: XVII International HIV Drug Resistance Workshop: basic principles & clinical implications  
CITY AND YEAR: **Sitges, Spain; June 10-14, 2008**

CONTRIBUTION: Oral presentation (abstract 49)  
TITLE: Evolution of HIV-1 pol under HAART does not restrict fitness progression of HIV-1 integrase  
AUTHORS: Buzón MJ, Marfil S, Puertas MC, García E, Clotet B, Blanco J, Martínez-Picado J, Cabrera C  
CONFERENCE: 6th European HIV Drug Resistance Workshop  
CITY AND YEAR: **Budapest, Hungary; March 26-28, 2008.**

CONTRIBUTION: Poster presentation (abstract 307c)  
TITLE: Severe Primary Sexually Transmitted HIV Infection Due to Dual-tropic HIV-1  
CONFERENCE: 15th Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Boston MA, USA; February 3-6, 2008**

CONTRIBUTION: Poster presentation (abstract 292)  
TITLE: Cell-to-cell HIV Transmission Targets CD45RO+ CD4 T cells through LFA-1-dependent and -independent Mechanisms  
CONFERENCE: 15th Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Boston MA, USA; February 3-6, 2008**

CONTRIBUTION: Poster presentation (abstract 289)  
TITLE: Characterization of a Novel Mechanism of an Envelope Glycoprotein-independent HIV-1 Capture and Transmission Mediated by Mature Dendritic Cells  
CONFERENCE: 15th Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Boston MA, USA; February 3-6, 2008**

CONTRIBUTION: Poster presentation (abstract P3.4/05)  
TITLE: Predicted Resistance to Tipranavir and Darunavir in Clinical Samples from 1999-2006 with Protease Resistance Mutations.

- CONFERENCE: 11th European AIDS Conference (EACS).  
CITY AND YEAR: **Madrid, Spain; October 24-27, 2007**
- CONTRIBUTION: Poster presentation (abstract 64)  
TITLE: Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plasma Levels determine different NNRTI-resistance Pattern in Virological Responders during TI.  
CONFERENCE: XVI International HIV Drug Resistance Workshop: basic principles & clinical implications.  
CITY AND YEAR: **Bridgetown, Barbados; June 12-16, 2007**
- CONTRIBUTION: Poster presentation (abstract 71)  
TITLE: Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir® and tenofovir with persistent viral replication.  
CONFERENCE: XVI International HIV Drug Resistance Workshop: basic principles & clinical implications.  
CITY AND YEAR: **Bridgetown, Barbados; June 12-16, 2007**
- CONTRIBUTION: Poster presentation (abstract 72)  
TITLE: Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T).  
CONFERENCE: XVI International HIV Drug Resistance Workshop: basic principles & clinical implications.  
CITY AND YEAR: **Bridgetown, Barbados; June 12-16, 2007**
- CONTRIBUTION: Poster presentation (abstract 559)  
TITLE: Expression of nucleoside analog uptake transporters and entry mechanisms of AZT in immune cells.  
CONFERENCE: 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Los Angeles, USA; February 25-28, 2007**
- CONTRIBUTION: Oral presentation  
TITLE: Mature Dendritic Cells Capture High Amounts Of HIV-1 Through An Envelope Independent Mechanism  
CONFERENCE: 2<sup>nd</sup> International Workshop on Targeting HIV Entry  
CITY AND YEAR: **Boston MA, USA; October 20-21, 2006**
- CONTRIBUTION: Poster presentation  
TITLE: Mecanismos de captación de 3'-azida-2,3'-dideoximidina (AZT) en linfocitos T  
CONFERENCE: XXIX Congreso de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM)  
CITY AND YEAR: **Elche, Alicante, Spain; September 7-10, 2006**
- CONTRIBUTION: Poster presentation (abstract 80)  
TITLE: Selection of drug-resistance mutations during guided treatment interruptions is associated with suboptimal antiretroviral treatments prior to HAART  
CONFERENCE: XV International HIV Drug Resistance Workshop: basic principles & clinical implications  
CITY AND YEAR: **Sitges, Barcelona, Spain; June 13-17, 2006**
- CONTRIBUTION: Poster presentation (abstract 147)  
TITLE: Drug uptake transporters expression on T-lymphocytes and their regulation during HIV-1 infection in vitro  
CONFERENCE: XV International HIV Drug Resistance Workshop: basic principles & clinical implications  
CITY AND YEAR: **Sitges, Barcelona, Spain, June 13-17, 2006**
- CONTRIBUTION: Poster presentation  
TITLE: Benefit of Call Conference Expert Advice Discussion in treatment-experienced patients with virologic failure  
CONFERENCE: 4th European HIV Drug Resistant Workshop  
CITY AND YEAR: **Monte Carlo, Cote d'Azur, France, March 29-31, 2006**
- CONTRIBUTION: Poster presentation (Abstract C-127)  
TITLE: Mature Monocyte Derived Dendritic Cells Capture and Trans Infect HIV-1 Independently of DC-SIGN.  
CONFERENCE: 13th Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **Denver, USA, February 05-08, 2006**
- CONTRIBUTION: Poster presentation (Abstract 2693)  
TITLE: Characterization of the  $\Delta 69$  of HIV-1 Reverse Transcriptase into a Multi-drug Resistant Background  
CONFERENCE: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)  
CITY AND YEAR: **Washington, D.C., USA, December 16-19, 2005**
- CONTRIBUTION: Poster presentation (Abstract 1642)  
TITLE: Increased antiretroviral (ARV) potency by the addition of enfuvirtide (ENF) to a four drug regimen in ARV naïve HIV-infected patients  
CONFERENCE: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)  
CITY AND YEAR: **Washington, D.C., USA, December 16-19, 2005**
- CONTRIBUTION: Poster presentation (Abstract )  
TITLE: Determinants of resistance to enfuvirtide in sequential clinical samples and in vitro sensitivity to new fusion inhibitors  
CONFERENCE: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)  
CITY AND YEAR: **Washington, D.C., USA, December 16-19, 2005**
- CONTRIBUTION: Oral Presentation (OP 5.4)  
TITLE: Expression of Equilibrative and Concentrative Nucleoside Transporters in T-lymphocytes, and their regulation during HIV-1 infection  
CONFERENCE: 2nd International HIV Persistence Workshop  
CITY AND YEAR: **Saint Martin, French West Indies, December 6-9, 2005**
- CONTRIBUTION: Invited speaker  
TITLE: Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus  
CONFERENCE: V International Workshop on HIV Eradication  
CITY AND YEAR: **Badalona, Barcelona, Spain, November 11, 2005**
- CONTRIBUTION: Poster presentation (Abstract 11)  
TITLE: Mature Monocyte Derived Dendritic Cells (mMDDCs) Capture and Transinfect pseudo-typed HIV-1 independently of DC-SIGN  
CONFERENCE: 6th International Workshop on HIV Cells of Macrophage/Dendritic Lineage, and Other Reservoirs  
CITY AND YEAR: **Varenna, Italy, October 5-7, 2005**
- CONTRIBUTION: Invited speaker  
TITLE: HIV evolution: CTL escape mutation and reversion after transmission  
CITY AND YEAR: **Centro Nacional de Microbiología. Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. September 30, 2005**
- CONTRIBUTION: Invited speaker  
TITLE: Prevalence of mutations associated with antiretroviral drug resistance in Spain  
CITY AND YEAR: **Gagoya National Hospital, Nagoya, Japan, July 13, 2005**
- CONTRIBUTION: Invited speaker  
TITLE: HIV evolution: CTL escape mutation and reversion after transmission  
CITY AND YEAR: **Institute of Medical Science, University of Tokyo, Tokyo, Japan, July 12, 2005**
- CONTRIBUTION: Invited speaker  
TITLE: Fitness variations and their impact on the evolution of antiretroviral drug resistance



**CITY AND YEAR: National Institute of Infectious Disease, Tokyo, Japan, July 11, 2005**

CONTRIBUTION: Poster presentation (Abstract 124, Antiviral Therapy 2005; 10:S137)

TITLE: Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during year 2004

CONFERENCE: XIV International HIV Drug Resistance Workshop: basic principles & clinical implications

CITY AND YEAR: **Québec City, Québec, Canadá, June 7-11, 2005**

CONTRIBUTION: Poster presentation (Abstract 167, Antiviral Therapy 2005)

TITLE: Resistance to enfuvirtide proceeds through selection of mutations in gp41 and gp120

CONFERENCE: XIV International HIV Drug Resistance Workshop: basic principles & clinical implications

CITY AND YEAR: **Québec City, Québec, Canadá, June 7-11, 2005**

CONTRIBUTION: Invited speaker

TITLE: Evolución del VIH: provocando a Darwin y a la medicina moderna

CITY AND YEAR: **Departament de Bioquímica, Universitat de Barcelona, Barcelona, Spain. April 29, 2005.**

CONTRIBUTION: Oral Presentation

TITLE: Parallel Evolution of HIV-1 Envelope and Antibody Neutralization Activity in Identical Twins and a Sibling Infected with the same Virus

CONFERENCE: 12th International Workshop on HIV Dynamics and Evolution

CITY AND YEAR: **Cleveland, OH, USA, April 23 - 26, 2005**

CONTRIBUTION: Oral presentation (Abstract 440)

TITLE: Evolution of HIV-1 envelope and antibody neutralization activity in identical twins and a sibling infected with the same virus.

CONFERENCE: HIV Vaccines

CITY AND YEAR: **Banff, Alberta, Canada, April 9-15, 2005**

CONTRIBUTION: Oral presentation (Abstract 61)

TITLE: Genotypic Evolution of T-20 Resistance-associated Mutations in Heavily Treated HIV-infected Patients on Long-term Treatment with T-20.

CONFERENCE: 3<sup>rd</sup> European HIV Drug Resistance Workshop

CITY AND YEAR: **Athens, Greece, March 30 - April 1, 2005**

CONTRIBUTION: Poster presentation (Abstract 66)

TITLE: Influence of Drug Resistance Mutations on Viral Load and CD4 Counts in Heavily Antiretroviral-Experienced HIV-Infected Patients.

CONFERENCE: 3<sup>rd</sup> European HIV Drug Resistance Workshop

CITY AND YEAR: **Athens, Greece, March 30 - April 1, 2005**

CONTRIBUTION: Poster presentation (Abstract 691)

TITLE: Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Chronically HIV-1-infected Patients.

CONFERENCE: 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Boston, MA, USA, February 22-25, 2005**

CONTRIBUTION: Poster presentation (Abstract 718)

TITLE: Genotypic Evolution of T-20 Resistance-associated Mutations in Heavily Treated HIV-infected Patients on Long-term Treatment with T-20.

CONFERENCE: 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Boston, MA, USA, February 22-25, 2005**

CONTRIBUTION: Poster presentation (Abstract 679)

TITLE: Selection of Drug-resistance Mutations in Chronic HIV-infected Patients during Therapy Interruptions Guided by CD4+ T-cell Counts and Viral Load Levels: The Tibet Study.

CONFERENCE: 12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

CITY AND YEAR: **Boston, MA, USA, February 22-25, 2005**

CONTRIBUTION: Poster presentation (Abstract MoPeB3144)

TITLE: Evaluation of Boosted Signal Amplification of Heat-Dissociated p24 (H-Dp24 Ag) antigen detection in HIV-1 Chronic Infected patients during Structure Treatment Interruptions (STIs).

CONFERENCE: XV International AIDS Conference

CITY AND YEAR: **Bangkok, Thailand, July 2004**

CONTRIBUTION: Poster presentation (Abstract WePeA5661)

TITLE: Implications of accumulation of drug resistant mutations in pol and gag genes during treatment in HIV-1 infected patients with sustained CD4 count despite a virologic rebound.

CONFERENCE: XV International AIDS Conference

CITY AND YEAR: **Bangkok, Thailand, July 2004**

CONTRIBUTION: Oral presentation (Abstract 12)

TITLE: Comparison of CD8 T-Cell Responses and Viral Escape in HIV-infected Monozygotic Twins

CONFERENCE: 11<sup>th</sup> Conference on retroviruses and opportunistic Infections

CITY AND YEAR: **San Francisco, USA, March 2004**

CONTRIBUTION: Poster presentation (Abstract 639)

TITLE: Replication Capacity of Multi-NRTI Resistant HIV-1 Strains Containing the Insertion 69 and Multiple Amino Acid Changes in the RT.

CONFERENCE: 11<sup>th</sup> Conference on retroviruses and opportunistic Infections

CITY AND YEAR: **San Francisco, USA, March 2004**

CONTRIBUTION: Poster presentation (Abstract 47)

TITLE: High Rate of Multidrug Resistance Genotypes in Heavily Treatment-Experienced Patients

CONFERENCE: 2nd European HIV Drug Resistance Workshop

CITY AND YEAR: **Rome, Italy, 11 - 13 March 2004**

CONTRIBUTION: Oral presentation (Abstract 69)

TITLE: Relative Replicative Capacity of MNR HIV-1 strain bearing dipeptide insertion in the fingers subdomain of the RT and mutations at codons 67and 215

CONFERENCE: 2nd European HIV Drug Resistance Workshop

CITY AND YEAR: **Rome, Italy, 11 - 13 March 2004**

CONTRIBUTION: Invited speaker

TITLE: Qumioteràpia de la SIDA a principis del segle XXI: bones i no-tan-bones notícies

CONFERENCE: Departament de Ciències Fisiològiques II

CITY AND YEAR: **Bellvitge, Universitat de Barcelona, 2004**

CONTRIBUTION: Oral presentation (Abstract 335)

TITLE: CD8 T Cell Responses and Viral Escape in HIV-Infected Monozygotic Twins Infected with the Same Virus

CONFERENCE: HIV Vaccine Development: Progress and Prospects; Keystone Symposia

CITY AND YEAR: **Whistler, British Columbia, Canada, 2004**

CONTRIBUTION: Invited speaker

TITLE: Es duro ser un virus: ¿cómo el VIH-1 mantiene su capacidad replicativa en presencia de antivirales?

CONFERENCE: Instituto de Biología Molecular y Celular de Plantas; Consejo Superior de Investigaciones Científicas-Univ. Politécnica de Valencia.

CITY AND YEAR: **València, 2004**

CONTRIBUTION: Invited speaker (Abstract LB05)

- TITLE: Alternation of antiretroviral drug regimens for HIV infection: a randomized, controlled trial  
CONFERENCE: 2nd International AIDS Society.  
CITY AND YEAR: **Paris, France, 2003**
- CONTRIBUTION: Poster presentation (Abstract 90)  
TITLE: Evidence for preferential genotyping of minority HIV populations due to primer mismatching during PCR-based amplification  
CONFERENCE: XII International HIV drug resistance workshop: basic principles and clinical implications  
CITY AND YEAR: **Los Cabos, Mexico, 2003**
- CONTRIBUTION: Oral presentation (Abstract 65)  
TITLE: A Multicenter, Randomized Controlled Clinical Trial of Continuous vs. Intermittent HAART Guided by CD4+ T Cell Counts and Plasma HIV-1 RNA Levels  
CONFERENCE: 10th Conference on retroviruses and opportunistic Infections  
CITY AND YEAR: **Boston, USA, 2003**
- CONTRIBUTION: Invited speaker  
TITLE: Implications of drug resistance for HIV biology: a clinically oriented review of basic concepts  
CONFERENCE: Symposium on HIV Resistance to Antiretroviral Drugs.  
CITY AND YEAR: **Madrid, 2003**
- CONTRIBUTION: Oral presentation (Abstract J41e)  
TITLE: Viral Populations Emerging in Plasma During Sequential Structured Treatment Interruptions in Chronically HIV-Infected Individuals are Genetically Distinct between Time-points and Tissues.  
CONFERENCE: 9<sup>th</sup> Conference on retroviruses and opportunistic Infections  
CITY AND YEAR: **Seattle, USA, 2002**
- CONTRIBUTION: Poster presentation 13  
TITLE: Novel mutations in a highly conserved region of HIV-1 gp41 are associated with T-20 treatment  
CONFERENCE: XI International HIV drug resistance workshop: basic principles and clinical implications  
CITY AND YEAR: **Seville (Spain), 2-5 July 2002**
- CONTRIBUTION: Poster presentation 111  
TITLE: A novel Taqman Real-Time PCR method to estimate HIV-1 fitness in the era of multi-target antiretroviral therapy  
CONFERENCE: XI International HIV drug resistance workshop: basic principles and clinical implications  
CITY AND YEAR: **Seville (Spain), 2-5 July 2002**
- CONTRIBUTION: Poster presentation 154  
TITLE: Virological and immunological benefit of salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption in advanced HIV-infected patients with multidrug resistance mutations (48 weeks follow-up)  
CONFERENCE: XI International HIV drug resistance workshop: basic principles and clinical implications  
CITY AND YEAR: **Seville (Spain), 2-5 July 2002**
- CONTRIBUTION: Invited speaker  
TITLE: HIV replication capacity and drug susceptibility  
CONFERENCE: Relevance of experimental models to HIV disease (NIH)  
CITY AND YEAR: **San Juan de Puerto Rico, USA, 2001**
- CONTRIBUTION: Invited speaker  
TITLE: Valor de la fitness viral en el diseño de la terapia antirretroviral  
CONFERENCE: VI Reunión de Avances en el Tratamiento de la Infección por el VIH  
CITY AND YEAR: **Seu d'Urgell, Lérida, Spain 2001**
- CONTRIBUTION: Invited speaker  
TITLE: Valor de la fitness viral en el diseño de la terapia antirretroviral  
CONFERENCE: II Seminario sobre Resistencias a Antirretrovirales y su Aplicación en la Clínica  
CITY AND YEAR: **Madrid, Spain, 2001**
- CONTRIBUTION: Poster presentation 36  
TITLE: Selection of the M184V mutation during repetitive cycles of structured treatment interruptions  
CONFERENCE: 5<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies  
CITY AND YEAR: **Scottsdale (AZ, USA), 4-8 June 2001**
- CONTRIBUTION: Poster presentation 67  
TITLE: Lopinavir resistance of amprenavir-selected, replication-impaired mutants of HIV-1  
CONFERENCE: 5<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies  
CITY AND YEAR: **Scottsdale (AZ, USA), 4-8 June 2001**
- CONTRIBUTION: Oral presentation 81  
TITLE: SWATCH study: a multi-centre trial of proactive treatment switching. Results at 48 weeks of follow-up  
CONFERENCE: 5<sup>th</sup> International Workshop on HIV Drug Resistance and Treatment Strategies  
CITY AND YEAR: **Scottsdale (AZ, USA), 4-8 June 2001**
- CONTRIBUTION: Invited speaker  
TITLE: Selection of drug resistant HIV-1 mutants in response to repeated structured treatment interruptions  
CONFERENCE: 8<sup>th</sup> Annual HIV Dynamics and Evolution Meeting  
CITY AND YEAR: **Paris, France, 2001**
- CONTRIBUTION: Invited speaker  
TITLE: Virus resistance and replicative capacity  
CONFERENCE: Massachusetts General Hospital HIV Resistance Preceptorship  
CITY AND YEAR: **Boston, Massachusetts, USA, 2001**
- CONTRIBUTION: Poster presentation 133  
TITLE: Alternation of antiretroviral drug regimens for HIV infection: a randomized, controlled trial  
CONFERENCE: 4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies  
CITY AND YEAR: **Sitges (Spain), 12-16 June 2000**
- CONTRIBUTION: Poster presentation 147  
TITLE: Reduced replicative fitness of amprenavir inhibitor-resistant mutants of HIV-1 in competitive cultures  
CONFERENCE: 4<sup>th</sup> International Workshop on HIV Drug Resistance & Treatment Strategies  
CITY AND YEAR: **Sitges (Spain), 12-16 June 2000**
- CONTRIBUTION: Invited speaker  
CONFERENCE: North American/European Advisory Panel Meeting  
CITY AND YEAR: **Cape Town, South Africa, 2000**
- CONTRIBUTION: Invited speaker  
CONFERENCE: 13th World AIDS Conference  
CITY AND YEAR: **Durban, South Africa, 2000**
- CONTRIBUTION: Oral presentation  
CONFERENCE: 7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections  
CITY AND YEAR: **San Francisco, CA, USA, 2000**
- CONTRIBUTION: Invited speaker  
CONFERENCE: 7<sup>th</sup> European Conference on Clinical Aspects and Treatment of HIV-Infection  
CITY AND YEAR: **Lisbon, Portugal, 1999**
- CONTRIBUTION: Poster presentation 72  
TITLE: Clonal sequencing for detection of resistance mutations and their linkage  
CONFERENCE: 3<sup>rd</sup> International Workshop on HIV Drug Resistance & Treatment Strategies

CITY AND YEAR: **San Diego (USA), 23-6 June 1999**

CONTRIBUTION: Invited speaker  
CONFERENCE: 1<sup>st</sup> German Conference on Resistance Testing  
for HIV Treatment Strategies  
CITY AND YEAR: **Berlin, Germany, 1999**

CONTRIBUTION: Oral presentation  
CONFERENCE: 3<sup>rd</sup> International Workshop on Drug Resistance  
and Treatment Strategies  
CITY AND YEAR: **San Diego, CA, USA, 1999**

CONTRIBUTION: Oral presentation  
CONFERENCE: 6th Conference on Retroviruses and  
Opportunistic Infections  
CITY AND YEAR: **Chicago, IL, USA, 1999**

CONTRIBUTION: Poster presentation 125  
TITLE: Molecular characterization of the latent reservoir of  
HIV-1 during maximally suppressed combination therapy  
CONFERENCE: 2<sup>nd</sup> International Workshop on HIV Drug  
Resistance & Treatment Strategies  
CITY AND YEAR: **Lake Maggiore (Italy), 24-7 June 1998**

CONTRIBUTION: Poster presentation 130  
TITLE: Replicative fitness of protease inhibitor-resistant  
mutants of HIV-1  
CONFERENCE: 2<sup>nd</sup> International Workshop on HIV Drug  
Resistance & Treatment Strategies  
CITY AND YEAR: **Lake Maggiore (Italy), 24-7 June 1998**

CONTRIBUTION: Oral presentation  
CONFERENCE: International Workshop on HIV Drug  
Resistance, Treatment Strategies and Eradication  
CITY AND YEAR: **St. Petersburg, FL, USA, 1997**

CONTRIBUTION: Oral presentation  
CONFERENCE: 5th Workshop on HIV Drug Resistance  
CITY AND YEAR: **Whistler, Canada, 1996**

CONTRIBUTION: Poster presentation 111  
TITLE: Replicative fitness of HIV variants resistance to protease  
inhibitors  
CONFERENCE: 1<sup>st</sup> International Workshop on HIV Drug  
Resistance & Treatment Strategies  
CITY AND YEAR: **St. Petersburg (FL, USA), 25-8 June  
1997**

---

## RESEARCHERS IN THE GROUP

### Present and past on alphabetical order:

Mònica Ballesteros Téllez; *post-graduated scientist: 2011*  
Dr. Ángel Bayón; *pre-doctoral scientist: 2019-2024*  
David A. Bejarano; *visiting scientist: 2018*  
Dr. Susana Benet; *pre-doctoral scientist: 2015-2021*  
Sílvia Bernal; *pre-doctoral scientist: 2018-2024*  
Dr. María José Buzón; *pre-doctoral scientist: 2006-2010*  
Gerard Campos; *pre-doctoral scientist: 2022-present*  
Dr. Jakub Chojnacki; *postdoctoral scientist: 2019-present*  
Dra. Mayte Coiras; *visiting scientist, Centro Nacional de Microbiología, Madrid, 12/2012*  
Rey Fernández; *visiting scientist, Johns Hopkins University, USA, 02/2024*  
Dr. Maria Francesca Cortese; *visiting scientist, Univ. of Rome "Tor Vergata", Italy: 2016-17*  
Dr. Judith Dalmau; *pre-doctoral scientist: 2008-2014; post-doctoral scientist: 2014-2023*  
Dr. Marie-Angélique De Scheerder; *visiting scientist, University of Ghent, Belgium, 2016*  
Itziar Erkizia; *senior lab assistant: 2002-2023*  
Dr. Cristina Gálvez; *pre-doctoral scientist: 2017-2021; post-doctoral scientist: 2021-2023*  
Dr. Mari Carmen García; *lab technician: 2019-present*  
Dr. Albert Garcia Miñambres; *post-graduated scientist: 2013*  
Dr. Eduardo García Zepeda; *visiting scientist, Univ. Nacional Autónoma de México, 2009-10*  
Dr. Lidia Garrido; *bioinformatician; 2022-present*  
Irene González; *pre-doctoral scientist: 2022-present*  
Dr. María González Cao; *post-graduated scientist: 2016*  
Gemma Hancock; *visiting scientist, Oxford University, 2014*  
Dr. Nuria Izquierdo-Useros; *pre-doctoral scientist: 2004-09; post-doctoral scientist: 2009-20*  
Claudia Juarez-Molina; *visiting scientist, Oxford University, UK, 07/2012*  
Fernando Laguía; *pre-doctoral scientist: 2021-present*  
Dr. Marta Martínez-Bonet; *visiting scientist, Hosp. Gregorio Marañón, Madrid, 01-04/2014*  
Dr. Peter Mesiaen; *visiting scientist, University of Ghent, Belgium, 05/2011*  
Dr. Gerard Minuesa; *pre-doctoral scientist: 2004-09; post-doctoral scientist: 2009-10*  
Dr. Sara Morón-López; *pre-doctoral scientist: 2013-16; post-doctoral scientist: 2011-present*  
Dr. Xabier Muñiz; *pre-doctoral scientist: 2017-2023*  
Dan Ouchi; *biostatistician: 2014-2016*  
Dr. Roger Paredes; *pre-doctoral scientist: 2008*  
Dr. Daniel Perez Zsolt; *pre-doctoral scientist: 2015-2020*  
Dr. Maria Pino; *post-graduated scientist: 2010-2011; pre-doctoral scientist: 2011-2016*

Dr. Patricia Piñol Jurado; *senior lab assistant: 2023-present*  
Dr. María Carmen Puertas; *post-doctoral scientist: 2006-present*  
Dr. Patricia Resa-Infante; *post-doctoral scientist: 2018-present*  
Dr. Julia G Prado; *pre-doctoral scientist: 2001-2005; post-doctoral scientist: 200820-11*  
Dr. Sílvia Ribó; *post-doctoral scientist: 2023-present*  
Dr. M<sup>a</sup> Teresa Rodríguez-Plata; *pre-doctoral scientist: 200820-13*  
Dr. María Salgado; *post-doctoral scientist: 2014-present*  
Lily Wai Yan Tam; *visiting scientist, University of British Columbia, Vancouver, Canada, 2006*  
Dr. Víctor Urrea; *biostatistician: 2016-present*  
Dr. Cristina Villena; *post-doctoral scientist: 2008-2009*  
Gisela Zamorano; *junior lab assistant: 2022-2024*

---

## DOCTORAL THESES

### **Ángel Bayón Gil**

Title: Analysis of distinctive host immune factors in HIV+ Viremic Non-Progressors

Director: Javier Martínez-Picado / M<sup>a</sup> Carmen Puertas

Institution: University of Barcelona (Spain), 19 January 2024

Qualification: *Cum Laude*

Current position: pending

### **Xabier Muñiz Trabudua**

Title: The potential role of Siglec-1 receptor as a therapeutic target against dendritic cell mediated dissemination of enveloped viruses

Director: Javier Martínez-Picado / Nuria Izquierdo-Useros

Institution: Universitat Autònoma de Barcelona, 15 December 2023

Qualification: *Cum Laude*

Previous positions: Clinical Research Associate at Zurko Research (Madrid, Spain)

Current position: Project leader at CQS Health “Chemical Health Consulting” (Rivas, Madrid, Spain)

### **Sílvia Bernal Santateresa**

Title: A new therapeutical approach to reduce viral persistence, immune activation, and inflammation in people with HIV-1 on antiretroviral therapy

Director: Javier Martínez-Picado / M<sup>a</sup> Carmen Puertas

Institution: Universitat de Vic – Universitat Central de Catalunya, 23 October 2023

Qualification: *Cum Laude*

Current position: Post-doctoral fellow at the John Hopkins University (Baltimore, USA)

### **Susana Benet Garrabé**

Title: Impact of a SIGLEC1 null variant on the pathogenesis of HIV-1 and *Mycobacterium tuberculosis* infection

Director: Javier Martínez-Picado / Nuria Izquierdo-Useros

Institution: Universitat Autònoma de Barcelona, 12 February 2021

Qualification: *Cum Laude*

Current position: Clinical researcher at Fundació de Lluita contra les Infeccions (Barcelona)

### **Cristina Gálvez Celada**



Title: Identification of immunovirological factors that determine an extremely low viral reservoir: approaching the cure of HIV-1 infection

Director: Javier Martinez-Picado / María Salgado

Institution: Universitat Autònoma de Barcelona, 29 January 2021

Qualification: *Cum Laude and Special University award to the best thesis in 2021*

Previous positions: IQVIA (Barcelona),

Current position: Data manager Officer IrsiCaixa (Barcelona)

### **Daniel Pérez-Zsolt**

Title: New therapeutic strategies targeting dendritic cell-mediated dissemination of enveloped viruses

Director: Javier Martinez-Picado / Nuria Izquierdo-Useros

Institution: Universitat Autònoma de Barcelona, 22 January 2020

Qualification: *Cum Laude and Special University award to the best thesis in 2020*

Current position: Postdoctoral researcher at IrsiCaixa (Barcelona)

### **Sara Morón-López**

Title: Evaluation of clinical strategies to cure HIV-1 infection in patients receiving antiretroviral therapy

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 20 September 2016

Qualification: *Cum Laude and Special University award to the best thesis in 2016*

Previous position: UCSF (San Francisco CA, USA)

Current position: Postdoctoral researcher at IrsiCaixa (Barcelona)

### **Maria Pino Clavería**

Title: HIV-1 immune activation induces Siglec-1 expression and enhances viral dissemination in myeloid cells

Directors: Javier Martinez-Picado / Nuria Izquierdo-Useros

Institution: Universitat Autònoma de Barcelona, 7 July 2016

Qualification: *Cum Laude*

Previous positions: Postdoctoral researcher at Emory University (Atlanta GA, USA)

Current position: BioNTech (Mainz, Germany)

### **Judith Dalmau Moreno**

Title: Viral and host factors involved in rapid HIV-1 disease progression

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 21 March 2014

Qualification: *Cum Laude*

Previous positions: Project Manager at IrsiCaixa (Barcelona)

Current position: Clinical study coordinator at IrsiCaixa (Barcelona)

### **M<sup>a</sup> Teresa Rodríguez Plata**

Title: Dendritic Cells and HIV-1: molecular mechanisms involved in viral capture, trans-infection and antigen presentation

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 2 July 2013

Qualification: *Cum Laude*

Previous positions: University College London UCL (London, UK); Tusk Therapeutics (London, UK); Black Belt Therapeutics (London, UK), Medicines and Healthcare products Regulatory Agency (South Mimms, UK).

Current position: Principal Scientist Immunology at NeoPhore (London, UK)

### **M<sup>a</sup> José Buzón Gómez**

Title: *Effect of the HIV-1 integrase inhibitor raltegravir on drug susceptibility, replication capacity and residual viremia in HIV-infected subjects*

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 23 September 2010

Qualification: *Cum Laude*

Previous positions: Ragon Institute of MGH, MIT and Harvard (Cambridge MA, USA)

Current position: “Miguel Servet” Researcher and Group Leader at Hospital Vall d’Hebron (Barcelona)

### **Gerard Minuesa Dinarés**

Title: *Uptake Transporters of Nucleoside-Derived Anti-HIV Drugs: Expression and Functional Analysis in Immune Cells*

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 26 June 2009

Qualification: *Cum Laude*

Previous positions: Postdoctoral researcher at the Sloan-Kettering Cancer Center (NY, USA); Moirai Biodesign (Barcelona)

Current position: Platform Leader of Biochemistry & Assay Development at Oryzon Genomics (Cornellà de Llobregat, Barcelona)

### **Nuria Izquierdo Useros**

Title: *Maturation of Dendritic Cells and HIV Transmission to CD4<sup>+</sup> T cells*

Directors: Javier Martinez-Picado & Julià Blanco

Institution: Universitat Autònoma de Barcelona, 17 April 2009

Qualification: *Cum Laude*

Current position: Group Leader at IrsiCaixa (Barcelona)

### **Julia García Prado**

Title: Variations in the HIV-1 fitness during antiretroviral therapy

Directors: Javier Martinez-Picado & Julià Blanco

Institution: Universitat Autònoma de Barcelona, 26 September 2005

Qualification: *Cum Laude and Special University award to the best thesis in 2005*

Previous positions: Oxford University (Oxford, UK)

Current position: “Miguel Servet” Researcher and Group Leader at IrsiCaixa (Barcelona)

### ***In progress:***

#### **Eva Armendariz Burgoa**

University of Barcelona (Spain)

#### **Fernando Laguía Nueda**

University of Barcelona (Spain)

#### **Irene González Navarro**

University of Barcelona (Spain)

#### **Gerard Campos**

University of Barcelona (Spain)

#### **Jon Izquierdo Pujol**

Autonomous University of Barcelona (Spain)

---

## MASTER THESES (from 2009)

### **Jon Izquierdo Pujol**

Title: Characterization of Post COVID-19 condition in children and adolescents: PBMC immunophenotyping and plasma immune profile

Directors: Javier Martinez-Picado and Sara Morón-López

Institution: Universitat de Barcelona, 19 July 2022

Qualification: 9.7/10

### **María González Cao**

Title: Determination of HIV-1 coreceptor tropism using proviral DNA (pvDNA) in patients on effective suppression treatment and correlation with proviral load

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 20 June 2016

Qualification: 10/10

### **Cristina Gálvez Celada**

Title: To establish and characterize a cohort of treated patients with low viral reservoir (LoViReT)

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 20 June 2015

Qualification: 10/10

### **Susana Benet Garrabé**

Title: Viral and host factors involved in rapid HIV-1 disease progression

Director: Javier Martinez-Picado & Nuria Izquierdo-Useros

Institution: Universitat Autònoma de Barcelona, 20 June 2014

Qualification: 10/10

### **Sara Morón López**

Title: Impact of IFN $\alpha$ -2a on the HIV-1 reservoir of CD4<sup>+</sup> T cells from patients co-infected with HCV

Director: Javier Martinez-Picado

Institution: Universitat Autònoma de Barcelona, 20 June 2014

Qualification: 10/10

### **Albert Garcia Miñambres**

Title: Analysis of HIV-Gag evolution patterns in viremic non-progressor HIV+ patients

Director: Javier Martinez-Picado & María Salgado

Institution: Universitat Autònoma de Barcelona, 2013

Qualification: 10/10

Present position: Scientist at CSL (Melbourne, Australia)

Previous positions: PhD student, Deakin University (Melbourne, Australia)

### **Mònica Ballesteros Téllez**

Title: Efecto de la intensificación con Maraviroc sobre una terapia triple en pacientes recientemente infectados por VIH-1: Estudio MARAVIBOOST

Director: Javier Martinez-Picado

Institution: Universitat Pompeu Fabra, 2011

Qualification: 10/10

### **Maria Pino Claveria**

Title: Caracterització d'aïllats virals del VIH en individus amb Ràpida Progressió a SIDA

Director: Javier Martinez-Picado & Julia García Prado

Institution: Universitat Pompeu Fabra, 2010

Qualification: 10/10

**María Teresa Rodríguez Plata**

Title: Dendritic Cell-based Vaccine against HIV: Deficient/Inactivated HIV-1 Capture and Infectious Transmission by Dendritic Cells

Director: Javier Martínez-Picado

Institution: Universitat Pompeu Fabra, 2009; Qualification: 10/10

---

## EXPERIENCE ORGANIZING R+D ACTIVITIES

(Scientific conferences, workshops, ...)

### **11<sup>th</sup> International Workshop on HIV Persistence during Therapy**

Member of the Organizing and Scientific Committee  
Fort Lauderdale (FL, USA), 10-13 December 2024

### **XV Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Zaragoza (Spain), 24-27 November 2024

### **16<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 24 October 2024

### **XIV Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
A Coruña (Spain), 26-29 November 2023

### **15<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 26 October 2023

### **The HIV Reservoirs and Immune Control FASEB Conference**

Member of the Scientific Program & Organizing Committee  
Malahide (Ireland) 1-4 October 2023

### **10<sup>th</sup> International Workshop on HIV Persistence during Therapy**

Member of the Scientific Committee  
Miami (FL, USA), 13-16 December 2022

### **XIII Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Sitges (Spain), 27-30 November 2022

### **14<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 8 November 2022

### **XII Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Malaga (Spain), 30 November - 3 December 2021

### **13<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 14 October 2021

### **11<sup>th</sup> Int'l AIDS Conference on HIV Science (IAS 2021)**



Member of the Programme Committee for the 2021 IAS HIV Cure & Gene Therapy Forum  
Virtual edition, 18 – 21 July 2021.

**12<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 22 October 2020 (virtual edition)

**XI Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Toledo (Spain), 10-13 December 2019

**9<sup>th</sup> International Workshop on HIV Persistence during Therapy**

Member of the Scientific Committee  
Miami (FL, USA), 10-13 December 2019

**11<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 23 October 2019

**X Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Madrid (Spain), 6-9 November 2018

**10<sup>th</sup> Workshop HOT TOPICS in HIV: vaccines, immune recovery and eradication**

Member of the Scientific Program & Organizing Committee  
Barcelona (Spain), 18 October 2018

**22<sup>nd</sup> International AIDS Conference**

Member of the Scientific Committee  
Amsterdam (Netherlands), 23-27 July 2018

**8<sup>th</sup> International Workshop on HIV Persistence during Therapy**

Member of the Scientific Committee  
Miami (FL, USA), 12-15 December 2017

**IX Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Vigo, 28 November - 1 December 2017

**16<sup>th</sup> European AIDS Conference / EACS**

Member of the Scientific Committee  
Milan (Italy), 25-28 October 2017

**VIII Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
San Sebastián, 29 November - 2 December 2016

**7<sup>th</sup> International Workshop on HIV Persistence during Therapy**

Member of the Scientific Committee  
Miami (FL, USA), 8-11 December 2015

**15<sup>th</sup> European AIDS Conference / EACS**

Member of the Local Organizing Committee  
Barcelona (Spain), 21-24 October 2015

**VI Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Málaga, 25-28 November 2014

**Towards an HIV Cure symposium**

Member of the Program Committee  
Melbourne (Australia), 19-20 July 2014

**V Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Sitges (Barcelona), 19-22 November 2013

**IV Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Toledo (Spain), 27-30 November 2012

**III Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Program & Organizing Committee  
Sevilla (Spain), 7-10 November 2011

**“Towards a Cure”: HIV Reservoirs and Strategies to Control them”**

Pre-International IAS Conference Basic Science Workshop  
Member of the Scientific Programme Committee  
International AIDS Society (IAS) meeting  
Vienna (Austria), 16-17 July 2010

**II Congreso Nacional GeSIDA (Grupo de estudio del SIDA – SEIMC)**

Member of the Scientific Programme & Organizing Committee  
Madrid, 30 November - 3 December 2010

**2<sup>nd</sup> Triennial Oxford-Barcelona HIV Workshop**

Member of the Scientific Programme & Organizing Committee  
Brasenose College  
Oxford, 13-14 May 2010

**“Advanced Microscopy Techniques for Immuno-nanoscopy”**

Translational biology-physics workshop  
Member of the Scientific Committee  
School of Physics, University of Barcelona  
Barcelona, 15-16 October 2008

**“11<sup>th</sup> European AIDS Conference” (EACS)**

Member of the Scientific Programme Committee  
European AIDS Clinical Society meeting  
Palacio Municipal de Congresos de Madrid  
Madrid, 24-27 October 2007

**1<sup>st</sup> Triennial Oxford-Barcelona HIV Workshop**

Member of the Scientific Programme & Organizing Committee  
Institut de Recerca Biomèdica Germans Trias i Pujol  
Barcelona, 7-8 June 2007

**Spanish National AIDS meeting (SEISIDA)**

Member of the scientific and organizing committee  
Barcelona, 29-31 March 2006

---

## AWARDS

- ❑ Elected member of the Royal Academy of Science and Arts of Barcelona (RACAB) since 2021
  - ❑ Research and Investigation Award 2024 by the Biologists Association of Catalonia
  - ❑ Listed in the Stanford/Elsevier Top Scientists 2021, 2022, and 2023 Ranking, which shows the top 2% of scientists who have had the greatest impact in their fields from around the world.
- 
- ❑ 1<sup>st</sup> Award ‘Vanguardia de la Ciencia’ (III edición), Barcelona 9 May 2013.
  - ❑ Award Diario Médico: ‘The Best Ideas in Healthcare 2007’
  - ❑ Grant of collaboration with the AIDS Research Unit in Montreal, Canada. Department of Microbiology and Immunology, Centre Hospitalier de l’Université de Montréal, Montréal, Canada. **ACES Program** from **the Catalanian Government**. 2004
  - ❑ Grant of collaboration with the University of California. **Program Gaspar de Portolà** from **the Catalanian Government**. 2002.
  - ❑ Award ‘Triangle Pharmaceuticals Young Scientist Scholarship’ to attend the 2<sup>nd</sup> International Workshop on Drug Resistance and Treatment Strategies". Baveno, Italy, June 1998.
  - ❑ Award ‘International Medical press Young Scientist Scholarship’ to attend the 1<sup>st</sup> International Workshop on Drug Resistance, Treatment Strategies and Eradication", Florida USA, June 1997.
  - ❑ Award ‘Grants for Research Projects’ (1990). Comisión Interdepartamental de Ciencia y Tecnología (CIRIT). Government of Catalonia.

---

## OTHER SCIENTIFIC, TECHNICAL OR EDUCATIONAL QUALIFICATIONS

- Member of the **MHRP RV254/RV217 Virology/Reservoir Working Group** for studies in acute HIV infection in Thailand and Africa (10/05/2018 – )
- Member of the Martin Delaney Collaboratory **RIDHIV** (16/08/2021 – 30/04/2026)
- Member of the Martin Delaney Collaboratory **BEAT-HIV Collaborative** (07/01/2016 – 06/30/2021)
- Member of the **American Society for Microbiology**, USA.
- Member of the **Consortium for Functional Glycomics** (CFG), USA.
- Member of the **Spanish Society for Virology**
- Member of the **Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) – GeSIDA**
- Member of the **Catalonian Society for Biology** (Virology Group)
- Member of the **External Advisory Board of the Spanish HIV BioBank** (since 2012)
- Member of the **Scientific Advisory Board of Albajuna Therapeutics**
- Member of the **Scientific Advisory Board of Plasmia Biotech**
- Member of the **Scientific Advisory Board of Innovex Therapeutics SL**
- **Ad Hoc Reviewer of Professional Journals** (in alphabetical order):
  - AIDS
  - AIDS Research and Human Retroviruses
  - Antiviral Therapy
  - Blood
  - Clinical Infectious Diseases
  - EBioMed
  - EMBL Molecular Medicine
  - HIV Medicine
  - Infection
  - Journal of AIDS
  - Journal of Antimicrobial Chemotherapy
  - Journal of Clinical Investigation
  - Journal of Clinical Microbiology
  - Journal of General Virology
  - Journal of Infectious Diseases
  - Journal of Virological Methods
  - Journal of Virology
  - The Lancet
  - The Lancet HIV
  - Nature Communications
  - Nature Medicine
  - Nature Microbiology
  - Open Forum for Infectious Diseases
  - Pathogens and Immunity
  - PLoS Pathogens
  - PLoS One
  - Retrovirology
  - Science
  - Virology
  - Virology Journal
  - Viruses
- **Ad Hoc Reviewer of Research Proposals of National and International Research Funding Agencies:**
  - Spanish Department for Research, Development and Innovation
  - Spanish Department for Health
  - Spanish Foundation for AIDS Research and Prevention



- Autonomous Community of Madrid
- Dutch Foundation for AIDS Research
- Creative and Novel Ideas in Research Awards Program (CNIHR)
- American Foundation for AIDS Research (amfAR)
- CFAR grants. University of Washington (USA)
- Pierre Bergé endowment fund & Sidaction (France)
- Member of the editorial board of Revista Multidisciplinar del Sida
- **Ad Hoc Member of the evaluation panel for professional promotion, review and tenure:** University of Delaware 2024 (USA); Institute Pasteur 2024 (France); University of Barcelona, 2024 (Spain); Fred Hutchinson Cancer Center Seattle, 2022 (USA), Institute Pasteur, 2022 (France), Erasmus University Medical Centre, 2022 (The Netherlands), University of Melbourne 2021 (Australia), Northwestern University, 2019 (USA); University of Sydney, 2018 (Australia); Johns Hopkins University, 2017 (USA); Vanderbilt University, 2007 (USA); University of Rochester, 2007 (USA).
- Ad Hoc Member of the evaluation board of INSERM unit E109 (Paris, March 2005).
- Course “Leadership and Management Skills”. hfp Consulting, Heidelberg. Barcelona 15-17 May 2024.
- Educational **advisor** for “La Caixa” Foundation, 2002-05
- Scientific **advisor** for the Wellcome Foundation, 2002-04
- **Chairman** at the XIV International AIDS Conference, Barcelona 2002
- **Scientific writing** seminar. Clinical research program. Harvard University & Massachusetts General Hospital. Boston, MA. October 1998.
- **Course** "AIDS Medicine: an intensive course", Cambridge, Massachusetts, November 18-19, 1997.
- **Course** "Biosafety in Biomedical laboratories". Massachusetts General Hospital & Harvard Medical School. Boston, Massachusetts, August 1997.
- **Course** "Computer applications for the analyses of biological sequences". Genetics Computer group & Whitehead Institute, Cambridge, Massachusetts, July 1997.
- **Course** “Confocal microscopy: applications in Cellular and Molecular Biology”, Spanish Society for Cellular Biology, Barcelona, May 1996.
- Fourth **Workshop** on Viral Resistances. Annapolis, Md (USA). Septiembre 1995.
- 2<sup>nd</sup> **Course** on Biological Sequence analyses EMBnet/CNB. Centro Nacional de Biotecnología. Madrid 1995.
- **Short stage** in the Biocomputing Laboratory. Molecular Biology Department. University of Bari. Italy, 1992.
- **Course** on Electron Microscopy. Scientific core services. University of Barcelona. 1990.